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SUMMARY 
Colorectal cancer is a major health problem, and many patients relapse despite apparently 
curative treatment. Local recurrence is an important factor, and is more common when 
cancer cells are present on the free serosal surface or circumferential resection margin. 
We hypothesised that detecting tumour cells in the peritoneal cavity during surgery (in 
peritoneal washings) or post-operatively (in drain fluids) would act as a marker for risk of 
local recurrence, and that the use of molecular biological techniques would allow for the 
sensitive detection of such cells. 
We collected samples of colorectal tumours, with washings from the peritoneal cavity at 
the start and end of surgery, and fluid from the surgical drain on the first and second post-
operative day. Epithelial cells in the peritoneal samples were enriched using magnetic 
cell separation (MACS). Using mutation specific PCR or a Mismatch Ligation Assay we 
detected common mutations of K-ras, TP53, APe and BRAF in primary tumour samples, 
and when such a mutation was found, we studied the peritoneal samples from that patient 
for the same mutation. 
We detected 23 mutations in 22 (out of 46) tumours from 21 patients. In 16 patients, at 
least one of the peritoneal samples gave a positive result for the same mutant DNA. 
Using MACS increased the proportion of positive samples. Half of the patients with 
positive peritoneal samples had Dukes' stage A or B tumours. Follow up is not yet long 
enough to allow conclusions to be drawn on the significance of these results. 
We have described techniques allowing mutations to be characterised in half of colorectal 
tumours and have demonstrated the presence of cells with the same mutation in 
peritoneal samples from three-quarters of patients. Longer follow up will show whether 
our tests are too sensitive, or whether they provide useful information about likely local 
recurrence. 
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CHAPTER 1: INTRODUCTION 
1.1 Colorectal cancer 
Colorectal cancer is a major health problem throughout the developed world. It is the 
second commonest cause of cancer death in the UK, and the leading cause of cancer 
death among non-smokers. In 1998, over 35,000 new cases were diagnosed, and in 200 I 
there were 16,000 deaths (Cancer Research UK website). In most cases, no obvious 
individual risk factors can be identified, although about 5% have a clear inherited basis 
(see section 1.6.1). A small proportion of patients also develop tumours on a background 
of chronic inflammation over many years, such as those suffering from ulcerative colitis. 
The commonest risk factor is increasing age, with a peak incidence in the eighth decade. 
On a population level, obesity and a diet high in fats and low in fruit and vegetables gives 
an increased risk of disease. 
Patients present with a variety of symptoms including alteration of bowel habit, overt 
rectal bleeding, anaemia due to chronic blood loss, abdominal pain and symptoms of 
more advanced disease such as weight loss. Surgery is the major form of treatment for 
colorectal cancer, and most cures are achieved by surgery. The nature of the surgery 
performed depends on the site of the primary tumour, but normally involves removing the 
tumour, with a margin of healthy bowel, and the lymph nodes along the blood vessels 
supplying the affected part of the bowel. Some patients benefit from additional radio-
and/or chemotherapy, which may be given before or after operation depending on the site 
and extent of the tumour (see section 1.2.1.2). Surgery may also be used to attempt cure 
of some patients with metastatic or recurrent disease (particularly in the liver), and 
palliative chemotherapy is widely used. 
The overall five-year survival rate remains at about 40% in the UK. Almost 25% of 
patients present with disease that is already incurable, having spread to the liver or other 
metastatic sites (Colonna et al., 2001; Newland et al., 1987). About one third of patients 
who have undergone surgery which removes all visible tumour, later succumb to their 
disease. Many of these can be predicted from the findings at operation, or the 
histopathologist's report, but a significant proportion occur without obvious risk factors. 
Although advances in surgical technique and adjuvant treatment are producing some 
benefits in survival, probably the best hope for improving the outcome for patients with 
colorectal cancer lies in diagnosing the disease at an earlier stage. This may be achieved, 
in part, by greater public awareness of the disease and its symptoms. Because colorectal 
cancer has a long and well-characterised pre-malignant phase (section 1.6.2), it may 
prove a good candidate for a programme of screening, and the possibility of this is being 
examined currently. 
Despite screening, many patients are likely to continue to present with established cancer. 
This group of patients will benefit from accurate assessment of the extent of their disease. 
Much can be done using current staging systems (see section 1.2), but further infonnation 
is likely to become available in future from the additional use of techniques to detect 
disseminated colorectal cancer cells using molecular markers. This additional infonnation 
will allow targeted follow up and adjuvant treatment, and may thus help to improve 
survival. 
This thesis is concerned with the detection of such disseminated tumour cells in the 
peritoneal cavity of colorectal cancer patients around the time of surgery. In this 
introduction, I will describe current systems in use to predict recurrence, how and where 
recurrent colorectal cancer occurs, how local recurrence may be prevented, predicted, 
recognised and treated, strategies for improving outcomes in colorectal cancer, and the 
relevant molecular biology of colorectal cancer, which aids in understanding and possible 
implementation of these improvements. 
1.2 Prediction of outcomes in colorectal cancer: rationale for staging and current 
practice 
Patients with colorectal cancer fonn a heterogeneous group, with tumours with a variety 
of characteristics, and with a range of possible outcomes. There is a long history of 
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attempts to classify colorectal tumours into groups, or stages, according to their 
histological features. The reasons for such classification are discussed below. 
1.2.1 Rationale for staging in colorectal cancer 
1.2.1.1 Prognostication 
Giving patients information about their disease is an important part of providing care for 
all patients, and particularly those with cancer. It has been shown that patients want 
information about their illness, and that providing such information can improve both 
physical and psychological outcomes. After the initial shock of a diagnosis of malignancy 
and the need for major surgery, the detailed histology report allows for reassurance that 
the surgery was necessary (especially if the pre-operative diagnosis was based on 
imaging rather than histological proof) and permits more personalised information to be 
given. 
Patients with early tumours (e.g. Dukes' stage A, see below) can be reassured that a cure 
is almost certain after surgery alone. Those with more advanced disease can be advised 
about the probability of cure or of recurrent disease. The risks and benefits of additional 
treatment and the need for more rigorous follow-up (see below) can be discussed. 
1.2.1.2 Selection of Patients for Adjuvant Treatment 
Radiotherapy has been shown to be beneficial in reducing the local recurrence rate after 
surgery for rectal cancer, and also increased five-year survival in one study (1996). 
Radiotherapy is not routinely used in colon cancer management. In Europe and the UK, 
radiotherapy for rectal cancer is usually given pre-operatively (as in the Swedish study), 
as either short course treatment, over five days immediately prior to surgery, or as a long 
course, over several weeks, usually in combination with chemotherapy. Long course 
treatment is used to reduce tumours in size, and to attempt to make fixed or inoperable 
tumours amenable to surgery. Pre-operative radiotherapy is generally better tolerated than 
post-operative treatment, with fewer withdrawals due to side effects (Ooi et aI., 1999). 
The use ofimaging investigations pre-operatively to assess tumour stage is important in 
selecting patients for radiotherapy, and attempting to reduce the morbidity caused by 
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unnecessary treatment. Imaging investigations are not completely accurate, however, and 
the histology report gives essential information about the circumferential resection 
margin. If this is involved with tumour, or if the tumour extends to within lmm of the 
margin (considered as an involved margin, Royal College of Pathologists, minimum data 
set for colorectal cancer) and the patient has not already received radiotherapy, then post-
operative treatment will be recommended. Accurate staging of the primary tumour in 
rectal cancer is therefore of particular importance. 
The role of chemotherapy in colorectal cancer has expanded rapidly in recent years, 
following a number oflarge, multi-centre trials, which demonstrated a survival advantage 
for patients with Dukes' stage C tumours (1995). Although having had all macroscopic 
tumour removed by surgery, and having no evidence of metastatic disease at the time of 
surgery (other than in lymph nodes removed with the specimen), about two-thirds of 
these patients will die from recurrent disease. Often, this will be disseminated disease, 
with the liver the most common site, due to spread through the portal circulation. The 
rationale for the use of adjuvant chemotherapy in these patients is to destroy any residual 
cancer cells at a time when their numbers are least, i.e. soon after surgery. The absolute 
survival advantage for patients with Dukes' stage C colon tumours who receive adjuvant 
chemotherapy is about 5%. Assigning patients accurately to Dukes' stage C has therefore 
become increasingly important, so that potentially beneficial treatment is not withheld. 
Currently, Dukes' B patients are not routinely given chemotherapy, except as part of a 
clinical trial, because the benefits of treatment are insufficient to justify the risks and 
costs. 
1.2.1.3 Audit and Quality Control 
Surgeons are increasingly required to demonstrate that their care is of an acceptable 
standard. The surgeon has been shown to be responsible for considerable variability in 
post-operative morbidity and mortality (McArdle and Hole, 1991). Measures that can be 
used in auditing quality of care for colorectal cancer patients include operative morbidity 
and mortality rates, local recurrence rate, survival rates at various time points and the rate 
of permanent stoma formation. To allow these to be compared between institutions or 
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surgeons in any meaningful way it is necessary to allow for case mix, the differences 
between the groups of patients treated. One major influence on outcome is stage of 
disease at presentation, and therefore it is important that this is assessed and recorded in a 
standardised format to allow comparisons of similar patients to be made. 
Accurate pathology reporting may also be useful in the assessment of the quality of 
surgery, especially for rectal cancer (Birbeck et al., 2002; Nagtegaal et al., 2002). 
Involvement of the circumferential resection margin after rectal cancer surgery has been 
shown to be associated with an increased risk oflocal recurrence (Quirke et al., 1986) 
and can be used as a tool to compare surgeons. Accurate pathological reporting has been 
important in trials designed to assess the benefits ofthe introduction of new surgical 
techniques, such as total mesorectal excision (Martling et al., 2000). 
1.2.2 Current Staging Systems 
A large number of different systems for staging colorectal cancer are in use around the 
world, and even at times within single institutions. This variety suggests that no single 
system is ideal for defining groups of patients with incurable disease, those who have 
been cured by surgery, and those who may benefit from adjuvant treatment. Many of the 
staging systems are based on that originally defined by Dukes, although sometimes with 
considerable modification, or even misunderstandings of his original definitions. The 
TNM classification is also in widespread use, and these two systems are discussed below. 
1.2.2.1 Dukes' Staging 
Dukes originally described his classification system for operable rectal cancers (Dukes, 
1932), although he did suggest that it was applicable to all intestinal cancers, and it is 
now commonly used for tumours of the whole colorectum. This classification divides 
patients into prognostic groups based on the depth of involvement of the bowel wall and 
the presence or absence of lymph node metastases. The original classification included 
just three categories, with stage A tumours limited to the bowel wall, stage B tumours 
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having spread in direct continuity into extra-rectal tissues, but without involved lymph 
nodes, and stage C being any tumour with regional lymph node involvement. 
Dukes' described the three groups as being different in survival at one, two and three 
years, different in distribution of histological grade (with higher grade tumours being of 
more advanced stage) and with higher operative mortality with increasing stage. Even 70 
years ago, he suggested that the classification would 'serve to inform the surgeon as to 
whether or not he is getting the best results with a particular type of case'. 
This classification has been revised a number of times and several different versions are 
in common use today. Patients with distant metastases are said to be stage D. Dukes 
himself subdivided stage C, with stage C2 corresponding to involvement of the apical 
lymph node (the node nearest to the tie on the main vascular pedicle of the specimen) and 
stage Cl any other nodal involvement. 
Stage B has also been subdivided (Astler, 1954) with A tumours confined to the mucosa, 
B 1 tumours extending into but not beyond the muscularis propria, and B2 including those 
tumours with direct spread beyond it. This so-called Astler-Coller modification of Dukes' 
staging included a similar division in stage C tumours, which additionally had involved 
lymph nodes. This classification has the advantage of sub-dividing the heterogeneous 
Dukes' stage B patients into two groups with different recurrence risks, according to the 
local extent of disease. However, it is not widely used in the UK, and is not used in the 
remainder of this thesis. 
Dukes' staging has the adv&ntages of simplicity, and of being widely understood. It does 
divide patients into groups with differing prognoses. For example, the five-year survival 
rates for patients in stages A, B and C are about 95%,65% and 35% respectively. Dukes' 
classification is still used in the selection of patients for adjuvant chemotherapy (see 
above). 
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However, Dukes' staging alone does not always provide sufficient information. In 
particular, there is no emphasis on peritoneal or lateral margin involvement, and vascular 
invasion is not considered. As we will see, these features can give important prognostic 
information. Although many of those with Dukes' B tumours will be essentially cured by 
their surgery, the remaining third will suffer from recurrent disease. This may include 
those with advanced primary tumours but without nodal involvement. Because of these 
limitations, other staging systems are in use alongside or instead of Dukes' staging. 
1.2.2.2 The TNM (Tumour, Nodes, Metastasis) Staging System 
The TNM system of the Union Intemationale Contre le Cancer (VICq is used in the 
classification of many types of cancer throughout the world, including colorectal cancer. 
This system allocates a different number for each aspect of the cancer being reported. 
The classification for coIorectal cancer is as follows (1997): 
T stage- Primary tumour 
TX: primary tumour cannot be assessed 
TO: no evidence of primary tumour 
Tis: intra-epithelial tumour only 
T 1: tumour invades submucosa only 
T2: tumour extending into but not through the muscularis propria 
T3: tumour extending through muscularis propria into subserosa or non-peritonealised 
pericolic or perirectal tissues. 
T4: tumour directly invading adjacent organs, or perforating the visceral peritoneum. 
N stage- regional lymph nodes 
NX: regional lymph nodes cannot be assessed 
NO: no regional lymph node metastases 
NI: metastases in 1-3 regional lymph nodes 
N2: metastases in 4 or more regional lymph nodes 
M stage- distant metastases 
MX: distant metastasis cannot be assessed 
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MO: no distant metastases 
M I: distant metastases 
The advantages of the TNM system are that it is widely understood across a large number 
of countries, allowing for international comparison. Its use for a variety of different 
cancers means that many clinicians are familiar with the system. The criteria for each 
stage are clearly defmed and regularly revised to take account of new research and 
developments. The allocation of a separate number for each element allows, for example, 
a locally advanced tumour without nodal metastases to be classified as T4NO, giving a 
clearer picture of the problem than just labelling it as Dukes' stage B. It is also possible to 
use the same classification system pre-operatively, based on imaging findings. 
One disadvantage of the TNM system is that it may be seen as too complex. Because 
each element of the disease is classified separately, the number of possible categories is 
large, and less easy to see at a glance than a simple letter. This has led to some groups 
subdividing the TNM classifications into 4 stages, which correspond to Dukes' stages A 
to D. This leads to the loss of many of the advantages of the TNM system. The lack of a 
specific classification for the involvement of the apical node (demonstrated to be an 
independent prognostic factor (Newland et al., 1994)) could also be a weakness. 
However, the number of involved nodes is also a prognostic factor (Jass et al., 1987). 
Any attempts to improve the usefulness of staging rely on an understanding of the 
behaviour of colorectal cancer, particularly the methods and patterns of recurrence, and 
this topic is considered next. 
1.3 Mechanisms and patterns of Recurrence in Colorectal Cancer 
1.3.1 Mechanisms of recurrence 
As with all solid tumours, colorectal cancer has four major modes of possible spread. 
These are: 
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Direct invasion. The tumour adheres to and then invades an adjacent organ, for 
example a loop of small bowel, in the case of a colonic tumour, or the vagina in the 
case of a rectal cancer. 
2 Lymphatic invasion. Tumour cells are transported to local and then regional lymph 
nodes via lymphatic channels. This route is common in colorectal cancer, and is 
addressed in all the staging systems in common use (see section 1.2). 
3 Haematogenous spread. Tumour cells gain access to the blood circulation either by 
invading capillary blood vessels locally or via the lymphatic system and are 
transported around the body to other organs, where some cells may escape from the 
circulation and form metastases. For colorectal tumours, these metastases commonly 
occur in the liver, the first capillary bed encountered by cells in the portal circulation. 
4 Transcoelomic spread. This occurs when tumour cells are released into the peritoneal 
cavity. This may occur due to full thickness invasion of the bowel wall by tumour or 
by leakage of cells from cut lymphatic channels during surgery. The cells may 
establish metastases locally, near the site of the original tumour, or elsewhere on 
peritoneal surfaces or the ovaries. 
All these forms of spread are common in colorectal cancer and give rise to the various 
patterns of recurrence discussed below. 
Colorectal cancer has a considerably higher rate of local recurrence when compared with 
some other solid tumours such as breast cancer. This high rate of local recurrence is 
postulated to occur because of the release of emboli of tumour cells from cut Iymphatics 
within the specimen during surgery (Sugarbaker, 1991). Tumour cells released into the 
peritoneal cavity during surgery are likely to be able to implant much more efficiently 
than those metastasising in the circulation are. Intact endothelium does not readily allow 
tumour cells to implant; however, raw surfaces, which occur following dissection, 
provide a more favourable environment. The tumour cells may be trapped in the fibrinous 
exudates formed as a response to surgery, and may be protected from host defences as a 
result. The later release of growth factors, during repair and remodelling, may increase 
the rate of tumour growth. 
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Recurrence of colorectal cancer at the anastomosis has received particular attention 
(Umpleby and Williamson, 1987). This is thought to result either from implantation of 
tumour cells or by metachronous carcinogenesis i.e. formation of a new tumour. If 
occurring as a result of implantation, the tumour cells may originate from outside the 
bowel, by mechanisms such as those described above, or rarely, from inside the bowel 
lumen. The fact that viable cells are shed within the bowel is illustrated by the occasional 
tumour arising in a fistula, fissure or haemorrhoidectomy wound from an unsuspected 
proximal tumour. The risk of anastomotic recurrence can be reduced by the use of 
cytocidal washouts of the bowel ends prior to formation of an anastomosis. Some later 
occurring anastomotic recurrences may be due to new tumours arising in mucosa that is 
vulnerable to carcinogenesis as part of a 'field change'. 
1.3.2 Patterns of Recurrence in Colorectal Cancer 
The literature on patterns of recurrence in colorectal cancer is somewhat confusing, with 
a large number of small series, and considerable variation in the definitions of local 
recurrence and distant metastases. For example, local recurrence is sometimes used to 
refer to only recurrence at the tumour bed or in the anastomosis, and in other papers also 
includes peritoneal seeding. Some authors use a broad classification of intra-abdominal 
recurrence, which includes the above categories as well as those with liver metastases. 
The rate of reporting ofmetastases at different sites will vary with the follow up 
investigations used. Another problem is that many of these series contain data on patients 
who had their surgery several decades ago, and who would not have had access to 
modem imaging, adjuvant treatment or surgical techniques. Some examples of reported 
recurrence rates at various sites are given below. 
An American series of 322 patients, followed after curative resection for colorectal 
tumours (Brethauer, 2002) included 48 patients with recurrence (on whom data were 
available). Of these, 15 had only local recurrence (tumour bed or anastomosis), 26 distant 
metastases only, six had a combination and two had peritoneal seeding, i.e. multiple 
widespread tumour deposits throughout the peritoneal cavity (in combination with local 
or liver recurrence). The mean time to diagnosis of recurrence was 24 months. 
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Russell and co-workers studied a large group of patients with tumours proximal to the 
peritoneal reflection (Russell et al., 1984). They initially described 245 patients who 
presented with disseminated disease. The liver was the only site of metastases in one 
third, and liver involvement was present in 80%. Other common types of metastases 
included unresectable proximal lymph nodes, direct invasion of a wide variety of other 
structures and peritoneal seeding, which was the only type of dissemination in 7.5% of 
this group. They followed a further 550 patients who had undergone surgery with 
curative intent, of whom one-third suffered recurrence, 72% within 2 years. Local 
recurrence (tumour bed, anastomosis, contiguous organs) occurred in 30%, and was the 
sole site of recurrence in 13%. Nodal involvement or peritoneal seeding was the sole site 
in 18% and some component of recurrence in almost 40%.22% had liver metastases 
alone. The same group studied the results of post mortem examinations on 53 patients 
who died with evidence of recurrent colorectal cancer after previous apparently curative 
resection (Russell et al., 1985). Ten patients had recurrence only in the operative bed or 
retroperitoneal nodes; 23 had disease confined to the abdomen, with 30 having 
widespread dissemination to sites including lung and brain. 
In another paper focussing on colonic cancer (Willett et al., 1984) over 500 patients 
underwent potentially curative surgery, and 31 % suffered recurrence in some form. 19% 
suffered local recurrence, with only one third of these having local recurrence alone. This 
relatively small proportion may be due to the classification of peritoneal surfaces and 
proximal lymph node groups as distant metastatic sites. 
An Austrian series (Schiessel et al., 1986) reported local recurrences in 90 of 715 patients 
having radical surgery for colorectal cancer (13%). Three-quarters of these patients had 
local recurrence only (defined as tumour growth in the region of the primary operation). 
Only one sixth of recurrences occurred more than two years after surgery. They noted 
that local recurrence was significantly more likely after treatment for rectal rather than 
colonic cancer. Very similar results were noted in a group of 500 Italian patients (Stipa et 
al., 1991). 31 % of patients relapsed, with 13.6% having local recurrence. One quarter of 
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the patients with local recurrence also had distant metastases. Again, local failure was 
commoner after treatment for rectal cancer. 
The impact of more modem imaging on detection of recurrence can be seen if these 
series are compared with that of (Cass et aI., 1976). This older series found a similar 
overall recurrence rate of 37%, but described 27% of patients as having some component 
oflocal recurrence. Perhaps some of these patients also had disseminated disease, which 
would have been detectable with ultrasound or CT scanning. This is not an isolated 
series, with others also reporting higher rates of local failure (Chung et al., 1983). Of the 
29% who developed recurrent disease, isolated local failure was found in almost half, and 
80% had some element of local recurrence. 
In summary, the overall rate of recurrence in these series of patients undergoing surgery 
thOUght to be curative was 30-35%. The variable definition of local recurrence makes 
comparison of the series difficult, as does the exclusion of rectal tumours from some 
studies, but between 13% and 80% of those patients whose disease recurs have some 
component of local recurrence. Isolated local recurrence is seen in 6-50% of those who 
suffer recurrence (typically 10%). 
1.4 Prevention, prediction, detection and treatment of local recurrence in colorectal 
~ 
1.4.1 Prevention of local recurrence 
The problem of local recurrence in rectal cancer has received particular attention in 
recent years, with developments in surgical technique and the increasing use of 
radiotherapy. As we will see, the rate of recurrence, and particularly local recurrence, is 
significantly higher in those patients with rectal rather than colonic cancer. Although this 
could reflect differences in tumour biology, it is more likely that the surgical 
inaccessibility of the rectum is responsible for much of the difference. Initially the 
problem was thought to relate to inadequate length of bowel excision distal to the tumour. 
However, it has been demonstrated that tumour deposits are very rarely found within the 
bowel wall more than 2cm distal to the primary tumour. The work of Heald in 
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popularising the concept of total mesorectal excision (TME) and of Quirke, in 
emphasising the need for accurate pathological assessment of the lateral or 
circumferential resection margin has focus sed attention in this area. 
Even recent review articles quote rates of local recurrence in rectal cancer as being as 
high as 40 or 50%, with rates of25% in the 'best centres'(Radice and Dozois, 2001; 
Temple and Saettler, 2000). Reports from single surgeons using TME have demonstrated 
local recurrence rates below 5% (MacFarlane et al., 1993). The TME procedure involves 
careful dissection in the so-called 'holy plane' around the mesorectal fascia, along with 
preservation of the pelvic nerves. For tumours of the middle and lower thirds of the 
rectum the whole mesorectum is excised, down to the pelvic floor; for tumours of the 
upper third the mesorectum is divided at least five centimetres below the tumour. This 
policy results from the detection of tumour deposits up to 5cm distal to the tumour in the 
mesorectum, but not in the bowel wall. It has proved possible to transfer the benefits of 
TME to other centres, with appropriate training of surgeons (Martling et al., 2000). This 
study reported the reduction in local recurrence rates, permanent stoma formation and 
mortality following the introduction ofTME surgery in Stockholm. 
Another mechanism for reducing local recurrence after rectal cancer surgery is the use of 
radiotherapy (1996). The rate of local recurrence was halved in this study, and a survival 
advantage was apparent. Radiotherapy has been considered further in section 1.2.1.2. 
Adequate surgical technique is also likely to be beneticial in reducing the local 
recurrence rate in colonic tumours (Read et al., 2002). In a study of over 300 patients, 
local control was achieved in 96% at 5 years with the use of careful anatomical resection 
and proximalligation of blood vessels. 
In patients with risk factors for local recurrence, such as perforation or invasion of 
adjacent organs, some authors advocate the use of chemotherapy within the peritoneal 
cavity (Sugarbaker, 1998). This can be used during surgery, when it is often heated to 
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enhance the cytotoxic effects, and also during the first few post-operative days. Full 
assessment of the role of this treatment awaits further research. 
1.4.2 Prediction of local recurrence 
Along with the interest in reducing local recurrence after rectal cancer surgery, there has 
been growing interest in the use of pathology to predict those at increased risk. Adequate 
assessment of the circumferential margin of the specimen requires specific preparation 
and examination techniques. Of the quarter of cases with involved margins in one study 
(Quirke et al., 1986),85% suffered local recurrence, compared with 3% in the group with 
clear margins. Circumferential margin involvement also reduces survival, and is 
suggested as a tool for surgical audit and the monitoring of surgical training programmes 
(Birbeck et al., 2002). 
Considering the prediction of the likelihood oflocal recurrence in all colorectal tumours, 
a number of authors have described a consistent set of risk factors. Those describing 
patterns of recurrence, plus others (Chung et aI., 1983; Michelassi et aI., 1990; Phillips et 
aI., 1984) describe a greater risk oflocal recurrence with: 
• Increasing stage of penetration of the bowel wall by primary tumour (advancing T 
stage) 
• Advancing Dukes' stage 
• Poorly differentiated tumours 
• Tumours presenting with bowel obstruction 
• Tumours clinically fixed to surrounding structures 
• The presence of vascular or lymphatic invasion 
• Rectal cancers compared with colonic cancers, and left rather than right colonic 
tumours. 
Efforts to increase the rate of detection of cancer cells in the peritoneal cavity, as a 
marker for bowel wall penetration (and therefore a risk factor for local recurrence) are 
discussed in section 1.5.3. 
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1.4.3 Detection of local recurrence 
Most current efforts to identify early those with local recurrence are based on clinical 
follow up, rather than any specific techniques. Some recent evidence, from a meta-
analysis ofrandomised controlled trials (Renehan et al., 2002), suggests that intensive 
surveillance of colorectal cancer patients may be beneficial. Those subjected to an 
intensive regime trying to detect extra-mural recurrent disease (by CT scanning and serial 
CEA measurements) had improved survival, with a risk ratio for mortality of 0.73 (95% 
confidence interval 0.60 to 0.89). The most notable difference was in the proportion of 
patients diagnosed with local recurrence at an isolated, and therefore potentially treatable 
stage (15% in the group with intensive surveillance, versus 9% in the group with routine 
follow up, risk ratio 1.61). These results contrast with previous work, which has tended to 
dismiss the value of intensive follow up (Kievit, 2002). 
One problem is the difficulty of distinguishing recurrence from scar tissue using eT 
scanning or other conventional imaging modalities. One possibility to improve the 
specificity offollow up is the use of positron emission tomography (PET). This technique 
relies on the increased metabolic activity of malignant tissue, compared with normal 
tissue. It has been shown to be \00% accurate (in 23 patients with 25 lesions) in 
distinguishing granulation tissue and recurrence in the pelvis after rectal cancer surgery 
(Takeuchi et al., 1999) and is said to be more sensitive and specific than CT in imaging 
local recurrence (Arulampalam et al., 2001). PET is not currently easily available in 
many UK centres, and therefore cannot be used routinely in all patients. It may be helpful 
to identify a group who are likely to suffer from local recurrence so that best use can be 
made of the facilities available. 
1.4.4 Treatment of local recurrence 
If local recurrence can be identified while it is still localised, then potentially curative 
treatment is possible in some patients. If such treatment is feasible (usually involving 
major surgery, often with excision of adjacent involved organs) then the 5 year survival 
rate is likely to be around 40% (Stipa et al., 1991). However, in this study, only 8% of 
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those with local recurrence were suitable for such treatment, despite being involved in a 
regular follow up programme, aimed at early detection of recurrence. 
The proportion of patients amenable to radical surgery is likely to be higher if intensive 
follow up means that many local recurrences are detected before they become 
symptomatic (Schiessel et al., 1986). This group found that 42% of patients were able to 
undergo potentially curative procedures. For those patients where radical surgery is not 
appropriate, palliative surgery may help to relieve symptoms. A few long-term survivors 
may be found after palliative radio- or chemotherapy. 
In a group of patients coming to surgery for local recurrence after primary treatment of 
rectal cancer, 29% were operated on with curative intent (Suzuki et al., 1996). This 
surgery sometimes involved partial excision of the sacrum. With the addition of chemo-
and/or radiotherapy in some cases, the median survival of the 'curatively' treated group 
was 44 months, with 38% disease free after 3 years. 
If re-resection with curative intent is possible, as it was in 24% of patients in a large 
Canadian series (Obrand and Gordon, 1997), then survival is prolonged compared to 
those undergoing palliative or no treatment. In this study, 47% of the group treated for 
cure were long term survivors. 
These studies show that treatment is possible for a proportion of patients who develop 
local recurrence of their colorectal cancers. If all detectable disease can be removed, than 
5 year survival figures are in the order of 40%. The challenge is to detect patients with 
local recurrence at a stage when such treatment is possible. Intensive follow up and PET 
scanning may prove to be of benefit. Additional techniques, focussing on the detection of 
peritoneal involvement with cancer, as a marker for likely local recurrence, are discussed 
below. 
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1.5 Improving outcomes in colorectal cancer 
1.5.1 Screening and early diagnosis 
As we will see, colorectal cancer has a long and well-characterised pre-malignant phase 
(adenoma). The most attractive way to reduce deaths from colorectal cancer is to reduce 
the number of cancers developing, by detection and removal of adenomas. American 
guidelines suggest that healthy adults should enter a programme of regular colonoscopy 
from the age of fifty. Mass colonoscopy is not considered feasible in the UK at present, 
but a programme of faecal occult blood testing, with colonoscopy for those with positive 
results, has recently been tested in two pilot areas, with the English pilot site being 
Coventry and Warwickshire. The result of this, regarding both benefits and costs is 
currently being analysed. 
Another possible means of improving outcome in colorectal cancer is to ensure that 
cancers are detected at an early stage. This may be achieved in part by screening, but 
would also be helped by greater public awareness of the symptoms of colorectal cancer. 
Prompt access to the necessary assessment and investigation should also be available. 
For the future, the use of chemopreventive strategies using drugs such as non-steroidal 
anti-inflarnmatories may become an option. 
1.5.2 Techniques Used to Improve Staging of Colorectal Cancer 
As we have seen in section 1.2.2, neither of the commonly used systems for staging 
colorectal cancer is ideal. A number of alternatives have been suggested, which attempt 
to address some of their weaknesses. Some of these have entered routine practice in 
particular regions or countries, while others currently remain as research tools only. 
The Australian Clinico-Pathological staging system (Newland et al., 1987) consists of 
four main stages divided into substages. The main features of this staging system are the 
subdivision of stage B (tumour invasion beyond the muscularis propria, without lymph 
node metastases) into Bland B2 on the basis of free mesothelial surface invasion, and 
the inclusion of stage D (incurable disease due to distant metastases), which can be 
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defined either histologically or clinically (D 1 or D2). This system has been used in a 
series of over 1000 cases with 14-year follow up, and has been shown to be valid, with a 
significant reduction in survival with free mesothelial surface invasion or apical lymph 
node involvement. 
Close attention has also been paid to the relationship between the tumour and the 
peritoneal surface in the concept oflocal peritoneal involvement or LPI (Shepherd et al., 
1997). LPI was divided into four categories, with 58% of patients falling into the less 
favourable groups 3 and 4. These patients had a significantly poorer prognosis, even after 
curative surgery, and all but one of the 46 patients with intra-peritoneal recurrence or 
persistence of disease were in these groups. 
Standardised pathology reporting has been introduced for colorectal cancer specimens. 
This specifies a minimum data set to be collected for each sample submitted. It includes 
both Dukes' and TNM stage to allow it to be understood readily by all members of the 
multi-disciplinary team. Use of this standardised format allows easier collection of data 
within an institution, and submission of data to regional or national databases, allowing 
for audit of workload and results. 
One aspect emphasised is the accurate recording of the number oflymph nodes examined 
from each specimen. Under-staging of colorectal cancer is more likely to occur if only a 
few nodes are examined, although the exact number required for accuracy is unclear, 
having been estimated at between 6 and 17 per patient (Csemi et al., 2002). This group 
found that survival increased with the number of nodes retrieved, in a group of patients 
with T3NO tumours, suggesting under-staging in those with fewer nodes retrieved. The 
TNM classification suggests that 'histological examination of a regional 
lymphadenectomy specimen will ordinarily include 12 or more lymph nodes'. The 
number of nodes recovered can be increased by clearing fat from the specimen, and this 
allows some patients to be reclassified from Dukes' B to Dukes' C (Koren et al., 1997; 
Scott et al., 1994). 
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Other workers have suggested means by which the nodes obtained can be examined more 
thoroughly. Current practice involves a single section from each node being examined 
after haematoxylin and eosin staining. Research has suggested that using multiple 
sections from each node may increase the detection of metastatic disease, but this causes 
considerable extra work for the histopathologist (van Wyk et aI., 2000). The use of 
immunochemical staining also increases the yield of positive results (Isaka et al., 1999). 
The concept of the sentinel lymph node (the first node draining the tumour) has been 
popularised in breast cancer and malignant melanoma, as a means of reducing the 
morbidity oflymph node dissection. Although this aspect is not likely to be so important 
in colorectal cancer, where most of the morbidity is due to the extent of the incision and 
the risk of anastomotic failure, there is evidence that focussing on one node for more 
detailed histological examination may be helpful.(Bilchik et al., 200 I; Wood et al., 2002) 
1.5.3 Techniques for the Detection of Peritoneal Involvement 
We have seen that involvement of the peritoneal (serosal) surface with tumor cells is an 
adverse prognostic feature, and is particularly associated with local recurrence of disease. 
Because of this, interest in the detection of cancer cells on the peritoneal surface of 
colorectal tumours or in washings taken from the peritoneal cavity during surgery is 
longstanding. 
Initially the washings were analysed by cytology alone, with Giemsa or Papanicolou 
staining. Moore found positive results in 18 of 77 patients with 'curable' disease and 20 
of 43 with incurable tumours (Moo re, 1961). He did note that there were problems with 
false positive results due to the difficulty in distinguishing altered mesothelial cells from 
malignant cells based on morphology alone. 
Because of these problems, a number of groups explored the use of monoclonal 
antibodies, for example to CEA or mucin, to improve the specificity of detection of 
malignant cells in peritoneal washings. Some of the results were disappointing, with poor 
correlation between results with monoclonal antibodies and conventional cytology 
(Ambrose et al., 1989), or a very low detection rate in tumours without widespread 
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dissemination (Murphy et al., 1993). Others were more successful, detecting cancer cells 
in a quarter of patients, with the rate increasing with advancing grade and stage (Juhl et 
al., 1994). More recently, the use ofa panel of antibodies allowed the detection of 
malignant cells in peritoneal washings in 34 of 109 patients with colorectal cancer 
(Schott et al., 1998). Those with positive results had significantly poorer 4 year survival 
overall, with the same pattern being seen across all stages of disease. 
The detection of serosal surface involvement by tumour cells may be improved by the 
scraping or imprinting of cells onto a slide, immediately after removal of the tumour 
specimen. Scraping the slide over the tumour and examining the result by conventional 
cytology showed serosal involvement by tumour in 23% (Zeng et al., 1992) Imprint 
cytology detected 6 of 7 patients with histological serosal involvement, and detected a 
further 5 cases (out of 20) which were not thought to have such involvement (Murphy et 
al., 1994) 
1.5.4 Molecular Biological Techniques in Colorectal Cancer 
The powerful tools of molecular biology have been applied to patients with colorectal 
cancer in recent years. This research has been driven by a desire to improve on the 
accuracy of currently available staging techniques. The aim of using such techniques is to 
detect very small numbers of cancer cells against a background of very large numbers of 
normal cells, with greater sensitivity than can be achieved with conventional 
histopathology, or even immunochemistry. It is believed that cells detected in this way 
act as markers for the likelihood of recurrence, and that detecting them is therefore 
important for all the reasons described above, particularly selection for chemotherapy. 
Some groups have also used molecular features of the primary tumours themselves in an 
attempt to predict prognosis. 
1.5.4.1 Detection of minimal residual disease 
Much of the work has concentrated on studying lymph nodes, as involvement of these 
with tumour is already known to be a prognostic factor. The techniques have also been 
applied to the blood (both in the draining mesenteric veins and in the general circulation) 
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to look for evidence of cells that may be in the process of metastasising. Although bony 
metastases are rare in colorectal cancer, it is believed that the bone marrow could act as a 
reservoir of cancer cells which later cause disease, and therefore malignant cells have 
been sought in this compartment. Relatively little work has been published on the 
peritoneal cavity as a possible site for residual cancer cells after surgery. This is in 
contrast with the situation in upper gastrointestinal tumours, where the peritoneal cavity 
is more commonly studied. 
Although many researchers have published findings in this field, with evidence that the 
detection of particular tumour associated DNA or RNA is associated with poorer 
prognosis, this work has not been standardised. Reported rates of detection vary widely, 
as do rates of false positives with particular markers. For this reason the results of 
molecular tests are not currently incorporated in the TNM classification (Hermanek, 
1999). It is suggested that they should be recorded clearly, with the precise technique 
noted, to allow comparisons between series. If some groups incorporate the results of 
molecular tests into the TNM classification, then stage migration may occur, hampering 
comparison of results. Cells detected by molecular techniques should be described as 
isolated tumour cells, rather than micrometastases, because the latter term has a specific 
definition implying arrest and implantation of tumour cells. 
Although the ability to detect very small numbers of residual malignant cells after 
surgery seems very attractive, and would intuitively seem to suggest that such patients 
should be offered chemotherapy, it is important to consider two points. Firstly, the vast 
majority of those who are cured of colorectal cancer are cured by surgery, with those 
treated with adjuvant chemotherapy only gaining a small additional benefit. Unless or 
until more effective adjuvant treatment is available, the benefits of treating those with 
minimal residual disease, diagnosed using molecular techniques, is likely to be small. 
Secondly, until more prolonged follow up is available, the appropriate degree of 
sensitivity for molecular tests is not clear. It is technically satisfying to be able to detect 
one malignant cell in a million or even ten million normal cells, but data are lacking on 
whether such cells are of any clinical significance (Sidransky, 1997). Tests that are only 
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able to detect one malignant cell in hundreds or thousands of normal cells may in fact be 
more appropriate in giving relevant prognostic information. 
The molecular biological techniques commonly used for detection of isolated tumour 
cells in colorectal cancer can be divided into two broad groups. The first and more 
commonly used group includes those techniques based on the detection of RNA, and the 
second group consists of DNA based techniques. The advantages and disadvantages of 
each, together with some examples of the results obtained, are discussed below. 
1.5.4.2 RNA based techniques 
Techniques based on the reverse transcriptase polymerase chain reaction (RT-PCR) 
involve the extraction of RNA from the tissue being studied, reverse transcription of this 
to form complementary cDNA and then amplification of this DNA with a polymerase 
chain reaction. These techniques have the major advantage that they can be applied to 
samples from all colorectal cancer patients, rather than those where specific mutations in 
the primary tumour have been characterised. These techniques rely on the detection of 
epithelial specific mRNA in an environment where epithelial cells would not normally be 
present, such as the bone marrow or the peripheral blood. It is assumed that all cells 
derived from epithelial tumours will express such mRNA, and this is significantly easier 
than attempting to look for particular DNA mutations, which vary from tumour to 
tumour. The relative fragility of RNA compared with DNA may also be an advantage 
because mRNA is most likely to be derived from a living cell, which could have gone on 
to form a metastasis, and not to be present freely in the circulation, or to come from a 
dead or damaged cell. 
The major disadvantage ofRT-PCR techniques is the very high rate of false positive 
results. All the suggested mRNA markers, which are used to detect isolated tumour cells, 
have produced false positive results under certain circumstances. A number of reasons 
have been suggested for these false positive results. It is possible that supposedly 
epithelial-specific mRNAs are expressed at low levels in mesenchymal tissue such as 
bone marrow (so-called illegitimate expression (Zippelius et al., 1997». If sufficient 
22 
amplification of the transcribed DNA was performed then this could result in a false 
positive result. Inflammation or hormonal effects may up regulate target mRNA 
expression. Secondly, primers may anneal to and amplify pseudo genes. These are non-
functional DNA sequences with a high degree of homology to the functional genes under 
study. Finally, epithelial cells may be introduced into the sample. This could occur during 
the passage of the venepuncture needle through the skin, and would seem likely to be a 
problem with samples collected from the peritoneal cavity during surgery, when skin and 
bowel are divided. False negative results may also be a problem because mRNA 
expressed in the primary tumour may be down regulated or lost in metastatic cells, or 
RNA may be degraded during processing (Vogel and Kalthoff, 200 I). 
Despite these problems, many groups have used RT-PCR to look for cells dispersed from 
colorectal tumours. For example, the proportion of patients with involved lymph nodes is 
increased ifRT-PCR is added to conventional histology or immunochemistry. At least 
two studies suggest that these patients have a poorer prognosis than those with no nodal 
involvement on molecular testing, but most studies are small, and a large variety of 
different mRNAs have been studied. A large number of studies have looked for 
circulating colorectal cancer cells with RT-PCR. Most of these have used 
carcinoembryonic antigen (CEA) or one of the cytokeratins (CK) as the epithelial-
specific mRNA to be sought. Many of the studies have demonstrated false positive results 
in healthy volunteers, limiting the usefulness of their results. However, most workers 
have concluded that there is an association between the presence of circulating tumour 
cells detected by RT -PCR and poor outcome (reviewed in(Tsavellas et aI., 2001). Fewer 
groups have examined the bone marrow of colorectal cancer patients, but the same 
problems of illegitimate gene expression and pseudogenes have caused problems. CK20 
is probably the marker giving the fewest false positive results. Although some studies 
have shown an adverse effect on outcome in those patients with colorectal cancer cells 
detected in this way, it is not clear whether this adds anything to standard histological 
assessment. 
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RT-PCR can be used in a quantitative fashion, with equipment such as the "Light 
Cycler". This relies on the generation of fluorescent PCR products, using specially 
designed primers, or the addition of a double-stranded DNA specific fluorescent dye, and 
the amount of product generated is recorded after each amplification cycle. An 
appropriate rate of increase of product fonnation can be defined, which may allow false 
positives from very low-level illegitimate expression of a particular mRNA to be 
reduced. This technique was used, in one study, to detect mRNA for CK20 and CEA in 
the peritoneum of colorectal cancer patients, and allowed the selection of a group of 11 
patients (out of 39) who had poorer disease free and overall survival. In this study, 
examining peritoneal washings proved a more reliable prognostic factor than the 
detection of malignant cells in the blood (Guller et al., 2002). 
1.5.4.3 DNA based techniques 
DNA based techniques rely on the polymerase chain reaction (PCR). This is used to 
amplify a specific portion of DNA millions of times over. When used to look for cancer 
cells bearing a specific mutation, either the PCR primers can be designed to produce a 
product only when mutant DNA is present (mutant-allele specific PCR, also called 
mutant-allele specific amplification or MA SA), or primers can be used which amplify 
both wild type and mutant versions of an allele, with further techniques used to 
distinguish between the two types of product (see below). 
The advantages of using DNA based techniques rather than RT-PCR are that DNA is 
more robust than RNA, reducing the risks of false negatives due to sample processing. 
The problem of illegitimate gene expression is removed by looking at the genetic code 
itself, rather than what has been transcribed from it. False positive results should not be 
caused by inflammation, which does not cause immediate DNA changes. These 
techniques are particularly important in an environment in which benign epithelial cells 
are likely to be present, where RT-PCR for epithelial specific-markers would be 
unhelpful, and this includes the peritoneal cavity around the time of surgery. 
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There are also major disadvantages of using DNA based techniques in colorectal cancer 
research. The most significant problem is the wide variety of different genetic changes 
seen in this disease. There is no single genetic mutation seen in all, or even most, 
colorectal tumours. Even when mutation of a particular gene occurs at high frequency, 
such as mutations of TP53, occurring in around 75% of cases, this consists of multiple 
different changes at different points in the gene. Because of this variability, it is not 
possible to use a single test when applying DNA-based tests in colorectal cancer. To be 
able to detect cells derived from even half of the tumours a panel of different tests is 
needed; our choice of mutations for study is discussed further in section 1.9. Indeed, 
some groups first determine the DNA sequence of commonly mutated genes by 
sequencing DNA from each tumour sample, and then design subsequent tests specifically 
for that tumour. Although the relative robustness of DNA can be advantageous, it may 
also be responsible for false positive results if DNA from lethally damaged cells can be 
detected. 
Despite these difficulties, PeR-based techniques have been used to detect colorectal 
cancer cells in a number of different body compartments. MASA has been used to 
examine histologically negative lymph nodes, and the same mutation was found in the 
node as in the primary tumour in about half of cases. Patients in this group were more 
likely to relapse than those with MA SA-negative nodes. Studying a combination of K-ras 
and TP 53 mutations meant that a mutation could be detected in 59% of the 120 patients 
studied (Hayashi et al., 1995). Ras mutations were also detected in the blood in around 
one third of those with mutations in the primary tumour, and those with mutations had a 
poorer prognosis (Hardingham et al., 1995). 
One area where DNA-based techniques may prove particularly useful is in the detection 
of mutant DNA in the stool as a potential screening test. This may eventually prove more 
reliable than faecal occult blood testing in the detection of adenomas and early stage 
cancers, because enterocytes are shed continually from the bowel surface, whereas 
tumours may bleed intermittently or not at all. The major challenge has been in extracting 
amplifiable DNA from stool, which requires special techniques to overcome the presence 
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ofPCR inhibitors. This problem has been overcome, and using a multi-target panel, 
including mutations of K-ras, p53, APC and Bat-26 (a marker of microsatellite 
instability), mutant DNA could be detected in the stool of 90% of cancer patients and 
80% of those with large adenomas (Ahlquist et al., 2000). 
Some examples of the different types of DNA based techniques are described below. A 
wide variety of different techniques is available for the detection of specific DNA 
mutations. The choice of appropriate technique depends on the exact nature of the 
mutation being studied, the type of samples available and local skills and experience. 
1.5.4.3.1 Mutant-Allele Specific PCR 
When a mutation occurring commonly in colorectal cancer has been characterised, it may 
be possible to design PCR primers, which will only amplify mutant and not wild type 
DNA. This may be straightforward in some types of mutation, for example a deletion of 
several bases, which causes considerable difference between wild type and mutant DNA. 
In the case of point mutations however, it may be very difficult to design a primer that 
will be specific enough to prevent amplification of wild type DNA when this is present in 
excess. The deliberate introduction of mismatches into the mutation specific primer, often 
in the penultimate base, may improve the specificity of priming (Newton et al., 1989). 
Nested PCR (in which the whole area of interest is first amplified, and then mutation 
specific primers used for a second round ofPCR) may increase the sensitivity of these 
tests (Iinuma et al., 2000). Other workers have used a blocking oligonucleotide, 
complementary to the wild type sequence, and having a 3' chain terminator, to improve 
the specificity of the reaction (McKinzie and Parsons, 2002). 
1.5.4.3.2 Distinguishing peR Products from Mutant and Wild Type DNA 
An alternative approach in the DNA based detection of small numbers of malignant cells 
is to use PCR to amplify the relevant gene in both normal and wild type variants, i.e. 
using primers which do not cross the mutation site. It is then necessary to use further tests 
to distinguish between the types of product generated. 
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Many ofthese tests rely on the mutant DNA having a different secondary structure, or 
being able to take up such a structure. This difference in structure may then cause 
different behaviour of the DNA during gel electrophoresis, and samples with this 
difference can then be assessed by direct sequencing. An example of such a technique is 
single strand conformation polymorphism, where peR products are thermally denatured 
before electrophoresis, and aberrantly migrating (mutant) bands can be identified. Mutant 
DNA will produce a peR product with different denaturation properties to those of wild 
type DNA. Gels with a gradient of temperature or concentration of denaturant will allow 
these products to be distinguished (Frayling, 2002). 
Restriction enzymes are also useful in distinguishing peR products derived from normal 
and mutant DNA. The presence of a mutation may either introduce a restriction site, 
allowing mutant DNA, but not wild type DNA to be cut by the relevant enzyme, or a 
restriction site may be removed by the mutation. It is also possible to design peR primers 
that deliberately introduce a restriction site, where one would not normally be present. 
This site would only be present in either mutant or wild type peR products, allowing 
them to be distinguished after restriction enzyme digestion (Jenkins et al., 2002). 
The Mismatch Ligation Assay (MLA) is another DNA based technique, useful for the 
detection of small numbers of malignant cells against a background of normal cells. The 
principle of this technique is described in detail in section 2.7.1. Briefly, it relies on the 
ability ofT4 ligase to join matched, but not mismatched oligonucleotides, with the 
incorporation of a radiolabel. As described in section 1.9, we chose to use MLA for 
detection of several mutations in the colorectal tumours we studied. The experience of 
those who have this technique for similar work is therefore reviewed here. 
Jen and co-workers (Jen et al., I 994b ) studied small dysplastic and non-dysplastic 
colorectal polyps and also microscopic aberrant crypt foci. They looked for mutations at 
codon 12A, 12B and 13 of K-ras. Ras mutations were found in 23% of hyperplastic 
polyps and 25% of dysplastic polyps. The authors also detected APC mutations using a 
different technique and suggested that an initial mutation in APC rather than K-ras was 
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more likely to cause small or microscopic colorectallesions to progress to dysplasia, with 
later ras mutations playing a part in that progression. 
Hibi and co-workers (Hibi et al., 1998) utilised the MLA technique to look for mutant 
DNA in the serum of colorectal cancer patients. They felt that identification of this 
mutant DNA may help to assess the extent of disease at the time of diagnosis. K-ras 
mutations were sought in the primary tumour and serum samples using the technique 
described by Jen. They also studied TP53 mutations by sequencing TP53 in the primary 
tumours and designing specific oligonucleotides for each mutation detected. Of 44 
tumours tested, 16 had K-ras mutations detectable by MLA, and in 3 of these patients the 
same mutation was detected in the serum. 33 tumours were tested for TP53 mutations and 
these were detected in 10 tumours. Using the specially designed oligonucleotides, the 
same mutation was detected in the serum in 7 of the patients. Of interest was the fact that 
all 3 of the patients with K-ras mutations in their serum samples had Dukes' stage C or D 
tumours whereas 5 of the 7 with TP53 mutations in the serum had Dukes' stage B 
disease. 
MLA has also been used to study lymph nodes in patients undergoing liver resection for 
colorectal metastases (Sanchez-Cespedes et al., 1999). They again detected K-ras and 
TP53 mutations, first detecting the mutations in samples from the liver metastasis to be 
resected and then using MLA to study DNA from perihepatic nodes for the same 
mutations. Standard oligonucleotides were used for K-ras and those for the TP53 
mutations were designed specifically for each tumour. They found MLA to be capable of 
detecting 1 tumour cell in 1000 normal cells. Mutant DNA was detected by MLA in 12 of 
51 nodes histologically and immunochemically negative for cancer cells. All 
histologically involved nodes were positive on MLA. Use of the molecular technique 
increased the number of patients with positive nodes from 5 to 8 out of 16, and these 
patients had a poor prognosis. The authors suggest that molecular techniques could be 
used to select a group of patients who will not benefit from aggressive surgery. 
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The possible use of these techniques as a screening tool rather than simply for 
prognostication in those known to have cancer has also been explored (Dong et al., 
2001). The feasibility of this was studied in 51 patients known to have colorectal cancer 
so that mutations found in the primary tumours could be compared with those detected in 
faecal DNA. MLA was chosen to look for TP53 mutations, and in this case, a panel of 
oligonucleotides was designed for use in 3 different reactions, which together could 
detect 9 TP53 mutations commonly found in colorectal cancer. TP53 mutations were 
detected in the primary tumours using peR and a ligation detection reaction and these 
were confirmed using MLA. The specific DNA mutations found in the stool samples 
matched those in the relevant tumour and TP53 mutations were only found in the stool 
samples of those having mutations in their primary tumours. This technique may be 
useful for screening in the future if it can be confirmed that adenomas shed sufficient 
DNA and if an appropriate panel of mutations can be studied to allow detection of most 
adenomas. 
MLA has also been used to study mutations in mitochondrial DNA in the serum of 
patients with colorectal cancer (Hibi et al., 2001). Mutations in the primary were detected 
by sequencing and the oligonucleotides for MLA were designed individually for each 
tumour with a mutation. 7 out of 77 tumours had mitochondrial DNA mutations and the 
same mutation could be detected in the serum of I of these 7 patients. 
Another group using MLA found K-ras mutations in 31 out of90 patients, and 11 of 
these (35%) had mutant DNA detectable in their serum, including patients with Dukes' A 
tumours (Ito et al., 2002). 
1.5.5 Molecular markers of prognosis in colorectal cancer 
In addition to the role of molecular biology in detecting minimal residual disease, the 
presence of particular mutations in a primary tumour may give information about the 
likely prognosis. Unfortunately, for many markers such as TP53 mutation, the 
relationship with prognosis has not been straightforward, probably due to the complex 
range of different mutations in particular genes, and their interaction with other gene 
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products (Roth, 1999). However, a number of possible molecular markers of prognosis 
have been described. 
Although TP53 mutation itself is not a clear prognostic marker, such mutation appears to 
be associated with a poorer response to chemotherapy (lacopetta, 2003). Cytoplasmic 
(but not isolated nuclear) staining for p53 was also associated with a poorer prognosis 
(Sun, 1992). 
Various allelic losses have been demonstrated to occur commonly in colorectal cancer. 
Loss of 18q has been consistently associated with worse outcome. Indeed, in patients 
with Dukes' stage B tumours, those without loss of 18q had 93% 5-year survival, 
compared with 54% in those with loss of 18q (Jen et al., 1994a). 
As we will see, a subset of colorectal tumours arises by a pathway known as 
microsatellite instability. Although there is some conflicting data, it appears that this 
group of tumours does have a relatively favourable outcome (Houlston, 200 I). 
With the advance of 'gene chip' technology, capable of analysing the expression of 
thousands of genes from a particular tumour, it is likely that, in the future, it will be 
possible to group tumours with common features together, allowing targeted follow up 
and treatment (Walker and Quirke, 2002). 
1.6 The genetic basis of Colorectal Cancer 
In order to benefit from the potential of these molecular biological techniques to detect 
minimal residual disease, or to predict recurrence, it is necessary to understand the 
genetic basis of colorectal cancer. 
As with all cancers, colorectal carcinogenesis involves alterations in DNA. Malignant 
cells arise from successive rounds of mutation, with clonal expansion of the cell with the 
newly mutated genotype, because it has acquired a growth advantage. These mutations 
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allow growth to occur beyond what is needed to maintain normal structure and function, 
and allow eventual migration of cells away from their original sites. 
In this section, I will review the more important genetic changes that occur in colorectal 
carcinomas. Most of these tumours arise in patients with no particular genetic 
predisposition (sporadic cancers) and are due to acquired DNA damage, occurring at the 
somatic cell level, through exposure to environmental carcinogens etc. There are, 
however, two distinct types of colorectal cancer that show a clear-cut pattern of 
inheritance, and the germ line mutations found in these conditions can give us useful 
information about the genetic changes occurring in sporadic cases. Although similar 
genetic changes occur in both inherited and sporadic forms of colorectal cancer, the 
inheritance of one of the relevant mutations means that cancer occurs at a much higher 
frequency, and at a younger age, in those with one of the syndromes discussed below. 
1.6.1 Inherited Predispositions to Colorectal Cancer 
1.6.1.1 Familial Adenomatous Polyposis (F AP) 
F AP is an autosomal dominantly inherited condition, which accounts for about I % of 
colorectal cancers, and has a popUlation incidence of about one in 8000. It is due to a 
germ-line mutation in the adenomatous polyposis coli (APe) gene, which as we will see 
is also important in sporadic colorectal cancer. The mutations in FAP commonly cause 
formation of an inactive truncated protein product. Patients develop large numbers of 
colorectal adenomas throughout their colons beginning in childhood or early adult life 
and, if untreated, colorectal cancer is inevitable at an early age. This type of mutation is 
also associated with other abnormalities such as duodenal tumours and abdominal 
desmoids and, in some cases, congenital hypertrophy of the retinal pigment epithelium 
(CHRPE). Individuals in affected families (identified on the basis of their history) are 
offered genetic screening (if the relevant mutation has been characterised). Those with 
the mutation, or where the mutation has not been characterised, require screening by 
endoscopy, when the typical multiple polyps can be seen. About one quarter of cases are 
due to a new mutation. Treatment is surgical, with excision of the at-risk mucosa by 
colectomy, often with formation of an ileal pouch. In members of families with an 
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attenuated form of the disease, with less than 100 adenomatous polyps, an ileo-rectal 
anastomosis with continued rectal surveillance may be used. 
A number of other germ line APC mutations have been described. Unlike those seen in 
FAP, they do not cause protein truncation, but cause amino acid substitution. The effects 
of this are not as severe as FAP, but consist of multiple adenoma formation and familial 
clustering of colorectal cancer. These missense mutations appear to exert a mild 
dominant negative effect (Fearnhead et al., 2001; Frayling et al., 1998). 
An animal model with an inherited APe mutation, the min mouse (multiple intestinal 
neoplasia) develops multiple small bowel polyps and tumours. These mice show an 
increased rate of production of new crypts in the intestinal mucosa by crypt fission. The 
molecular mechanisms by which APC mutations cause colorectal cancer are discussed 
below (section 1.6.3.1). 
1.6.1.2 Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
HNPCC is another autosomal dominantly inherited condition giving rise to colorectal and 
other malignancies (especially endometrial cancer). These patients were originally 
described as suffering from 'Cancer Family Syndrome' (Lynch et al., 1966). HNPCC 
causes about 5% of colorectal cancers and has a population incidence of around 1 in 500. 
As the name implies, the increased risk of colorectal cancer does not occur due to 
widespread polyposis (unlike FAP). About 80% of patients with a germ line mutation of 
one of the genes affected in HNPCC develop colorectal cancer, and their tumours occur 
at a younger age than those with sporadic cancers (Lawes et al., 2002). The tumours are 
more likely to occur on the right side of the colon (two thirds proximal to the splenic 
flexure), and are, on average, of more favourable Dukes' stage when compared with 
sporadic tumours. Some studies suggest that survival is also improved, compared to 
patients with sporadic cancer of the same stage. Patients with HNPCC do develop colonic 
adenomas, at a similar rate to the normal population, but these progress to cancers more 
rapidly than sporadically occurring adenomas, because the abnormality in HNPCC 
involves genes concerned with DNA repair (see below). This contrasts with FAP where 
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patients develop far more adenomas than the normal population but each progresses 
towards cancer at a normal rate (Kinzler and Vogelstein, 1996). 
HNPCC affected families are identified using the Amsterdam criteria: 
At least three affected relatives in at least two generations 
One must be a first degree relative of the other two 
Two successive generations must be affected 
At least one person aged less than 50 at diagnosis of colorectal cancer 
F AP should be excluded 
Tumours must be verified pathologically. 
These criteria have recently been broadened to include cancers of the endometrium, small 
bowel, ureter or renal pelvis (all of which are rare in the general population) as well as 
colorectal cancers. 
Members of affected families are offered screening. In about 70% of cases a specific 
mismatch repair gene mutation can be identified, and molecular screening performed. 
Only those family members with the specific mismatch repair gene mutation are at 
increased risk of colorectal cancer and require follow-up. Those with the relevant 
mutation and those from families where a mutation cannot be identified require 
surveillance by colonoscopy. 
1.6.2 Colorectal Carcinogenesis- The Adenoma~Carcinoma Sequence 
The genetic events leading to colorectal cancer formation have been particularly well 
studied, when compared with other cancers. This has been possible because colorectal 
cancer is common, its development from normal tissues, through adenoma to carcinoma 
is well characterised, and because of the availability of material for study from various 
stages of development of tumours. This is due to the frequent and relatively non-invasive 
removal ofpre-malignant lesions, and the routine excision of both primary colorectal 
tumours and metastatic lesions. 
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There is a large amount of both clinical data (from the study of patients with untreated 
polyps) and histopathological data (including the frequent occurrence of adenocarcinoma 
within an existing polyp) to suggest that the vast majority, if not all, colorectal cancers 
arise within pre-existing benign lesions. These adenomas probably arise in 
hyperproliferative areas of epithelium, and gradually increase in size, become more 
dysplastic and develop villous (rather than tubular) morphology. Although developing 
continuously, the stages of adenoma development can be conveniently considered as 
early ($ lcm diameter), intermediate (> lcm diameter, without focus of cancer) and late 
(> I cm and containing focus of cancer). It is proposed that step-wise progression through 
the stages occurs through the accumulation of multiple genetic changes. 
Typical genetic changes at each stage involving well-known oncogenes and tumour 
suppressor genes have been described, and many of these are discussed in more detail 
below. For example, the earliest change normally involves chromosome 5q (the site of 
the APe gene), and this occurs with the change from normal to hyperproliferative 
epithelium. The K-ras and BRAF genes typically are mutated during the change from 
early to intermediate adenoma. The TP53 gene is rarely mutated in adenomas, but its 
mutation is said to be characteristic of the change from adenoma to carcinoma. Further 
changes, involving cell adhesion molecules, and tissue proteases occur during the change 
to a metastatic phenotype. Although these mutations characteristically occur at different 
stages in the adenoma-carcinoma sequence, generally it is the accumulation of a number 
of different mutations rather than their exact sequence that is significant (Fearon and 
Vogelstein, 1990). It is likely that most tumours require four to six independent mutations 
in order to progress. 
1.6.3 The Major Genes Subverted in Colorectal Cancer 
Mutations occur in both oncogenes and tumour suppressor genes. Oncogenes are cellular 
genes, which are activated in carcinogenesis. These genes often control normal growth 
and development, and gain cancer-promoting potential by a change either in their coding 
region or in their regulation. The version of the gene present in normal cells is called the 
proto-oncogene. This can be mutated to produce a product that has increased activity, 
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more of a normal product (by modification of gene regulation) or a product with a 
prolonged active life. Any of these changes can increase the rate of replication of cancer 
cells. Mutations of oncogenes act in a dominant fashion, with only one copy of the gene 
needing to be mutated to have the cancer-promoting effect. An example of an oncogene 
commonly mutated in colorectal cancer is K-ras. 
Tumour suppressor genes are genes that are inactivated in carcinogenesis. These genes 
typically function to control or restrain cell proliferation. Because these genes function in 
a recessive fashion, loss of function normally requires changes to both alleles of the gene 
in a particular cell (Knudson's two hit hypothesis (Knudson, 1971)). Often the first copy 
is inactivated by mutation (cf APC in F AP), with the second being destroyed by a 
deletion or insertion or by loss of heterozygosity. Occasionally, as with TP53 mutations, 
the first allele to be mutated causes the formation of a protein which binds to and inhibits 
the function of the normal protein, and this mutation is described as a dominant negative. 
APC is an example of a suppressor gene commonly mutated in colorectal cancer. Further 
examples of oncogenes and tumour suppressor genes are given in table 1.1. 
Oncogenes in colorectal cancer Tumour suppressor genes in colorectal cancer 
K-ras APC 
BRAF TP53 
CTNNBl hMLHl 
hMSH2 
E-cadherin 
TGFBR 
Table 1.1 Oncogenes and tumour suppressor genes in colorectal cancer 
Since these genes are frequently altered in colorectal carcinoma, potentially they all can 
be used to identify cancer cells and so detect minimal residual disease. Hence, I shall 
discuss each in turn, particularly the ones studied in this thesis. 
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1.6.3.1 Somatic APe mutations 
Acquired (somatic) mutations in the APe gene, as opposed to the germ line mutations 
occurring in FAP, occur in about 80% of cases of sporadic colorectal cancer. Mutations 
generally occur at an early stage of the adenoma-carcinoma sequence (see above), and 
have been noted in adenomas less than Smm in diameter. APe is a large gene with over 
8S00 base pairs in 21 exons, although most mutations occur in exon IS, which contains 
7S% of the coding sequence. Almost all somatic APe mutations involve a truncated 
protein product with abnormal function. 
APC is involved in a number of different cellular functions, abnormalities of which can 
contribute to malignant change in cells. Probably the most significant change occurs in 
the Wnt signalling pathway. This pathway plays a key role during normal animal 
development in a wide variety of organisms. In the absence of a Wnt signal, cytoplasmic 
j3-catenin is destabilised by a complex including axin and the APC protein. When Wnt 
stimulation occurs, axin is removed from the j3-catenin-binding complex, and j3-catenin 
moves to the nucleus where it stimulates DNA transcription, acting as a co-activator ofT 
cell factors (Tc£). Absence of functional APC, or impaired function due to protein 
truncation, leads to a reduction in the destabilisation of j3-catenin. The APe mutations 
commonly found in colorectal tumours lead to a loss of j3-catenin degradation sites 
(Bright-Thomas and Hargest, 2003). The build up ofj3-catenin leads to an activation of 
transcription of a number of genes including c-myc and cyclinD 1, which is involved in 
controlling progress through the cell cycle. This is illustrated in figure 1.1. Many 
colorectal tumours that do not have APe mutations have other mutations affecting the 
Wnt signalling pathway (see section 1.6.3.2). Polyps form after APe mutation because 
activated Tcf causes cells to remain as crypt cells rather than differentiating and 
migrating up crypts to be shed (Bienz and Clevers, 2000). 
APe has been described as having a 'gatekeeper' role in colorectal tumorigenesis. 
(Kinzler and Vogelstein, 1996) Gatekeeper genes are responsible for maintaining a 
balance between cell division and cell death. APe seems well suited to this role in the 
colon for a number of reasons. Firstly, APe mutations are detectable in the earliest 
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neoplastic lesions in the colon, very small adenomas. Secondly, patients with FAP do not 
develop a large range of other cancers, suggesting a specific role for APC in the large 
bowel. Thirdly, cells with TP53 or K-ras mutations, but with wild type APC, do not 
progress to form clinically important tumours. Therefore, it appears that APC mutations 
are the exception to the rule that the order in which mutations occur in colorectal cancer 
is unimportant. 
Figure 1.1 The function of APe and ~-catenin in normal and mutant forms. The first 
panel illustrates the normal role of APC and glycogen synthase kinase 3 (GSKJ) in 
targeting l3-catenin for destruction. This pathway is inhibited by the Wnt signalling 
pathway acting via frizzled and dishevelled (DSH). The second panel illustrates the 
situation in the absence of functional APC; levels of l3-catenin increase, and it acts as a 
cofactor for Tcf-4 causing transcription of target genes. The fmal panel shows the 
situation when l3-catenin is mutated and cannot be targeted for destruction by APC. 
Again, transcription of target genes is increased. (E-cad= E-cadherin, see section 1.6.3.7) 
From Fearon, Human Cancer Syndromes: Clues to the origin and nature of cancer (1997). 
A variety of other roles for APC have been described, and suggested as additional ways 
in which mutation of APC causes colorectal cancer. These include cell-cell adhesion, 
cytoskeletal stability, cell cycle regulation and apoptosis. All these complex interacting 
pathways are undergoing further research. 
1.6.3.2 B-catenin 
As djscussed above, an alternative means by which the Wnt signalling cascade can be 
inappropriately activated in colorectal cancer, is through mutation of l3-caterun (see 
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Figure 1.1). In colorectal tumours without APC mutations, point mutations have been 
found in the gene coding for J3-catenin (CTNNB1), which render it refractory to 
destruction by the APC complex (Bienz and Clevers, 2000). Experimental evidence has 
demonstrated colorectal cancer cell lines with wild type APC, but with constitutive 
activity in the J3-cateninlTcftranscription pathway, and these cell lines have been shown 
to have mutations in CTNNBl (Morin et al., 1997). APC and J3-catenin mutations in 
colorectal cancer appear to be mutually exclusive, giving a low overall frequency of 13-
catenin mutations, for example 2 of 92 tumours in one series and 9 of 202 in another. 
When only tumours with wild type APC are considered, J3-catenin mutations were found 
in as many as 13 of 27 tumours (Polakis, 2000). J3-catenin mutations are also seen more 
commonly in tumours with microsatellite instability (see section 1.6.3.3) than those 
which are microsatellite stable. 
1.6.3.3 DNA mismatch repair genes 
As described above, HNPCC occurs due to a germ line mutation of one of a number of 
DNA mismatch repair (MMR) genes such as hMSH2 and hMLHl. The same mutations 
are also found in a proportion of sporadic tumours, in perhaps as many as 15% of cases. 
The role of the products of these genes is to check for errors occurring in DNA after 
replication, and to excise and replace mismatched bases. DNA repair is important 
because the genome may undergo tens of thousands of modifications per day, each of 
which could lead to residual damage. Absence or deficiency of MMR allows DNA 
mutations to accumulate, predisposing to cancer if present as a germ line mutation, or 
allowing tumour progression if occurring in a tumour. Mutation rates in tumours with 
MMR deficiency are 2 to 3 orders of magnitude higher than those seen in normal cells 
(Kinzler and Vogelstein, 1996). 
DNA mismatch repair gene mutations can be detected by studying areas of DNA with 
repeated bases. These areas, known as microsatellites, will be unstable in cases of 
HNPCC, or in sporadic tumours with MMR mutations. Such tumours are said to have 
microsatellite instability (MSI). MSI is detected by using PCR to amplify five regions of 
DNA containing repeated sequences. MS} causes alteration in product length, or 
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appearance of a new band above or below the expected band. Tumours with MSI have 
abnormalities in 2 or more of the 5 markers. Some workers have described a group of 
tumours with low level MSI, and abnormality of only one marker, but these tumours do 
not share the characteristics of MS I tumours (Ward et al., 2001). Sporadic tumours with 
MSI share a number of clinical and pathological characteristics when compared with 
microsatellite stable (MSS) tumours. They are more likely to be found in the right colon, 
to be poorly differentiated, of mucinous phenotype and to contain increased numbers of 
intraepitheliallymphocytes. TP53 mutations (see section 1.6.3.6) are much less frequent 
in MSI tumours. MSI tumors have been reported to present at an earlier stage and have a 
better stage for stage prognosis than MSS tumours. Although these trends were 
confirmed in Ward's study, the differences did not reach statistical significance. 
One gene commonly mutated in MSI tumours is that coding for the RH subunit of the 
TGF-~ receptor (TGFBR). TGF-~ normally acts in a growth-inhibitory fashion on 
colorectal epithelial cells. The affected gene contains a repeated polyadenine sequence, 
which is mutated in about 90% of MSI tumours, introducing premature stop codons and a 
truncated protein product (Markowitz, 2000). 
A similar situation is seen with mutations in the gene for hTCF4, leading to uncontrolled 
transcription of its target genes (see above). Such mutations are found in 50% of MS I 
tumours, but rarely in micro satellite stable tumours (Bright-Thomas and Hargest, 2003). 
1.6.3.4 K-ras 
The products of the ras genes, p21 ras, play a key role in growth factor signalling 
pathways. Ras genes were named because they were first described in rat sarcoma 
viruses. There are several members of the ras family, with K-ras taking its prefix from 
the Kirsten murine sarcoma virus in which it was first described. K-ras codes for one of a 
series of proteins involved in transduction of signals between the cell membrane and the 
nucleus. Normal p21 ras is active when bound to GTP, but not when bound to GDP. The 
intrinsic GTPase activity ofp21 ras hydrolyses GTP to GDP and controls p21 ras activation. 
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K-ras is located on the cytoplasmic surface of the cell membrane, and receives input 
signals from several different pathways. Its most important effect in terms of proliferation 
is its attachment to RAF, which it recruits to the cell membrane. The serine kinase 
activity of RAF is normally inhibited, but binding to p21 ras removes this inhibition. RAF 
is the first in a series ofkinases, and activates subsequent members of the cascade, 
culminating in the phosphorylation and therefore activation of the transcription factor c-
jun (Peyssonnaux and Eychene, 2001). 
Mutations of K-ras occur in approximately 50% of colorectal cancers and large adenomas 
(Fearon and Vogelstein, 1990). These occur most commonly in codons 12 and 13, with 
codon 12B the most frequent site. Codon 12 represents part of the GTP binding region of 
the molecule, and mutation leads to decreased GTPase activity. Because the mutated 
p21 ras is unable to hydrolyse GTP to GDP, it is constitutively activated and this leads to 
increased cell proliferation. An activating mutation such as this only needs to occur in 
one allele to have its effect on the cell. Although specific chemical mutagens have been 
described which cause ras mutations in rats, the cause of K-ras mutations in human 
colorectal cancer is not known. Ras pathways are attractive targets for drug development 
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because they are affected in so many types of human cancer. To date, however, no 
successful drugs have been produced. 
Mutations in K-ras may have effects on other pathways in colorectal tumorigenesis. For 
example, activation of the p21 ras driven cascade (involving RAF and other enzymes) 
induces Mdm2, which causes degradation ofp53. Thus, in tumours with ras mutations, 
the function ofp53 can be impaired even in the absence of mutation. (Ries et al., 2000). 
Activation of the ras pathway also causes release of~-catenin from its interaction with E-
cadherin (see below), and stabilises free ~-catenin within the cell (Bright-Thomas and 
Hargest,2003). 
1.6.3.5 BRAF 
As I have indicated, the raj gene product transmits the growth factor signal from p21 ras 
onwards through the other MAP kinases. Because of this association, and the 
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identification of a constitutively active form of raj as a viral oncogene, rqf was chosen as 
one of the initial targets for the systematic search for mutations in human cancers that has 
developed from the Human Genome project. When a pathway includes one member 
known to be involved in many types of cancer, other members of the pathway are 
considered good targets for study. The knowledge of the DNA sequence for the whole 
human genome is giving the opportunity for researchers to seek out new cancer-
associated mutations, to increase our knowledge of the biology of various cancers, and 
perhaps, eventually, provide new treatments. One of the first discoveries in this process 
has been the finding of mutations in the BRAF gene. 
Workers at the Sanger Institute reported that BRAF somatic missense mutations were 
found in two-thirds of malignant melanomas, and a smaller proportion of a variety of 
other cancers.(Davies et al., 2002) These mutations were initially detected using 
sequencing techniques, in a small panel of cancer cell lines where a lymphoblastoid cell 
line was available from the same patient for comparison. After establishing the presence 
of acquired mutations, a much larger panel of cell lines, and then the genomic DNA from 
a large number of primary human cancers was studied. In DNA from primary tumours, 
BRAFmutations were detected in 6 of9 melanomas, 4 of33 colorectal tumours and 5 of 
35 ovarian tumours. A trend was noted for BRAF mutations to occur in tumour types 
known to have a greater proportion of cases with ras mutations. 
Almost 90% of the mutations found in BRAF occurred within the activation domain, most 
commonly a single base substitution at codon 599. This mutant was shown to have ten 
times the basal kinase activity when compared with wild type BRAF. Normally, amino 
acids in the activation domain require phosphorylation, which occurs when the BRAF is 
recruited to the cell membrane by activated p21 ras. The BRAF mutations described in this 
activation segment appear to mimic phosphorylation and hence activate kinase activity in 
the absence of p21 ras signalling. Cells with this mutation were able to continue 
proliferating in culture after the addition of a p21 ras neutralising monoclonal antibody, 
indicating that this mutation uncouples the cell from its requirement for p21 ras function. 
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Of interest is that none of the samples with codon 599 BRAF mutations had a ras 
mutation. 
Further work has confirmed that BRAF mutations are found in almost 10% of colorectal 
tumours. (Rajagopalan et al., 2002) This group studied 330 cases of colorectal neoplasia, 
finding BRAF mutations in 32, with 28 of these being a single T to A transversion at 
position 1796 (codon 599). In the same set of tumour samples, 169 had ras mutations, but 
no sample had both mutations (p< 10-6). This could be expected since both function in the 
same pathway. 
Both Ras and BRAF mutations occurred at all stages of cancer and were commoner in 
adenomas over Icm diameter rather than smaller lesions. These results support the theory 
that Ras and BRAF mutations have similar effects in tumorigenesis, and occur at a 
similar stage in the adenoma- carcinoma sequence. An interesting difference between Ras 
and BRAF mutant tumours is that BRAF mutations are considerably more common in 
mismatch repair deficient tumours (Le. tumours with MS I) compared to those with a 
proficient mismatch repair system. This pattern is not seen with Ras mutations, and is 
evidence that the specific mutation spectrum seen in a tumour depends on the underlying 
cause of genetic instability. (Kinzler and Vogelstein, 1996) 
BRAF mutations in colorectal cancer have also been studied in samples obtained from 
patients in Hong Kong (Yuen et al., 2002). In this group, 5.1 % of colorectal cancers (11 
of 215) had BRAF mutations, with only four of these being the T to A mutation at base 
1796. There was no significant association of BRAF mutation with patient age or gender, 
or tumour site or differentiation. BRAF mutations were more common in tumours of less 
advanced Dukes' stage, but in this study, no association with MSI was shown. This group 
also studied colorectal adenomas and concluded that BRAF mutations occur in the 
adenoma stage, i.e. a similar stage to Ras mutations. 
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1.6.3.6 TP53 
TP53 is described as the "Guardian of the Genome" because its major function appears to 
be in maintaining the genetic integrity of cells (Lane, 1992). This it does by controlling 
the apoptotic pathway to eliminate DNA-damaged cells. TP53 is mutated or lost in over 
half of all human cancers. In colorectal cancer this figure is around 75%, with TP53 
mutations tending to occur at the stage of progression from a severely dysplastic 
adenoma to an invasive cancer (Navaratnam et aI., 1999). 
The nonnal function of p53 is to block the progress of a cell into mitosis if DNA damage 
is present, enabling DNA repair to proceed. If the damage cannot be repaired then the cell 
will undergo apoptosis, so that DNA mutations are not passed on to its daughter cells. 
Nonnal p53 activity is triggered by DNA damage, which is recognised by various 
molecules involved in cell cycle checkpoints. This leads to phosphorylation ofp53, 
which changes it from a latent into an active fonn. The stability ofp53 is also increased 
by being released from Mdm2. p53 increases the expression of proteins that block the cell 
cycle, allowing DNA repair to occur if possible (Houlston, 2001). If this is not possible, 
apoptosis begins to occur within a few hours of damage occurring, but this is absent in 
cells lacking p53. 
If a cell has lost the function of p53, it is able to divide with damaged DNA, passing on 
mutations to the next generation of cells. A large number of different TP53 mutations 
have been described, but all disrupt the ability ofp53 to bind to DNA, and therefore to 
perfonn its function as 'guardian of the genome'. As stated previously, TP53 mutations 
are an example of a dominant negative effect. p53 functions as a dimer, and when a 
heterodimer is fonned with one mutant and one wild type p53 this is not able to bind 
DNA. This means that only one mutant allele is sufficient to impair p53 function (King). 
Functioning p53 can also reduce the rate of cancer progression by killing cells that 
attempt to divide in oxygen-poor regions of tumours; mutant p53 cannot prevent such cell 
division. Tumours with TP53 mutations may respond poorly to radio- and chemotherapy, 
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because these treatments depend, for at least part of their effect, on cell suicide in 
response to DNA damage. When TP53 is mutated, such suicide is less likely to occur 
(King). 
1.6.3.7 E-cadherin 
E-cadherin (epithelial cadherin) is a member of a family of adhesion molecules 
concerned with intercellular contacts and the maintenance of normal tissue structure. The 
intracellular portion of E-cadherin binds to ~-catenin. It has a dual role of promoting 
intercellular adhesion and inhibiting cell mobility (Navaratnam et al., 1999). Loss of E-
cadherin expression, which is found in about half of colorectal tumours, has been 
associated with tumour progression, invasion and metastasis. Experimental E-cadherin 
activation causes growth inhibition in tumour cell lines. Despite this important role, the 
loss of E-cadherin protein expression is not due to mutation or allele loss. Instead, 
hypermethylation of the promoter region of the gene has been shown to be responsible 
(Garinis et al., 2002). Lack ofE-cadherin may release ~-catenin, increasing levels within 
the cell. If this cannot be broken down because of a lack of functioning APC, this may 
lead to increased activation of the Wnt signalling pathway. These interactions are 
illustrated in figure 1.2. 
E-Cadherin ligand binding domain 
plasma membrane 
E-Cadherin intracellular domain 
I cytosol 
proteasome 
Figure 1.2 Interaction of E-cadherin, IJ-catenin and APC 
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1.6.4 Cell cycle control in colorectal cancer 
All cells that are continuing to divide pass through the cell cycle. This is closely regulated 
at a number of stages, to ensure that the number of cells in a population remains stable, 
and that each daughter cell has one perfect copy of the DNA in the parent cell. One 
method by which cancer cells escape from normal control is by evading the so-called 
mitotic checkpoints that regulate the cell cycle. This allows the accumulation of 
mutations. One study showed that over 90% of colorectal tumours had abnormalities in 2 
or more cell cycle control factors (McKay et al., 2002). 
Misregulation of growth factors may increase the proportion of cells actively cycling by 
driving cells from the quiescent state GO where they are viable, but not dividing, into 
cycle and then past the 'restriction point' beyond which further mitogenic signalling is 
not required. The normal cell cycle with the position of the two major checkpoints is 
illustrated in figure 1.3. 
Growth factors 
G 1 checkpoint - p105RB 
~G1 _________ / 
GO \ 
s 
M~ (G2 G2/' checkpoint 
daughter cell 
Figure 1.3 The cell cycle. GO quiescent cells, G I actively cycling cells, S synthesis of 
DNA, G2 pause before mitosis, M mitosis, pI 05RB retinoblastoma protein. 
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Early in G 1, the retinoblastoma protein, plOSRB is bound to the transcription factor E2F. 
During GI, plOSRB is phosphorylated by cyclin dependent kinases. This releases E2F, 
which is then able to cause transcription of genes such as DNA polymerase. producing 
enzymes necessary for DNA synthesis in S phase (Sherr, 1996). Phosphorylation of 
pl0SRB is normally prevented by kinase inhibitors such as p 16INK. P 16INK is 
commonly mutated in cancer cells, allowing phosphorylation of p IOSRB, and this 
releases the cells from the G 1 mitotic checkpoint. The same result is also achieved in 
those tumours with loss ofpl0SRB function. 
Cyclin dependent kinase/cyclin complexes are also inhibited by p21 WAFI • One of the 
ways in which pS3 inhibits cell cycling in the presence of damaged DNA is by acting as a 
transcription factor, increasing the levels of p21 WAFI and thus limiting progress through 
the cell cycle. Cancer cells without functioning pS3 lose this regulatory mechanism 
(Wang et al., 1999). 
The G2 checkpoint controls entry to mitosis. Again, this checkpoint involves the 
combination of a cyclin dependent kinase (cdc2) and a cyclin (cyclin B), which binds to 
cdc2, priming it for activation. Final activation depends on the balance between a kinase 
(weel) and a phosphatase (cdc25). The breakdown of wee 1 at the entry to mitosis allows 
activation of the complex, which migrates to the nucleus and causes nuclear membrane 
breakdown. Cyclin genes are frequently over expressed in cancers, pushing the balance 
towards progress through the cell cycle. 
Further checkpoints occur during mitosis (M phase checkpoints) preventing progression 
of mitosis unless all chromosomes are correctly replicated and aligned on the mitotic 
spindle. Failure of this mechanism results in aneuploidy, commonly seen in those 
colorectal cancers developing via the micro satellite stable (chromosomal instability) 
pathway. 
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1.7 Hypothesis 
We have seen that local recurrence is a significant problem for patients with colorectal 
cancer. It has been well documented that the best predictor of local recurrence is an 
advanced stage of the primary tumour, and in particular the presence of free malignant 
cells on the serosal surface of colonic tumours, or circumferential margin involvement in 
the case of rectal cancers. A considerable amount can be done to improve on the standard 
of current staging by careful attention to these aspects by the pathologist. However, 
despite careful pathological examination of the resected specimen, it can sometimes be 
difficult to be certain whether the serosal surface has been breached. Even careful 
examination of the specimen cannot give information about what is happening in the 
peritoneal cavity in the days following surgery, after the specimen has been removed, 
when tumour cells could be shed from cut lymphatic channels. 
We hypothesise that the detection offree malignant cells in the peritoneal cavity during 
the resection of a colorectal tumour, or in the post-operative drain fluid, could act as a 
marker for serosal involvement, circumferential margin involvement or the leaking of 
tumour cells from cut lymphatics into the tumour bed. The presence of such cells would 
therefore put patients into a group at increased risk of recurrent disease, particularly local 
recurrence. Given the paucity of work using molecular biological techniques to examine 
the peritoneal cavity in colorectal cancer, we also hypothesise that the use of such 
techniques may allow a greater proportion of such patients to be detected. 
1.8 Aims 
Our primary aim was to describe techniques to permit identification of isolated malignant 
cells in the peritoneal cavity of patients undergoing surgery for colorectal cancer, both 
during surgery (in peritoneal washings) and in the first two days after surgery (in post-
operative drain fluids). 
Secondary considerations were to relate our results to the stage of tumour at presentation, 
and to follow the patients with both positive and negative results, to attempt to relate our 
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results to later patterns of recurrence and survival. We wished, if possible, to attempt to 
quantify any malignant cells detected. Finally, if techniques for detecting cells in this 
environment were successfully developed, we wished to streamline them as far as 
possible, to increase the applicability of our results in routine practice. 
1.9 Experimental Strategy 
In order to achieve these aims we obtained ethical approval to collect samples from 
patients undergoing surgery for gastrointestinal cancer. Initially we collected samples 
from those with gastric or oesophageal tumours, as well as colorectal cancer patients. 
However, the results from the upper gastrointestinal samples were disappointing, perhaps 
because they have a different mutation spectrum from colorectal tumours. This policy 
was therefore abandoned, and only samples from colorectal cancer patients were 
collected. 
We decided to attempt to increase the proportion of epithelial cells in our peritoneal 
samples by subjecting them to an enrichment step using MACS (magnetic activated cell 
separation). This technique had been used in our laboratory previously for a number of 
different types of sample from colorectal cancer patients, with considerable success 
(Wong et al., 1997). The necessity for this step was later considered in a series of 
experiments recorded in chapter 7. 
As described above we elected to use molecular biology techniques to look for malignant 
cells in our peritoneal samples. This decision was made because of the reported 
sensitivity of theses techniques in the detection of very small numbers of malignant cells 
against a background of normal cells. It was also interesting to apply these techniques to 
a site that had received relatively little attention in colorectal cancer. We elected to use 
techniques to detect specific DNA mutations, rather than to use RT-PCR based methods. 
This decision was made because of the disadvantages of using RNA based techniques, 
described in section 1.5.4.2. We feared these would present particular problems in our 
situation for several reasons. Firstly, the samples, particularly the drain fluids, were not 
kept in ideal conditions for the preservation of good quality RNA. Indeed, we did attempt 
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to extract RNA from some of our samples in order to try to achieve our aim of 
quantifying any malignant cells detected, and sufficient good quality RNA could not be 
obtained. Secondly, non-malignant epithelial cells may be present in the peritoneal cavity 
around the time of surgery, from skin or divided bowel ends, and these would be detected 
by tests designed to distinguish epithelial cells rather than those with specific mutations. 
Finally, the problems of illegitimate mRNA expression, leading to false positive results, 
may be increased by inflammatory stimuli, such as surgery. 
Given the paucity of previous data on the use of molecular techniques to detect cancer 
cells in the peritoneal cavity, it was not possible to make any sensible prediction about 
the likely rate of positive samples. Because of this uncertainty, we were unable to make a 
power calculation regarding the number of tumours and peritoneal samples to be studied. 
We chose to collect as many samples as could be processed by a single worker in the 
time available. 
Among the many different types of test described to detect mutant DNA, we chose to use 
mainly the Mismatch Ligation Assay (MLA). The reasons for choosing this were 
primarily practical; papers were available describing clearly the necessary 
oIigonucleotides and reaction conditions to detect common K-ras and p53 mutations 
(Dong et al., 2001; Jen et al., I 994b ), which we had selected as our initial targets, and the 
techniques need to perform the MLA were in use by other workers in our laboratory. The 
techniques had also been shown to be useful in detecting mutant DNA in a number of 
different environments (reviewed in section 1.5.4.3.2). 
We elected to use the same technique to first look for mutations in the primary tumour 
samples and then, when a mutation had been detected, to study the peritoneal samples 
from that patient. This had the advantage of allowing us to develop our mutation 
detection techniques on samples with adequate amounts and concentrations of DNA, and 
where we would expect a significant proportion of cells to contain the mutation being 
studied. One alternative to this strategy would have been to perform direct sequencing on 
the tumour samples, looking for mutations commonly associated with colorectal cancer, 
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and then to examine the peritoneal samples for the same mutation with a different 
technique. 
We chose K-ras as our initial target mutation because, although it is only mutated in 40% 
to 50% of tumours, most of these mutations are concentrated at a particular site (codon 
12B). About 75% of col or ectal tumours have mutations of TP53, but these mutations 
occur at a large number of different sites within the gene. The particular TP53 mutation 
we chose to investigate was selected for the practical reason that a cell line with that 
mutation was available as a positive control. 
Rather than continue to repeat the work of others by attempting to detect further TP53 
mutations as described by Dong, we decided to explore other mutations, and the APe 
gene, mutated in almost all micro satellite stable tumours, was an obvious target. 
Although this a very large gene, with a huge variety of documented mutations, there are 
two 'hot-spots' (Fearnhead et al., 2001) which are sensible targets for research of this 
type. After initial difficulties in attempting to design MLA oligonucleotides, described in 
section 4.7.3, it finally proved possible to detect one of these mutations with a mutant-
allele specific peR. 
BRAFwas recently shown to be mutated in several forms of human cancer, including 
about 10% of colorectal cancers. The fact that most of these tumours have a single point 
mutation (T ~A at codon 599) made this an appropriate target for detection with MLA. 
In addition, this mutation has not been found in tumours with mutations of K-ras (this 
because both activate the same growth factor signalling pathway), and thus the ability to 
detect BRAF mutations would increase the proportion of cases in which we were able to 
detect a mutation. The design of a MLA to detect BRAF mutations is described in section 
4.7.4. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Patient selection and recruitment 
We obtained ethical approval from the South Warwickshire Local Research Ethics 
Committee (reference number RE464, January 2001). Patients were approached if 
they were undergoing elective surgery for colorectal cancer, or occasionally, in the 
early stages of the project, for upper gastrointestinal tumours. A number of patients 
with benign disease were invited to take part as controls. During the early part of the 
project we only approached patients if we anticipated that a drain would be placed at 
operation, but later in the study a number of patients not having drains were included. 
The consultant surgeons vary in their use of drains for different procedures, but no 
patient had a drain placed solely because of this project. We explained the reasons for 
the project, the nature of samples to be collected and the need for review of the notes 
in the future for follow up. We gave patients an information sheet, which they were 
encouraged to read and retain. If they agreed to participate in the study, we asked 
them to sign a consent form. Copies of the patient information leaflet and consent 
form are given in the appendix, together with the Ethics Committee approval letter. 
2.2 Sample collection 
Peritoneal washings were collected at the start and end of surgery. Approximately 
150-200ml of 0.9% saline (at 37°C when available) was introduced into the peritoneal 
cavity by the operating surgeon. This was gently agitated for a few seconds and then 
as much as possible (typically about 100ml) was aspirated with a 60ml catheter tip 
syringe and collected in a gallipot. After this was handed out from the sterile field we 
added approximately 800 units ofunfractionated sodium heparin. The sample was 
divided into up to four 50ml sterile Falcon tubes (Sarstedt, Numbrecht, Germany), 
each containing approximately 25ml of RPM I 1640 tissue culture medium (Gibco 
BRL, Paisley, UK) with 10% (v/v) foetal calf serum (Life Technologies Ltd., Paisley, 
UK) and mixed. The addition of the medium and the serum was to provide better 
transport medium than the saline, which contains only sodium and chloride ions and is 
unbuffered. The sample was held at 4°C until returned to the laboratory. 
The washing at the start of surgery ('pre-operative wash') was obtained as soon as the 
surgeon had access to the tumour to be resected. On most occasions this was 
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immediately after opening the abdomen and performing the initial laparotomy, 
however at times this was delayed by the need to take down adhesions or to perform 
some preliminary dissection to allow the wash to be instilled around the area of the 
tumour. For tumours below the peritoneal reflection, the initial wash was made in the 
pelvic cavity after lifting out the small bowel, but before the pelvic dissection was 
begun. The wash towards the end of surgery ('post-operative wash ') was performed at 
some convenient time after resection of the tumour, and usually after formation of any 
necessary anastomoses. We instilled saline into the part of the abdomen or pelvis from 
which the tumour had been resected, and removed it as described above. For 
oesophageal tumours, which were resected by a two-stage Ivor-Lewis procedure, the 
'pre-operative wash' was performed on opening the pleural cavity rather than in the 
abdomen. 
Once the tumour specimen was removed from the patient it was handed out of the 
sterile field. Outside the operating theatre it was cut open, with care not to impair the 
later pathological assessment. Any intestinal contents were washed off with tap water 
and a small piece of visibly and palpably malignant tissue was excised using scissors. 
We divided this into 2 and put the pieces into separate freezing vials, which had been 
pre-cooled in liquid nitrogen. The vials were returned to the liquid nitrogen and 
transported back to the laboratory where they were stored at -80De until needed. 
At the end of the procedure, if a drain was used, we put a label on the collection bag 
asking the nursing staff on the ward not to empty the drain, to allow fluid to build up 
for collection the following morning. Approximately 500 units of the sodium heparin 
solution were introduced through the drainage port of the collection bag to help to 
prevent the sample from clotting. 
We collected samples from the drain bag or bottle on the first and second post-
operative mornings, while the patient was on the ward or intensive care unit. Up to 
lOOml of drain fluid was collected and any residual fluid was discarded to allow fresh 
drain fluid to collect over the subsequent 24 hours. Samples were not routinely kept 
cool while in the drain bag or after collection but were returned promptly to the 
laboratory for processing. 
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Information about patient demographics, site of tumour, operation and surgeon's 
assessment of whether the procedure was curative, was collected at the time of 
surgery and stored in an Excel spreadsheet. Histological information was collected 
once the formal report had been prepared and was added to the spreadsheet. 
2.3 Treatment of peritoneal washings and drain fluids 
We performed density centrifugation and MACS on each sample on the day it was 
obtained. 
2.3.1 Density centrifugation 
We removed red blood cells from the peritoneal washings and drain fluids by density 
centrifugation. Samples in SOml Falcon tubes were centrifuged at 1600 rpm for 10 
minutes. Supematants were discarded and the cell pellets resuspended in RPMI 1640 
medium with 10% FCS. If the sample had been collected in multiple tubes these were 
combined at this point, and the total volume made up to ISm!' The cell suspension 
was layered onto 10ml of Lymphoprep (Sodium Diatrizoate 9.1% w/v and 
Polysaccharide 5.7% w/v, Axis-Shield, Oslo, Norway) in a 2Sml universal container 
(Scientific Laboratory Supplies, Nottingham, UK). This was centrifuged at 1600 rpm 
for 30 minutes. The mononuclear cell layer at the interface, containing Iymphocytes 
and any epithelial cells present was then aspirated using a Pasteur pipette, taking care 
not to aspirate Lymphoprep. The aspirated layer was placed in a ISml Falcon tube and 
the volume made up to ISml with RPMI 1640 with 10% FCS. This was centrifuged at 
1600 rpm for 15 minutes. The supematant was discarded, and the pellet resuspended 
in ice cold PBS. We counted the number of cells retrieved using a haemocytometer 
(Neubauer improved, Marienfeld, Germany), having first mixed the cells with an 
equal volume of trypan blue (Sigma-Aldrich, Irvine, UK) to ensure only viable cells 
were being counted. 
2.3.2 Magnetic activated cell separation (MACS) 
2.3.2.1 Principle of technique 
MACS was developed in Germany in 1990 as a technique to allow separation of cells 
in suspension into different types, depending on their cell surface markers (Miltenyi et 
al., 1990). The technique involves the use of magnetic microbeads, which are less 
than IS0nm in diameter. This tiny size means that cell viability and function is not 
53 
affected when the microbeads bind to the cell, and cells can be used for cell culture, 
flow cytometry and other molecular biological techniques after MACS separation. 
Cells labelled with microbeads are passed through a magnetisable matrix (in the form 
of a column), placed in a strong magnetic field, and are trapped in the column. When 
the column is removed from the magnet the labelled cells are eluted. MACS can be 
used in two main ways, for enrichment or depletion of cell populations. In enrichment 
procedures (also called positive selection), microbeads are attached to the cell type of 
interest, and these cells are initially retained in the magnetised column while 
unwanted cells run through. The required cells are then eluted after removing the 
column from the magnet. Positive selection is demonstrated in Figure 2.1 a and b. In 
depletion procedures the 'unwanted' cell type in a mixture is magnetically labelled, 
and the cells of interest are allowed to run through the magnetised column, with the 
labelled cells retained. 
Figure 2.1a Principles of MACS enrichment. Labelled cells (red) are trapped in 
the magnetised column (magnet shown in green) while unlabelled cells (blue) pass 
through and are collected as the negative fraction 
Figure 2.th Principles of MACS enrichment continued. When the column is 
removed from the magnet, the labelled epithelial cells are eluted, and collected as 
the positive fraction. 
MACS has found a variety of uses, particularly in separation oflymphocyte subsets. It 
has also been used in a number of different applications in cancer research, and has 
been shown to be capable of enriching epithelial tumour cells 10,000-fold in blood 
samples, increasing the probability of detection of circulating turnour cells (Martin et 
al., 1998). Previous work in this laboratory used MACS, combined with 
immunochemistry to detect circulating tumour cells in patients with colorectal cancer 
(Wong et al., 1995). Ber-EP4 was found to be the most suitable primary antibody for 
labelling unf1xed cells from clinical samples, and therefore was chosen for use in this 
study. It has also been demonstrated (Latza et al., 1990; Sheibani et al., 1991) that 
Ber-EP4 does not cross react with mesothelial cells. This is particularly important in 
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trying to improve the sensitivity of any separation involving samples from the 
peritoneal cavity, which is lined with mesothelial cells. The disadvantage of using 
Ber-EP4 is that this antibody is not available directly conjugated to magnetic 
microbeads. It is therefore necessary to use a two-stage antibody labelling process, 
using a mouse anti-human Ber-EP4 antibody and then a secondary anti-mouse 
antibody (usually goat), which is bound to magnetic microbeads. 
2.3.2.2 MACS Methods 
For most of the peritoneal samples, (washings and drain fluids) the whole sample was 
subjected to MACS separation. Samples from the last 17 patients were split at this 
stage, with halfbeing used for MACS and the remainder being left without separation 
(see chapter 7, Is MACS Necessary?). The protocol for MACS is given in the 
appendix. Briefly, the cells were washed in ice cold PBS, incubated with the primary 
antibody (mouse anti-human Ber-EP4, DAKO AlS Glostrup, Denmark), washed again 
and incubated with the secondary antibody (goat anti-mouse IgG, conjugated to 
magnetic microbeads, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). After 
being washed again, they were resuspended in ice cold MACS buffer (PBS with 2mM 
EDTA (Gibco BRL) and 0.5% bovine serum albumin (Sigma Aldrich». Samples 
were run into a miniMACS column (Miltenyi Biotec) held in a specially designed 
magnet, and the negative fraction of unlabelled cells was washed through. After 
removing the column from the magnet, the positive fraction of cells was eluted. For 
reasons of economy, we reused each miniMACS column once, for samples from the 
same patient, after washing it with approximately 10 column volumes of ice-cold 
MACS buffer. We counted the number of cells in both fractions for the first 85 
samples, and in the positive fraction only in later samples. Cells in both positive and 
negative fractions were pelleted by centrifugation at 3000rpm for 8 minutes, the 
supernatant was removed and the cells stored at -80°C until needed. 
2.4 DNA Extraction 
2.4.1 Tumour samples 
Tumour samples were removed from the freezer and kept on dry ice. We ground each 
tumour sample, under liquid nitrogen, with a separate pestle and mortar, which had 
previously been heated to 200°C overnight to destroy any contaminating DNA. The 
ground tumour was placed in a pre-cooled Eppendorf, and DNA was extracted using 
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the 'Tissue Protocol' of a Qiagen DNA mini kit (Qiagen, Hilden, Germany). The 
average lysis time was 3 hours at 56DC. DNA was eluted in buffer AE (as supplied 
with kit, total volume 400~1) and stored at _20DC until needed. DNA in a number of 
samples was quantified using a spectrophotometer. 
2.4.2 Cell pellets from peritoneal samples 
DNA from these samples was extracted using the 'Blood and body fluids spin 
protocol' of a Qiagen DNA mini kit. Where fewer than 105 cells were in any fraction, 
then 1~1 ofa solution ofpolydeoxyadenylic acid (polydA), 5~g/~1 (Sigma-Aldrich) 
was added at the start of DNA extraction. DNA was eluted in buffer AE (between 50 
and 200~1, depending on starting number of cells) and stored at _20DC until needed. 
DNA in a number of samples was quantified using a spectrophotometer. 
2.5 PCR (polymerase chain reaction) 
We performed PCR to amplify exon 1 of K-ras, exon 8 ofp53 and exon 15 of BRAF. 
Details of primer sequences and reaction conditions are given in the appendix. Details 
about optimisation of peR reactions and pictures of typical gels are shown in chapter 
4. Each peR performed included a negative control, with no DNA, to detect any 
contamination. PCR products were mixed with loading dye (orange G (Sigma 
Aldrich) in 30% glycerol), and loaded into a 1 % agarose gel, containing ethidium 
bromide (Sigma Aldrich, 0.3~g/ml of gel). The products were separated using a 
voltage of 100 to 150V, depending on size of gel. The gel was imaged under 
ultraviolet light, and results recorded photographically. If a clear band of the 
appropriate size was seen after electrophoresis, then the PCR products were frozen at 
-20De until needed. 
2.6 Mutant allele specific PCR 
Mutant- allele specific peR was used to detect mutations at codon 1309 of the APe 
gene. Details of primers and reaction conditions are given in the appendix; 
information on optimisation is in chapter 4. Each reaction included a negative control, 
with no DNA, a positive control, with DNA from a tumour cell line known to have 
the specific mutation under study, and DNA from a healthy volunteer, as a control for 
the specificity of the reaction. Each tumour DNA was examined at least twice. The 
more stringent conditions described in chapter 4 were used to examine tumour DNAs. 
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The more sensitive but less stringent conditions were used to look for mutant DNA in 
the peritoneal samples, where DNA concentrations were typically lower. 
2.7 Mismatch Ligation Assay (MLA) 
2.7.1 Principle of Technique 
The Mismatch Ligation Assay (MLA) is a technique based on the ability of two 
oligonucleotides to anneal adjacent to one another on a complementary DNA strand. 
These oligonucleotides will only be joined covalently by a DNA ligase if the 
nucleotides on either side of the join are correctly base-paired. (Landegren et al 1988) 
This specificity allows single nucleotide mutations to be distinguished. 
The relevant segment of target DNA, derived from a primary tumour sample or from 
a cell pellet from a peritoneal sample is amplified using peR. The target DNA is 
denatured, and two oligonucleotides are permitted to hybridise to it. One 
oligonucleotide is complementary to the mutant DNA sequence being sought (i.e. 
mutation specific). Up to three possible mutation-specific oligonucleotides can be 
used in each reaction, being complementary to the three possible non-wild-type bases 
at the site of mutation. The other oligonucleotide is designed to anneal immediately 3' 
of the mutation site i.e. with its 5' end adjacent to the 3' end of the mutation-specific 
oligonucleotide. The 5' end of this oligonucleotide is radiolabelled with 32p. When 
mutant DNA is present in the target sample the two oligonucleotides can be joined by 
DNA ligase and the 32p is incorporated into the DNA chain. A blocking 
oligonucleotide, complementary to the wild type sequence, is present in excess, to 
prevent any binding of the mutant-specific oligonucleotides to wild type DNA. 
Alkaline phosphatase is added to the reaction and is able to remove 32p from any 
oligonucleotides that are not incorporated by the ligase reaction. The reaction 
products are separated by denaturing polyacrylamide gel electrophoresis and detected 
using a phosphoimager. Figures 2.2a, band c illustrate the situation occurring in the 
presence of mutant DNA, wild type DNA binding to blocking oligonucleotide, and 
wild type DNA binding to mutation specific oligonucleotide respectively. 
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32p 
TTGGAGCTGCTGGCGTAGG 
TCGAC<fACCGCA 
T4 LIGASE ~ 
. 3~ 
TTGGAGCTGCTGGCGTAGG 
-------TCGACGACCGCA--------
Figure 2.2a MLA in the presence of mutant DNA. This shows annealing of 
mutation specific (shown in red) and end labelled (shown in blue) oligonucleotides to 
mutant K-ras (shown in black, with mutation site in red). The oligonucleotides are 
joined by T4 ligase, because they are correctly matched, and 32p is incorporated into 
the DNA chain. 
AGCTGGTGGCG 
---------TCGACCACCGC--------
Figure 2.2b MLA with wild type DNA binding to blocking oligonucleotide. This 
shows annealing of blocking oligonucleotide (shown in green, present in excess) to 
wild type K-ras 
32p 
TTGGAGCTGCtGGCGTAGG 
TCGACCACCGC 
T4 LIGASE 1 
32p 
TTGGAGCTGCtGGCGTAGG 
TCGACCACCGC 
ALKALINE PHOSPHATASE 1 
TTGGAGCTGCTGGCGTAGG 
TCGACCACCGC 
Figure 2.2c MLA when mutation specific oligonucleotide anneals to wild type 
DNA. If a mutation specific oligonucleotide anneals to wild type K-ras it cannot be 
ligated to the end-labelled oligonucleotide because of the mismatch. The 32p is 
therefore not incorporated and is removed by alkaline phosphatase. 
59 
2.7.2 Method for MLA 
A detailed protocol for each variation of this assay is given in the appendix, together 
with details of the suppliers of enzymes. In summary, the relevant oligonucleotide 
was first labelled with 32p at its S' end, by incubation with T4 polynucleotide kinase, 
32pyATP and the relevant buffer. The T4 kinase was then heat inactivated. We 
prepared a master mix including mutation specific and blocking oligonucleotides, 
together with spermidine (Sigma-Aldrich), T4 gene 32 protein (to stabilise single 
stranded DNA, Roche, Mannheim, Germany) and T4ligase buffer made to the 
appropriate volume with 0.9% saline. The relevant PCR product was added to each 
tube and the labelled oligonucleotide was also added. Each reaction included one 
sample with PCR product of the relevant exon from a cell line known to have the 
mutation being studied, as positive control, and one sample with PCR product of the 
relevant exon from the DNA of a healthy volunteer, as a negative control. The 
mixture was heated to 9SoC for S minutes to denature the PCR products and then 
allowed to cool for IS minutes at room temperature while annealing occurred. We 
then added T4ligase and incubated for I hour at 37°C followed by heat inactivation. 
Alkaline phosphatase with the appropriate dephosphorylation buffer was then added 
and incubated for 30 minutes at 37°C. Each sample was mixed with a denaturing 
loading dye, containing formarnide, and heated again to 90°C for S minutes before 
being loaded into a pre-warmed 12% denaturing polyacrylamide gel. 
Electrophoresis was performed at 300V, with O.S x TBE as running buffer. The 
samples were run as far as possible, to achieve maximum separation between reaction 
products and the solvent front. After electrophoresis we soaked the gel in 10% acetic 
acid, 20% methanol for 10 minutes and then 20% glycerol for 30 minutes. The gel 
was dried overnight under 2SmmHg vacuum with heating to 80°C for the first 3 hours 
of drying. Gels were wrapped in cling film and placed in a previously 'blanked' 
phosphoimager cassette for approximately 4 hours. Images were collected using a Fuji 
phosphoimager and analysed using Image Quant software. 
2.8 Cell culture 
The cell lines shown in table 2.1 were maintained in culture to provide material for 
spiking experiments and DNA for use as positive controls. All these cell lines are 
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derived from human colorectal tumours. All cells were grown in the medium shown, 
with the addition of 10% v/v foetal calf serum (Life Technologies Limited), 2% v/v 
200mM L-glutamine (Gibco BRL) and 500U penicillin and 500llg streptomycin 
(Sigma-Aldrich). RPMI 1640 medium (without L-glutamine, with Na HC03) was 
obtained from Gibco BRL, and L-15 medium, without L-glutamine was obtained 
from Sigma-Aldrich. 
All cell lines were maintained in an incubator at 37°C with 5% carbon dioxide. The 
medium was changed once or twice per week and the cells were subcultured when 
confluent, after trypsinisation. Cell lines grown in LI5 medium were cultured in non-
vented flasks; all others were cultured in vented flasks. 
Cell line ATCC Source Medium used Mutation 
No. 
HT-29 HTB-38 Or A Morris RPMI1640 P53 codon 273, 
BRAF codon 599 
SW480 CCL-228 ATCC L-15 and RPMI P53 codon 273, 
1640 K-ras codon 12 
LS1034 CRL-2l58 ATCC RPMI1640 APC codon 1309 
COLO 205 CCL-222 Or A Morris RPMI1640 BRAF codon 599 
SW1417 CCL-238 Or A Morris L-15 APC codon 1450, 
BRAF codon 599 
Table 2.1 Table showing details of cells maintained in culture. 
Information about particular mutations found in various colorectal cancer cell lines 
was found on the website of the American Type Culture Collection (ATCC, 
www.atcc.org) or from the literature (Fearnhead et al., 2001; Gayet et al., 2001) 
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CHAPTER 3: PATIENT DEMOGRAPHICS AND HISTOLOGY 
3.1 Patient Selection and Patient Details 
Samples were collected from 58 patients undergoing major abdominal surgery at 
Warwick Hospital between 25/4/01 and 11/9/02. Operations were performed by one of 
the 3 surgeons having a special interest in gastrointestinal surgery and only patients 
having elective procedures were included, to allow sufficient time for informed consent 
to be obtained. Only 2 patients declined to take part in the research project, both were 
extremely anxious about their forthcoming surgery. 
Of the 58 patients, 53 underwent surgery for neoplastic disease. After some early samples 
were used to prepare techniques. 50 tumour samples from 47 patients were searched for 
mutations. These were 44 colorectal cancers. 2 colorectal adenomas and 4 upper 
gastrointestinal cancers. 3 oesophageal and one gastric. As discussed in section 1.9 the 
patients with upper gastrointestinal tumours are not considered fUlther, because their 
tumours were not amenable to analysis using the same tests applied to the colorectal 
tumours. Samples from the remaining 5 patients. who underwent surgery for benign 
diseases. were used to optimise techniques and to assess sensitivity after adding cells 
from cultured colorectal cancer cell lines. Details of the 43 patients with tumours used in 
the study are shown in table 3.1. together with infonnation about the type of tumour 
(adenoma or cancer) and the operation performed. 
Details of the patients with benign diseases. whose samples were used as controls, are 
shown in table 3.2. 
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tumour no age sex op date diagnosis operation performed 
I 73 female 08/05/2001 eRe right hemicolectomy 
2 82 female 12/06/2001 eRe right hemicolectomy 
3 67 male 14/06/2001 eRe anterior resection 
4 66 female 19/06/2001 Adenoma anterior resection 
5,6* 60 male 19/06/2001 eReleRe panproctocolectomy 
8 84 male 28/06/2001 eRe sigmoid colectomy 
9 71 female 05/07/2001 eRe anterior resection 
ID 75 male 18/07/2001 eRe anterior resection 
12 78 male 06/09/2001 eRe Ipanproctocolectomy 
13 74 female 11/09/2001 eRe completion colectomy 
14 74 male 26/09/2001 eRe anterior resection 
16 62 male 05/10/2001 eRe abdominoperineal resection 
17 56 male 11/1012001 eRe anterior resection 
18 77 female 18/10/2001 eRe anterior resection 
19 81 female 04/12/2001 eRe right hemicolectomy 
20 78 male 0511212001 eRe anterior resection 
21 73 male 08/01/2002 eRe extended right hemicolectomy 
22 57 female 12/03/2002 eRe right hemicolectomy 
23 74 male 13/03/2002 eRe SB resection & Hartmanns 
24 70 female 19/03/2002 eRe left hemicolectomy 
25 80 male 19/03/2002 eRe sigmoid colectomy, SB resection 
26 59 female 25/03/2002 eRe anterior resection & hysterectomy 
27 63 female 28/03/2002 eRe anterior resection 
28 75 female 08/0412002 eRe right hemicolectomy 
29 67 male 10/04/2002 eRe anterior resection 
30 82 male 11/04/2002 eRe abdominoperineal resection 
31 68 female 16/05/2002 eRe anterior resection & hysterectomy 
32 73 female 19/06/2002 eRe anterior resection & hysterectomy 
33 54 male 26/06/2002 eRe extended right hemicolectomy 
34 73 male 26/0612002 eRe right hemicolectomy 
35 60 female 27/06/2002 eRe left hemicolectomy 
36,37· 55 male 10/07/2002 eRe/eRe left hemicolectomy 
38,39· 73 male 25/07/2002 Adenoma/eRe right hemi. and anterior resection 
40 56 male 30/07/2002 eRe left hemicolectomy 
41 54 female 31/07/2002 eRe right hemicolectomy 
42 52 male 01/08/2002 eRe anterior resection 
43 54 female 06/08/2002 eRe left hemicolectomy 
44 75 male 08/08/2002 eRe left hemi. & SB resection 
45 77 female 21/08/2002 eRe anterior resection 
46 68 female 0410912002 eRe abdominoperineal resection 
47 84 male 09/09/2002 eRe anterior resection 
48 76 female 10/09/2002 eRe extended right hemicolectomy 
49 73 male 11/09/2002 eRe right hemicolectomy 
Table 3.1 Information about the patients with colorectal tumours recruited to the 
study. CRC colorectal cancer, SB small bowel, * 2 tumours from same patient 
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control operation 
no. age sex date diagnosis operation 
1 52 male 03/05/2001 colitis panproctocolectomy 
2 60 female 12/06/2001 crohns disease right hemicolectomy 
3 53 female 05/07/2001 colitis proctectomy 
4 37 male 12/07/2001 diverticular disease sigmoid colectomy 
5 76 female 05/09/2001 diverticular disease anterior resection 
Table 3.2 Information about participating patients with benign diseases. 
3.2 Pathological Data 
Data were collected in a standardised way from the pathology reports issued by the 
histopathologists at Warwick Hospital. Although most specimens were reported on by a 
pathologist with a special interest in gastrointestinal tumours this was not universal. In 
the later part of the study, colorectal cancer specimens were reported according to a 
standard minimum data set. Information was collected on degree of tumour 
differentiation, presence of a mucinous component, modified Dukes' stage, TNM stage, 
macroscopic invasion of adjacent organs, whether preoperative treatment had been given 
with chemotherapy and/or radiotherapy and whether the surgeon considered that the 
operation was curative, palliative or uncertain. This data collection was modified for 
adenomas. Table 3.3 shows the pathological data concerning the cancers collected, and 
table 3.4 shows data about the adenomas. 
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Tumour Dukes' Differentiation TNM surgeon's comments 
number stage stage assessment 
I A mucinous T3NOMX curative vel}' high CEA pre operativcly 
2 8 moderate T3NOMX uncertain clinically T4, stuck to ileum 
3 D moderate T3N2MI palliative ~e-~erative radiotherapy 
5 8 well/moderate T3NOMX uncertain 
6 8 well/moderate T3NOMX uncertain 
8 8 moderate T3NOMX uncertain 
9 A moderate T2NOMX curative 
10 A moderate TINOMX curative 
12 D moderate T3NIMI Ipalliative multiple large po~ 
13 8 moderate T3NOMX curative APR 1996. Tumour stuck to SB 
14 8 moderate T3NOMX curative 
16 C2 poor T2N2MX curative ~evious local excision (pT2) 
17 8 moderate T3NOMX curative 
18 Cl moderate T3NIMX curative 
19 A moderate T2NOMX curative 
20 Cl moderate T2N2MX curative 
21 Cl mucinous/moderate T3N2MX curative 
22 Cl well/moderate T3NIMX curative 
23 moderate Ipalliative recurrent CRC. R hemi. Jan 200 I 
24 B moderate T4NOMX uncertain local perforation 
25 D moderate T4N2MI Ipall iati ve ~erforation. Bladder & SB stuck 
26 8 mucinous/moderate T4NOMX ~alliative perforation. Invading uterus 
27 D moderate T4N2MI palliative local abscess 
28 B moderate T3NOMX curative 
29 B mucinous/moderate T3NOMX curative 
30 Cl moderate T3NIMX curative 
31 B moderate T4NOMX uncertain abscess. Stuck to POD/vagina 
32 B moderate T3NOMX curative IPre-op radiotherapy/ defunctioned 
33 Cl moderate T3NIMX curative trace of ascites 
34 B moderate T3NOMX curative 
35 Cl moderate tr3NIMX curative ascites, perineural invasion 
36 D moderate T3NIMI Ipalliative Ibladder involved 
37 D moderate T3NIMI Ipalliative bladder involved 
39 B moderate T3NOMX curative incidental ~enectom~_ 
40 C2 moderate T3N2MX curative 
41 B moderate T3NOMX curative 
42 D moderate T3NOMI ~alliative 
43 Cl moderate T2NIMX curative previous breast cancer 
44 D moderate T4NIMI !palliative invading S8 throu~h to mucosa 
45 Cl moderate T3N2MX curative close circumferential margin 
46 A mucinous/moderate T2NOMX curative pre-operative radiotherllJ>Y 
47 B moderate T3NOMX curative 
48 C2 mucinous/poor T4N2MX curative separate peritoneal nodule with ca 
49 A moderate TINOMX curative submucosal vascular invasion 
Table 3.3 Pathological data for colorectal cancers collected. APR abdominoperineal 
excision of rectum, CEA carcinoembryonic antigen, POD pouch of Douglas 
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tumour no. type degree of dysplasia 
4 villous adenoma severe 
38 tubulo-villous adenoma moderate/ severe 
Table 3.4 Pathological features of adenomas. 
3.3 Are our Study Patients a Representative Sample? 
Considering only those patients with primary colorectal cancer there were 42 patients. 23 
men and 19 women (male: female ratio 1.2:1) of mean age 69.5 years. A recent large 
national audit of patients presenting with colorectal cancer in the UK (Tekkis, 2002) 
included data from over 8000 patients. The median age at presentation in this audit was 
72 years (although the audit also included patients treated as emergencies or not 
undergoing surgery, who tend to be older) and the male: female ratio was 1.24: I. Our 
patient population is therefore well matched in age and sex distribution to the typical UK 
population with colorectal cancer. 
Table 3.5 compares the distribution of colorectal Cancer sites between the tumours in the 
national audit and the 43 primary colorectal tumours in our study. 
Site of tumour National audit Tumours in study 
Rectum 32% 16/43 (37%) 
Sigmoid/left colon 36.5% 14/43 (33%) 
Right/transverse colon 31% 13/43 (30%) 
Table 3.5 Sites of colorectal tumours in National audit and this research. 
The higher proportion of rectal cancer patients in our study could represent a difference 
in classification of tumours at the rectosigmoid junction. It could also represent a bias in 
recruiting patients. Surgery for rectal cancer involves pelvic dissection and therefore 
drains are more commonly inserted. Patients undergoing rectal cancer surgery were 
therefore more likely to be recruited to the study. 
A comparison of Dukes' stage of those patients in the national audit undergoing surgery 
and the patients in our study is shown in table 3.6. 
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Dukes' stage National audit Patients in study 
A 795/6247 (12.7%) 6/43 (14%) 
B 2276/6247 (36.4%) 17/43 (40%) 
C 2189/6247 (35%) 12/43 (28%) 
D 987/6247 (15.8%) 8/43 (19%) 
Table 3.6 Analysis of study patients by Dukes' stage compared with national audit 
It can be seen that the Warwick patients are well matched in terms of stage with the data 
collected in the National Audit. 
The surgeon rated each patient at the time of operation as to whether the resection was 
felt to be curative in intention, clearly palliative (multiple liver metastases or obvious 
residual tumour) or uncertain. 28 patients (67%) had surgery thought to be curative, 21 % 
(9 patients) had a palliative resection, and the surgeon was uncertain in the remaining 5 
patients. These figures are similar to a large Scottish audit in which 70% of patients had 
surgery thought to be curative (McArdle and Hole, 2002). 
Both of the adenomas that were resected were severely dysplastic at least in part, and 
neither was amenable to colonoscopic removal. The caecal adenoma was resected during 
the same operation as excision of a rectal cancer by anterior resection. 
3.4 Samples Collected 
Tumour samples, usually in duplicate were collected from all patients with cancer or 
adenomas. A peritoneal washing at the start of surgery was collected from each patient, 
and a wash at the end of surgery from all except one patient. One of the samples at the 
start of surgery consisted of ascites rather than peritoneal wash fluid. In 7 patients an 
abdominal drain was not used (intentionally in 6, surgeon forgot in 1).2 patients' drains 
produced no output on either the first or second post-operative day, and in 2 others 
nothing drained between 24 and 48 hours after surgery. In 2 patients a special type of 
abdominal drain connected to the wall suction unit was used. This was found to cause 
lysis of the cells and therefore drain samples from these 2 patients were not analysable. It 
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was not always possible to collect drain fluid samples on the second post-operative day if 
this fell on a weekend. 
For the 50 tumours studied (including the upper gastrointestinal tumours), one paired 
peritoneal sample was available in I case, 2 samples in 10 cases, 3 samples in 21 and the 
complete set of peritoneal washings and first and second day drain fluids in 18. A median 
of three peritoneal samples was available for comparison with each ofthe tumour 
samples collected. 
3.5 Follow up data 
To reduce demands on participating patients, no specific follow up appointments or 
investigations were required as part of this study. Follow up data therefore represents the 
latest information available in the patients' records, after clinical review, or the 
investigations ordered routinely, or in response to patients symptoms, by the consultant 
surgeons concerned. Data regarding length of follow up, adjuvant treatment received and 
whether patients have suffered from recurrent disease are given in table 3.7. The variable 
length of follow up in patients having their operations at similar times represents 
differences in follow up regimes. Some data may be in case notes of the regional 
oncology centre and therefore unavailable for this study. Of the 43 patients, 5 have died. 
One patient suffered a myocardial infarction (MI) in the immediate post-operative period 
and died shortly after discharge from hospital. Two of the others had metastatic disease at 
presentation, one other suffered local recurrence (Dukes' B, pT3 tumour with clinical 
small bowel involvement) and another, with a Dukes' C tumour suffered from liver 
metastases. 10 patients are alive with metastases from their colorectal cancer, and one 
patient has metastatic malignant melanoma. 27 patients (63%) are alive without evidence 
of recurrent cancer; the median follow up for this group is 10 months, range 3-21 months. 
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Tumour Length of follow up Adjuvant Status 
number (months) treatment 
I 15 Alive with disease (liver metastases) 
2 21 A&W 
3 21 Alive with disease (liver, lung) 
4 5 A&W 
5&6 16 A&W 
8 4 A&W 
9 19 A&W 
10 15 A&W 
12 14 Died with disease (liver metastases) 
13 10 Died with disease (local recurrence) 
14 18 A&W 
16 18 Alive with disease (inguinal nodes) 
17 17 Alive with disease (liver, ?pelvis) 
18 17 Alive with disease (liver metastases) 
19 10 A&W 
20 <I Died, post-operative MI 
21 10 Chemotherapy A&W 
22 7 Chemotherapy Died with disease (liver metastases) 
23 3 Chemotherapy Alive with disease (peritoneal) 
24 10 Chemotherapy A&W 
25 6 Alive with disease (liver metasta.~es) 
26 9 Chemotherapy A&W 
27 11 Died with disease (pelvic recurrence) 
28 \0 A&W 
29 10 A&W 
30 10 A&W 
31 11 Radiotherapy Alive, no disease but complications of 
su~ 
32 9 Alive, metastases from malignant melanoma 
33 4 Chemother~ A&W 
34 12 A&W 
35 12 A&W 
36 & 37 6 Alive with disease (liver metastases) 
38 & 39 9 A&W 
40 3 Chemotherapy A&W 
41 7 A&W 
42 10 Chemotherapy Alive with disease (liver metastases) 
43 6 Chemotherapy A&W 
44 6 Alive with disease (liver metasta.~es) 
45 6 A&W 
46 6 A&W 
47 6 A&W 
48 7 Chemotherapy A&W 
49 6 A&W 
Table 3.7 Follow up data for study patients. A&W= alive and well, with no known 
recurrent disease. 
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3.6 Discussion 
We have described a group of 43 patients with 46 colorectal tumours, 43 primary cancers, 
2 adenomas and I recurrent tumour. These patients are of similar age and sex distribution 
to the UK population with colorectal cancer, and have disease of similar stage. 63% of 
these patients are alive without evidence of recurrent disease after a median follow up 
period of 10 months. Evidently a longer follow up is necessary before any conclusions 
can be drawn concerning the risk of recurrence if tumour cells are detected in the 
peritoneum. 
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CHAPTER 4: DEVELOPMENT OF PROTOCOLS AND VALIDATION OF 
TECHNIOUES 
4.1 Introduction 
As discussed in section 1.9 (experimental strategy) we chose to use magnetic cell 
separation to enrich the epithelial cells in our samples, and then molecular biological 
techniques to search them for DNA with specific mutations known to occur in colorectal 
cancer. It was important to ensure at each stage of the experiments that the techniques we 
were using were capable of allowing detection of mutant DNA in the relevant samples. 
To ensure that we were able to detect such mutant DNA, when it was present in small 
amounts against a background of large amounts of normal DNA (a situation we could 
expect in our clinical samples) we performed a series of 'spiking' experiments. These 
involved adding known numbers of cells from cancer cell lines to samples from patients 
undergoing surgery for benign diseases, or to peripheral blood mononuclear cells from 
healthy volunteers working in the laboratory. Different cell lines were required for the 
various mutations under study. Details of the cell lines used, and the mutations present in 
each cell line are given in section 2.8. Spiking experiments were performed at each stage 
of our protocols to assess the sensitivity of our results. 
Another important consideration, especially during the early stages of processing the 
samples (density centrifugation and MACS analysis) was to ensure that we were not 
destroying cells by repeated manipulation such as washing and centrifugation. If 
excessive numbers of cells were lost during these processes then the chances of our 
detecting mutant DNA would be decreased. We therefore made efforts, particularly with 
the earlier samples, to count the number of cells present at each stage, to assess them for 
viability and to calculate the proportion being lost. 
4.2 Density Centrifugation 
To ensure that a satisfactory proportion of mono nu dear cells were recovered after density 
centrifugation, about IOml from a number of the early peritoneal washing samples was 
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sent for cell counting on the coulter counter of the Haematology Laboratory at Warwick 
Hospital (by kind permission of Dr Peter Rose). Table 4.1 shows the results, with the rate 
of recovery varying from 20% to 150%. 
CONCENTRATION VOLUME TOTAL WBCAFTER PERCENTAGE 
WBC IN SAMPLE INML WBC LYMPHOPREP RECOVERED 
1 0.1 x 10 "/1 85 8.5 x 106 1.3 X 10' 153% 
2 0.1 x 10"/1 100 107 2 X 106 20% 
3 0.2 x 10"/1 100 2 x 10 9.5 x 10° 48% 
Table 4.1 Recovery of mononuclear cells after density centrifugation. WBC = white 
blood cells. 
Why are these results so variable? Firstly, the coulter counter in the clinical laboratory is 
not set up to allow such small numbers of white cells to be counted routinely. The 
concentrations in our samples are so low because they consist of bloody fluid, which is 
then diluted with the 100ml of saline used to retrieve the sample. This low concentration 
may lead to inaccuracies, with values less than 0.1 x 109/1 automatically being rounded 
up. Secondly, the numbers oflymphocytes in the samples sent to the laboratory were too 
low to register. It is mononuclear cells that are preferentially concentrated by 
Lymphoprep. Finally, there was a tendency for the early samples in the series to clot 
before they were returned to the lab for processing. This was overcome later by the 
addition of heparin after collection and before storage and transport. If a sample was 
particularly clotted this could cause an unexpectedly low recovery rate because a 
significant number of cells would be discarded with the clots. 
In the case with more than 100% recovery, this may be due to contamination by 
erythrocytes. These are typically 1-5% of total cells recovered using Lymphoprep 
(product datasheet), but at times are clearly visible as red cell contamination of the pellet 
and may be more than this. Excessive recovery may also represent inaccuracies in 
counting with the haemocytometer. 
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These results were sufficient to convince us that the number of cells being recovered was 
of the same order of magnitude as the number of cells in the sample initially, and given 
the limitations outlined above further samples were not sent for counting. 
4.3 Numbers of Cells in Samples 
There was a wide range of numbers ofnucIeated cells, recovered after density 
centrifugation, from the various types of sample collected. Overall, the samples contained 
a median of 1.6 x 107 cells, (n = 157) with a range of 2.2 x 105 cells to 4 x 10R cells (mean 
3.2 x 107). If the 10 extreme high and low values are discarded the mean number is 2.5 x 
107 cells per sample with a range from 1.5 x 106 to 1 X lOB. Even without the extreme 
values these numbers differ by a factor of 67. 
The numbers of cells in the samples varied over the time course of sample collection. The 
median number of cells (in millions) was 8.5 in pre-operative washes, 17 in post-
operative washes, 47 in day 1 drain fluids and 20 in day 2 drain fluids. There were 
significantly more cells in the day 1 drain fluid than in the pre-operative (p<O.OO 1) or 
post-operative washes (p<O.OI, Dunn's multiple comparisons test). These figures are as 
expected from observation of the samples, which tended to be relatively lightly 
bloodstained at the start of surgery (especially when diathermy was used to open the 
abdomen), bloodier by the end of surgery and heavily bloodstained on the first post-
operative day. The first day drain fluids may also contain proportionally more white 
blood cells given the major inflammatory stimulus of surgery. 
The number of cells in the Ber EP4-positive fraction after MACS also varied widely. The 
median value for the 160 samples was 1.2 x 105 cells, range 0 to 1.1 x 107 (mean 6.3 x 
10\ Again, excluding the 10 extreme high and low values gives a mean number of3.7 x 
105, with a range of2 x 104 to 2.3 X 106. 
The proportion of cells in the positive fraction after MACS is important in calculating the 
enrichment obtained by the process, and in determining whether MACS is helpful or 
necessary. The median value for the proportion of cells in the positive fraction (n = 157) 
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was 1.03% with a range of 0 to 33% (mean 2.5%). Excluding the extreme values as 
before the mean is 1.5% and the range 0.18% to 8.3%. Thus for a sample with the median 
proportion of cells in the positive fraction, it appears that an enrichment of almost 100 
fold occurs after MACS separation. This enrichment is only achieved if we assume that 
all the epithelial cells are present in the positive fraction after separation. Although work 
in our laboratory has demonstrated that excellent separation of epithelial cells from other 
cell types can be made using MACS techniques (V Swales, personal communication, 
separation of epithelial cells from disaggregated tumour samples), it is likely that the 
recovery of epithelial cells from these samples is less complete, simply because there are 
so few of them. 
4.4 Recovery of Cells with MACS 
The MACS process described (see section 2.3.2 and appendix) involves four 
centrifugation steps and two incubations. The cells are also passed through a column and 
then forcibly washed out. Each of these steps could cause cells to be damaged or lost, and 
it was important for us to clarify whether or not significant numbers of cells were 
affected. For the first 85 samples we therefore performed counts of the number of cells 
retrieved after density centrifugation and the numbers in the positive and negative 
fractions after MACS. The first count was compared with the sum of the other two, to 
give the percentage of cells recovered. The median recovery after MACS was 70%, range 
5% to 208%, interquartile range 44% to 100%. 
For samples with up to 5 X 107 cells (87% of samples) before MACS, there was a 
correlation between the number of cells in the initial sample and the recovery rate, with a 
greater proportion of cells recovered from larger samples (r = 0.3491, p= 0.0023). This 
correlation is shown in figure 4.1. 
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Figure 4.1 Graph showing percentage recovery of cells after MACS against number 
of cells present in sample after density centrifugation (for samples with up to 5 X 107 
cells). 
If samples larger than 5 x 107 cells are included then this correlation is lost. This may be 
because larger samples exceed the capacity of the miniMACS columns, and a greater 
proportion of cells are trapped within the column at the end of the process. Very large 
samples therefore have a lower rate of cell recovery than moderately large samples. 
4.5 Is MACS Effective In Enriching Epithelial Cells? 
Although MACS has previously been shown to be effective in enriching colorectal cancer 
cells from blood and from tumour cell suspension, it was important to demonstrate that 
the particular conditions we had chosen to use were effective in our samples. Cytospin 
slides were prepared from the positive fractions of38 samples, and stained with 
haematoxylin and eosin. These were examined by Dr Mark Newbold, consultant 
histopathologist at University Hospital Coventry and Warwickshire. No clearly malignant 
cell s were seen in these samples. Given previous results in our laboratory we wou ld have 
expected some positive results in this number of samples. The possible reasons for our 
failure to see cells include -
I. Inadequacy of MACS technique 
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2. Patient selection - the early patients in our series had more favourable tumours 
than average, and a significant number were rectal cancers, which may be below 
the peritoneal reflection and therefore not involve the peritoneum. 
3. Insufficient material from the positive fraction being loaded into the cytospin 
preparation- in an attempt to preserve enough cells for later molecular analysis 
(from the sometimes small positive fractions) many of the slides contained only 
scanty cells. 
4. Inadequate staining technique - resolved for the later slides. 
In order to check whether our MACS technique was able to separate epithelial cells from 
peritoneal washings and drain fluids we performed spiking experiments using cells from 
the colorectal cancer cell lines HT29 and SW480, which were maintained in culture in 
the laboratory. Varying numbers of cancer cells were introduced into samples from 
patients with benign conditions undergoing surgery of similar magnitude to a cancer 
resection (see chapter 3). Between 105 and 102 cells were added to samples (typically 
100ml in volume) before density centrifugation, and these were then processed using the 
same protocols as the patient samples. Cytocentrifuge slides were prepared from all these 
samples, in some cases using only a little of the available material from the positive 
MACS fraction, and in other cases using the whole positive fraction either by repeated 
loading of the cytospin chamber or by preparing several different slides. When not all 
cells were used to make slides the remainder were pelleted and frozen at -80°C. DNA 
from these pellets was used to assess the sensitivity of molecular techniques at a later 
stage (see section 4.8). After fixation and haematoxylin and eosin staining the slides were 
examined. Cancer cells were identified by their large size and high nuclear to cytoplasmic 
ratio. Although some of the slides were of poor quality or contained only scanty cells, 
cells thought to be from the cell lines were seen after 10 cells were added per millilitre of 
initial sample, suggesting adequate enrichment by the MACS process. Examples of slides 
obtained from the positive and negative fraction are shown in figures 4.2 and 4.3. 
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Figure 4.2 Positive fraction after MACS separation. A group of large cells, with large, 
deeply staining nuclei is seen (haematoxylin and eosin staining). 
Figure 4.3 Negative fraction after MACS separation. A large number of leucocytes are 
seen (haematoxylin and eosin staining). 
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These pictures suggest that the populations of cells in the positive and negative fractions 
after MACS are different, with the positive fraction containing the malignant cells added 
to the sample as well as some white blood cells that become trapped in the column. We 
thus appear to be achieving our aim of enriching the epithelial cell population in our 
samples, and thus increasing the chance of detecting small numbers of malignant cells in 
our patient samples. 
Further evidence that MACS provides enrichment of cancer cells in peritoneal samples is 
given in Chapter 7 'Is MACS necessary?' 
4.6 DNA Extraction And Quantification 
DNA was extracted from tumour samples and from frozen cell pellets derived from 
peritoneal samples as described in sections 2.4.1 and 2.4.2. The concentration of DNA 
extracted from the first 19 tumours was quantified using the spectrophotometer, and was 
a median of 7411glml, range 13-265 llglml. Later samples were assessed for the presence 
of amplifiable DNA by using them in an established PCR reaction (for K-ras, TP53 or 
wild type APe). Three of the tumour samples gave DNA that would at times fail to 
amplify with PCR, in one case despite DNA extraction from a duplicate sample. Two 
peritoneal samples did not yield amplifiable DNA; in a further three samples either the 
MACS positive fraction or the non-separated fraction failed to amplify. Considering the 
small numbers of cells in many of the samples, it is perhaps surprising that so few failed 
to give usable DNA. 
4.7 Polymerase Chain Reaction (PCR) Optimisation and Seguencing 
PCR is a technique that is able to amplify a particular segment of DNA millions of times 
in a matter of hours. Each PCR reaction requires specific concentrations of reagents in 
order to give optimal amplification but maintain specificity. The optimisation process for 
each reaction may require variation in magnesium concentration, annealing temperature 
of number of cycles as well as concentration of enzymes or dNTPs. 
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Taq polymerase requires free magnesium for activity. The amount of free magnesium 
depends on other reaction components such as template DNA. If excess magnesium is 
present then enzyme fidelity is reduced. It is therefore important to use the lowest 
concentration of magnesium that allows for reliable amplification of DNA. This varies 
with each reaction, and indeed may vary for the same reaction with different brands of 
enzyme (see below). Initial difficulties in obtaining reliable amplification were due to a 
failure to realise that magnesium chloride solutions form a concentration gradient on 
freezing and require thorough mixing before use. 
The temperature used during the annealing phase of each PCR cycle also needs to be 
adjusted for each reaction. The melting point (T m) of the primers gives a guide to the 
likely temperature required, with attempts at optimisation beginning with annealing 
temperatures about SoC below the T m. A high annealing temperature increases the amount 
of specific product formed and reduces primer-dimer formation. 
Once a PCR reaction is producing a product, it is necessary to ensure that the correct 
portion of DNA is being amplified. The size of band produced after gel electrophoresis 
can be compared with a standard ladder. The appropriate size can be predicted from 
knowledge of the sequence of the DNA to be amplified. The PCR products can also be 
analysed by DNA sequencing. The resulting sequence can be compared with the expected 
sequence, if known, or can be checked using programmes such as the National Center for 
Biotechnology Information's BLAST programme (NCBI BLAST). 
The optimisation for each PCR reaction performed, and sequencing data to confirm that 
the appropriate section of DNA was being amplified are presented below. Details of the 
optimum conditions for each reaction (magnesium chloride concentration and cycle times 
and temperatures) are given in the appendix. 
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4.7.1 K-ras 
Primer sequences were obtained from the literature (Sidransky et al., 1992). A 
magnesium concentration of3mM was found to give reliable amplification; results were 
unpredictable when lower concentrations were used. A band of approximately 200 base 
pairs was seen after electrophoresis in a 1 % agarose gel. The predicted size of the 
fragment was 202 base pairs. Figure 4.4 shows the result of a typical PCR for K-ras. 
f- K-ras PCR product 
Lane 1 2 3 4 5 6 7 8 
Figure 4.4 Typical gel showing result of peR to amplify K-ras. Lane 1: 1 kb ladder, 
lane 2: negative control, lanes 3-8: DNA from various tumour samples. 
Samples ofPCR products from this reaction were submitted for sequencing analysis and 
this confirmed that K-ras was being amplified. To detect mutations of codon 12 more 
clearly on sequencing analysis, alternative primers, obtained from Shoo Yee Wong, 
giving a larger PCR product (approximately 400bp) were used. Primer sequences and 
reaction conditions are described in the appendix. An example of a sequencing result for 
K-ras is shown in figure 5.2. 
4.7.2 TP53 
The primer sequences for the arnpJi fication of exon 8 of TP 53 were obtained from the 
literature (Dong et al., 2001), as were the cycle times and temperatures. These are 
detailed in the appendix. A magnesium concentration of3mM was found to give good 
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amplification without primer-dimers. A PCR product of between ISO and 200 base pairs 
was obtained. A typical result ofa PCR to amplify exon 8 ofp53 is shown in figure 4.5 . 
~ TP53 PCR product 
2 3 4 5 6 7 8 
Figure 4.5 Typical gel showing result of peR to amplify TP53. Lane I : 50bp ladder, 
lane 2: negative control, lane 3: positive control (DNA from HT29 cell line), lanes 4-8: 
DNA from various HT29-spiked peritoneal samples 
Samples ofPCR products from this reaction were submitted for sequencing analysis, and 
the resulting sequence analysed using the NCBJ BLAST programme. The sequence 
obtained was shown to be that of human TP53, confinning the specificity of the primers. 
An example of a sequencing result from a tumour with a TP53 mutation is shown in 
figure 5.5. 
4.7.3 APe (adenomalous polyposis coli gene) 
Initially primers were designed to amplify part of the mutation cluster region of the APe 
gene including the two commonest mutation sites, codons 1309 and 1450. Details of 
these mutations were obtained from the literature (Fearnhead et al., 2001) and confirmed 
on a website containing a database of APe mutations: 
http://p53.curie.fr/p53%20site%20version%202.0/APCdatabase.html#Anchor-47857 
The DNA sequence of this exon was obtained from the NCBI website: 
http://www.ncbi.nlm.nih.gov/mapview/seCLreg.cgi?chr=5&from= I 12490538&to= 11 262 
8882 
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The relevant portion was submitted to the 'primer designer' programme. A set of primers 
was selected (see appendix) and, because their T m was similar to those of the TP 53 
primers the same reaction conditions were used and found to be satisfactory. The 
predicted size of the PCR product was 536 base pairs, and as this figure shows, the band 
obtained was between 517 and 550 base pairs in length. 
f- APe PCR product 
2 3 456 7 
Figure 4.6 Results of peR to amplify APe (wild type) Lane I : I kb ladder, lane 2: 
negative control, lanes 3-6: cell lines and normal DNA, lane 7: 50bp ladder. 
PCR products from this reaction were subjected to sequencing analysis with NCBI 
BLAST and were shown to have the sequence of human APe. 
We initially attempted to use this DNA in a mismatch ligation assay to detect the two 
commonest somatic APe mutations. These are a single base substitution at codon 1450, 
and a 5 base pair deletion at codon 1309. This proved unsuccessful, with the MLA for the 
codon 1450 mutation failing to give a positive result even with a cell line known to have 
that mutation, and the MLA for the codon 1309 mutation giving false positive results . 
With hindsight, the PCR product was too long for satisfactory MLA results, and the 
nature of the codon 1309 mutation (loss of a repeated sequence) contributed to the poor 
results. 
Because ofthese problems, we decided to use mutant allele-specific PCR to look for the 
mutation at codon 1309. This mutation is a 5bp deletion of a repeated AAAAG sequence. 
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The sense primer was designed to have the mutation site close to its 3 ' end. Because the 
deleted bases are part of a repeated sequence, it was not possible to have the mutation at 
the end of the primer. The anti-sense primer was the same as that used to amplify wild 
type APC. 
Figure 4.7 shows the sequence of part of the APC gene. The original sense and anti-sense 
primers for the amplification of wild type APC are highlighted, as is the five base pair 
repeat which is deleted in codon 1309 mutations. The sense primer for mutation specific 
peR for codon 1309 mutations is also indicated. 
GCTAATACCCTGCAAATAGCAGAAATAAAA 
GllllliATTGGAACTAGGTCAGCTGAAGATCCTGTGAGCGAAGTTCCAGC 
AGTGTCACAGCACCCTAGAACCAAATCCAGCAGACTGCAGGGTTCTAGTTT 
ATCTTCAGAATCAGCCAGGCACAAAGCTGTTGAATTTTCTTCAGGAGCGAAA 
TCTCCCTCCAAAAGTGGTGCTCAGACACCCAAAAGTCCACCTGAACACTAT 
GTTCAGGAGACCCCACTCATGTTTAGCAGATGTACTTCTGTCAGTTCACTTG 
ATAGTTTTGAGAGTCGTTCGATTGCCAGCTCCGTTCAGAGTGAACCATGCAG 
TGGAATGGTAAGTGGCATTATAAGCCCCAGTGATCTTCCAGATAGCCCTGG 
ACAAACCATGCCACCAAGCAGAAGTAAAACACCTCCACCACCTCCTCAAAC 
AGCTCAAACCAAGCGAGAAGTACCTAAAAATAAAGCACCTACTGCTGAAAAG 
Figure 4.7 Part of the sequence of the APC gene, showing position of primer 
sequences. Primers to amplify wild type APC are highlighted in red, the 5bp deletion 
found at codon 1309 in some colorectal tumours is bracketed and highlighted in green 
and the sense primer for mutant allele specific peR consists of the bases highlighted in 
yellow. 
The optimisation of the mutation specific peR was performed in two stages. The aim of 
the first stage was to ensure that a positive result was obtained with mutant, but not with 
wild type DNA. The colorectal cancer cell line LS I 034 has been shown to have the 
relevant mutation and DNA from these cells was used as a positive control. Each reaction 
also included 2 negative controls; one tube with no DNA as a control for contamination, 
and one tube containing DNA from a healthy volunteer, to check for specificity. 
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Conditions were made more stringent (higher annealing temperature, lower magnesium 
concentration) until this was achieved. An annealing temperature of 59°C and a 
magnesium concentration of2mM were found to produce clear results in the positive but 
not the negative controls. 
PCR products from normal DNA and from LS1034 (mutant DNA), amplified using the 
'wild type' APe primers, were submitted for sequencing analysis. The results of 
sequencing normal and mutant APe are shown in figures 4.8 and 4.9 respectively. 
550 560 
'l' AAAA G AAAA G A TT GG AA C 
Figure 4.8 Sequencing result from tumour with wild type APC at codon 1309. The 5 
base pair repeated AAAAG sequence is seen, beginning at base 545. 
40 
T A A A A G G AT T G C A A C 
Figure 4.9 Sequencing result from LSI034 cell line, with 5 base pair deletion at 
codon 1309 of APC. Loss of the repeated AAAAG is seen. 
The second stage of the optimisation was necessary to ensure that the test was sensitive 
enough to detect low levels of mutant DNA on a background of normal DNA. A series of 
samples were prepared containing 106 normal cells mixed with 105, 104 and 103 LS I 034 
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cells, giving a concentration of one mutant cell in ten, one hundred and one thousand 
respectively. With the conditions described above it was only possible to detect one 
mutant cell in one hundred normal cells. A number of experiments were performed to 
balance the need for sensitivity against the need for specificity. An annealing temperature 
of 57°C, with a magnesium concentration of 2.5mM allowed one mutant cell in 1000 to 
be detected, with no amplification of wild type DNA. These results are illustrated in 
figure 4.10. As described in chapters 5 and 6, the more stringent PCR conditions were 
used to examine DNA from primary tumours, with the more sensitive conditions being 
used to examine peritoneal samples from the same patients (where a much lower 
proportion of mutant cells would be expected). 
~ APe codon 1309 mutant PCR product 
Figure 4.10 Gel showing optimisation of mutation specific peR for APe codon 1309 
mutation, to give improved sensitivity. Lane 1: I kb ladder, lane 2: negative control (no 
DNA), lane 3: control for specificity (normal DNA), lane 4: positive control (DNA from 
LS 1034 cell line, lane 5: 1 mutant cell in 10 normal cells, lane 6: 1 mutant cell in 100 
normal cells, lanes 7 & 8: 1 mutant cell in 1000 normal cells. 
4.7.4BRAF 
As discussed in chapter 1, BRAF, recently found to be mutated in about 10% of colorectal 
cancers (Davies et al., 2002; Yuen et al. , 2002) was a good target for detection in our 
study. Tumours with the commonest BRAF mutation, a T ~A mutation at codon 599 do 
not have K-ras mutations. This meant that we were likely to be detecting mutations in 
tumours in which we had not found a mutation previously, rather than detecting second 
mutations in tumours. We decided to use a Mismatch Ligation Assay to detect these 
mutations because we were familiar with this technique, and it was applicable to both 
tumour DNA and peritoneal samples. 
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The first step in designing an MLA to detect BRAF mutations was to amplify the area of 
DNA containing the mutation, using peR. The optimal size of peR product for MLA is 
less than 100 base pairs (K. Hibi, personal communication). For this reason, the primers 
described by Davies (supplementary information to paper, given on Nature website, 
http://www.nature.com!cgi-
taflDynaPage.taflfile=/nature/journal!v417/n6892/fuII/nature00766 _ fs.html), which give 
a product 224 base pairs long, were not suitable. The DNA sequence of BRAF exon 15 
was obtained from the website of the Sanger Institute 
(http://www.ensembl.orgIHomo_ sapiens/geneview?gene=ENSGOOOOO 157764), and 
Primer Designer software (Scientific & Educational Software, Durham, Ne, USA) was 
used to select a pair of primers to amplify the relevant portion of exon 15, without 
overlapping the mutation site. It proved difficult to design an ideal set of primers, and the 
subsequent peR was prone to primer dimer formation. Reaction conditions were 
optimised, and these are detailed in the appendix. An example of a peR to amplify BRAF 
is shown in figure 4.11 . 
~ BRAF peR product 
2345678 
Figure 4.11 Gel showing peR to amplify short section of BRAF exon 15 
Lane I: lkb ladder, lane 2: negative control (no DNA), lanes 3-8: various tumour DNAs. 
4.8 Mismatch Ligation Assays (MLA) 
4.8.1 Oligonucleotide design and reaction conditions 
Details of oligonucleotides and reaction conditions for MLA to detect K-ras and TP53 
mutations were available in the literature (Dong et al., 200 I ; Jen et al., 1994b). These 
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details are listed in the appendix. For the MLA to detect mutant BRAF, oligonucleotides 
were designed, using the principles apparent in the literature, and described in section 
2.7.1. These sequences are shown, in alignment with the wild type and mutant sequences, 
in figure 4.12. 
Wild type BRAF sequence 
GTCTAGCTACAGTGAAATCTCGATGGAGT 
Blocking oligonucleotide (complementary to wild type sequence on opposite strand) 
ACAGTGAAATC 
Mutant BRAF sequence (mutation highlighted in red) 
GTCTAGCTACAGAGAAATCTCGATGGAGT 
Mutation specific oligonucleotide (BRAF 5) 
TAGCTACAGA 
Nucleotide for 5' end-labelling (BRAF 3) 
GAAATCTCGA 
Figure 4.12 Oligonucleotides for BRAF MLA. These are shown in alignment with 
wild type and mutant BRAF sequences. 
Three ofthe cell lines available in our laboratory have been shown to have the relevant 
point mutation in BRAF (COLO 205, HT 29 and SWI417). These were used as positive 
controls. DNA from healthy volunteers was initially used as a negative control, and later 
DNA from a tumour shown to be wild type on MLA testing (and confirmed by direct 
sequencing). An example of an MLA showing that mutant and wild type BRAF can be 
distinguished using these oligonucieotides is shown in figure 4.13. 
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f- band indicating presence of mutant BRAF 
23456789 
Figure 4.13 Example of MLA to detect mutant BRAF. Lane 1: No DNA, lane 2: PCR 
product from DNA of healthy volunteer, lane 3: HT 29, lane 4: COLO 205, lanes 5-9: 
tumours 1-5. A clear band is seen in both tumour lines but not in negative controls, or 
these tumours. 
MLA was optimised using conditions similar to those found to be appropriate for other 
reactions. 200ng of blocking oligonucleotide and 25ng of mutation specific 
oligonucleotide per reaction gave the clearest results. Full details of the reaction 
conditions are given in the appendix. 
The presence of the expected mutation in the positive control cell line, and the lack of a 
mutation in the negative control tumour sample were confirmed by sequencing. PCR 
products for the sequencing reaction were prepared using the exon 15 primers described 
previously (Davies et al. , 2002, see website address above). The longer PCR product 
amplified by these primers was more suitable for sequencing analysis . PCR products 
were purified prior to sequencing using a PCR Purification Kit (Qiagen), used according 
to the manufacturers' instructions. Results are shown below, in figures 4.14 and 4.15. It 
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was also possible to confirm that tumours giving positive results with the other MLAs 
contained the relevant mutations, using direct sequencing. Examples of this are given in 
the relevant sections of chapter 5. 
20 
G C T A C A G T G A A A 'l' C 
Figure 4.14 Sequencing result for tumour 1. This shows wild type BRAF with Tat 
position 1796 (base 24 in this sample). The sequence shown is GCT ACAGTGAAA TC. 
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G C T A C A G A G AAA T C 
Figure 4.15 Sequencing result for COL0205 cell line. The sequence shown is 
GCTACAGAGAAATC. This confirms aT -7A mutation at position 1796 (base 71 in this 
sample). 
4.8.2 Assessment of Sensitivity ofMLA 
The sensitivities of the various MLA reactions were assessed using spiked samples. 
Samples to assess K-ras and TP53 assays were prepared, containing varying numbers of 
cells from colorectal cancer cell lines. These cells were introduced into washings and 
drain fluid samples from patients undergoing surgery for benign diseases. The cancer 
cells were introduced as soon as the samples were brought to the laboratory, and the 
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samples were then subjected to density centrifugation and MACS separation, with the 
pellets being frozen down. DNA was extracted from the pellets. and the appropriate ex on 
amplified by PCR. PCR products were used in a MLA. Samples spiked with SW480 cells 
could be analysed with MLA for both K-ras codon 12 and TP53 codon 273 mutations. 
Samples spiked with HT-29 cells were analysed with MLA for the TP53 codon 273 
mutation. Because the samples were spiked at an early stage in the process of analysis 
they give an indication of the efficiency and sensitivity of the combination of techniques 
used, rather than just the MLA, but they provide a more realistic assessment of our ability 
to detect tumour cells in our samples than simply adding cells after density centrifugation 
and MACS. 
The MLA to detect BRAF mutations was assessed for sensitivity using samples that were 
prepared by adding known numbers of cells from the COLO 205 cell line to mononuclear 
cells derived from the peripheral blood of healthy volunteers. These samples were not 
subjected to MACS separation. They therefore give a more accurate estimation of the 
sensitivity ofMLA alone, rather than the combination of techniques. 
The number of cells spiked into the washings and drain fluids (which were normally 
100ml volumes) varied from 105 cells down to 102 cells i.e. from 1000 cells per ml down 
to I cell per ml. Given the median number of cells in our samples (1.6 x 10\ the samples 
with fewest cells represent I malignant cell in approximately 105 normal cells. 
Considering those samples assessed with the K-ras MLA, mutant DNA could be detected 
in 2 of the 4 samples spiked with 103 cells but in neither of the samples spiked with 102 
cells. The TP53 MLA is possibly more sensitive. Both of the samples spiked with 10) 
cells were clearly positive, one of the 4 spiked with 103 cells, and 2 of the 3 spiked with 
102 cells. An example of this is shown in figure 4.16. 
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~position of band in presence of TP53 
mutation 
2 3 4 5 
Figure 4.16 Results of spiked samples in pS3 MLA. The first lane shown demonstrates 
a positive result in tumour 28. Lanes 4 and 5 show positive results from samples spiked 
with 103 and 102 SW480 cells respectively. 
As explained above, the BRAF MLA was assessed using a different type of sample. 
Samples were prepared containing one mutant cell in 30 to 3200 normal cells, and each 
sample was analysed at least twice. Clear positive results were shown with the sample 
containing one mutant cell in one thousand normal cells. An example of this is shown in 
figure 4.17. 
~ position of band in presence of BRAF mutation 
3 4 
Figure 4.17 Results of spiked samples in BRAF MLA. Lane I: negative control, lane 2: 
positive control, lane 3: 1 mutant cell in 1000 normal cells, lane 4: I mutant cell in 3200 
normal cells. 
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In order to reduce concerns about possible false positive results when using MLA to test 
peritoneal samples, washings and drain fluids from 4 patients undergoing surgery for 
benign diseases were subjected to various MLA tests, and all gave negative results. 
4.9 Discussion 
As far as possible, we have attempted to validate each section of our experimental 
strategy, with quantification of our results wherever possible. Each experiment has 
incorporated appropriate positive and negative controls, with the negative controls for the 
MLA reactions including the relevant PCR product rather than no DNA. We have 
demonstrated reasonable recovery of mononuclear cells after density centrifugation and 
that losses during the MACS process were at an acceptable level. We have successfully 
obtained amplifiable DNA from almost all our samples, despite the small number of cells 
in many ofthem. We have been able to confirm that our PCR and MLA reactions are 
amplifying and detecting the appropriate areas or mutations in DNA by sequencing 
analysis. 
A few questions remain about the sensitivity of MLA. The results from the BRAF 
samples suggest that the technique, when used alone, is able to detect one mutant cell in 
one thousand normal cells. This is consistent with results reported in the literature 
(Sanchez-Cespedes et al., 1999). The results from the samples subjected to density 
centrifugation and MACS are less clear-cut. Although positive results could be obtained 
with one mutant cell per millilitre of initial sample in some cases, these results could not 
be repeated in a number of later samples. This variability may be due to the large number 
of different processes needed to produce the final MLA result. It is possible that results 
could be influenced by the use of different batches of antibodies or by the change in 
supplier of many of the enzymes used for these reactions during the course of this 
research. 
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CHAPTER 5: DETECTION OF MUTATIONS IN PRIMARY TUMOUR 
SAMPLES 
5.1 Introduction 
As discussed in section I, we elected to use DNA based techniques to search for cancer 
cells in the peritoneal samples from our patients. The disadvantage of DNA based 
techniques for detection of small numbers of colorectal cancer cells is the lack of a single 
mutation that occurs in all or even most colorectal tumours. This means that it is 
necessary to look for mutations in a number of different genes (and different mutations 
within those genes) in order to assess the full range of tumours. It is therefore not 
practical to test samples for minimal residual disease for all possible colorectal cancer 
associated mutations, whether the samples are bone marrow, lymph nodes or, in this case, 
peritoneal washings and post-operative drain fluids. In order to reduce the number of tests 
needed, it is first necessary to determine whether a particular mutation is present in the 
primary tumour from a given patient. When a mutation is detected the other samples from 
that patient are examined to determine whether the same mutation is present in cellular 
material, indicative of the presence of cancer cells. 
This chapter describes the results of our experiments to detect mutations in the DNA 
from our primary tumour samples. As discussed in chapter I, we decided to use the same 
techniques to look for mutations in the primary tumours and then in the peritoneal 
samples. However, where possible, the presence of the mutations detected by these 
techniques was confirmed by sequencing analysis. 
The choice of mutations as targets for detection is discussed in chapter I and sections 
4.7.3 and 4.7.4. 
5.2 Sample Collection and Processing 
Samples of 46 primary tumours were collected as described in section 2.2 and stored at 
-80oe until needed. DNA was extracted from the tumours after grinding under liquid 
nitrogen (section 2.4.1). The concentration of DNA extracted was quantified for the first 
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19 tumours using a spectrophotometer. The mean DNA concentration was 92ng/~1 (range 
13- 21Ongllll). Later samples were not tested as all tumours yielded amplifiable DNA; 
however, the DNA from three tumours sometimes failed to amplify at the first attempt. 
5.3 K-ras Mutations 
Exon I of K-ras was amplified in a PCR reaction: typical results are shown in figure 4.4. 
We were able to amplify this exon from all tumour DNA samples, although sometimes 
this took several attempts. The products from this PCR were used in a mismatch ligation 
assay (MLA), the principles of which are described in section 2.7.1. The master mix 
included the three oligonucleotides complementary to the three possible mutant bases at 
codon l2B. This allowed us to detect all possible point mutations at this position. A 
blocking oligonucleotide, complementary to the wild type sequence was included to 
reduce the risk of false positive results. A common oligonucleotide, complementary to 
the sequence immediately adjacent to the mutation site, was 5' end labelled using 32p 
yATP and then added to each sample. Oligonucleotide sequences are given in the 
appendix. 
Each tumour sample was analysed at least twice by MLA, and any sample giving at least 
one unequivocally positive result was considered to contain a mutation at codon 12B of 
K-ras. 13 tumours from 12 patients had K-ras mutations; tumours 36 and 37 were two 
separate left colonic tumours in the same patient. A gel showing positive results from 
several of these tumours is shown in figure 5.1. Pictures of other gels showing positive 
results from the other tumours listed are included in the appendix. As seen in this figure, 
a typical gel from a K-ras MLA experiment gave an appearance of multiple bands in the 
positive control and in the samples giving positive results. The exact nature of these 
bands is unclear. The bands close to the solvent front were seen repeatedly in positive 
samples, and have been noted by others using MLA (K Hibi, personal communication). 
They are not seen in the negative control samples, which, as explained previously, 
contain PCR product of the appropriate exon from a healthy volunteer. The larger bands, 
towards the top of the gel, probably represent residual double stranded DNA, where 
radio labelled MLA product is annealed to template PCR product. These bands were 
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sometimes seen in negative control lanes, and cannot therefore be considered to show 
positive results. 
We attempted to confirm our positive results by sequencing analysis. Primers amplifying 
a longer stretch of the K-ras gene (389bp, including exon I) were used for this purpose. 
Primer sequences and reaction conditions are given in the appendix. An example of a 
G~A mutation at codon 12B is shown in figure 5.2. The sample contained a mixture of 
cells with the mutation and with the wild type sequence, giving the double peak shown. 
The characteristics of the tumours giving positive results are shown in table 5.1, along 
with the results of sequencing analysis for each tumour sample. 
TUMOUR DUKES' TNMSTAGE SEQUENCING RESULT 
NO. STAGE 
2 B T3NOMX G-7A 
4 ADENOMA G-7A 
13 B T3NOMX G-7A 
20 Cl T2N2MX NO RESULT 
23 RECURRENT DISEASE G-7A 
26 B T4NOMX G~A 
29 B T3NOMX G~A 
31 B T4NOMX G~C 
32 B T3NOMX WILD TYPE 
36 D T3NIMl WILD TYPE 
37 D T3NIMI WILD TYPE 
42 D T4NIMI WILD TYPE 
49 A T1NOMX G-7A 
Table 5.1 Characteristics of tumours with K-ras mutatIOns, and results of 
sequencing analysis. 
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I 2 3 4 5 6 7 8 9 10 11 
Figure 5.1 Example of gel showing positive result for K-ras mutations in tumour 
samples. K-ras experiment 28, showing positive results in lanes I, 4, 6, 10& I I . Lane I, 
positive control (SW480 cell line), lane 2, negative control (K-ras peR product from 
healthy volunteer), lane 3 tumour I, lane 4 tumour 2, lane 5 tumour 3, lane 6 tumour 4, 
lanes 7-9 tumours 9, 10 & 14, lane 10 tumour 20, lane 11 tumour 23. 
The four tumours, which gave a wild type result on sequencing, may represent false 
positive results from the MLA tests. Given the use of stringent negative controls in al\ 
MLA experiments, however, it is perhaps more Ijkely that they represent tumours in 
which only a fraction of the cells from which DNA was isolated contained the relevant K-
ras mutation. Sequencing may well not detect mutant DNA against a background of 
excess wild type DNA. This wiIJ always be present in a tumour, especially when the 
oncogene mutation is dominant, and so cancer cells are likely to be heterozygous (as is 
the case with K-ras). It can be seen from the sequencing data in figure 5.2, that even 
when mutant DNA is clearly seen, a large amount of the wild type base is also present. 
Tissue cut from a colorectal tumour, without microscopic dissection, will contain stromal 
cells and blood cells, as well as epithelial cells. It is also possible that not all the epithelial 
cells in the sample were derived from the cancer, with some possibly coming from 
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residual adenomatous tissue or adjacent normal mucosa. Even within the cancer cells of a 
tumour, not all may contain the same mutation. 
240 
A G T T G G A G e T G G T 
Figure 5.2 Sequencing result from tumour 4 showing the presence of a K-ras 
mutation. The base at position 242 shows a mixture ofG and A. The sample contained 
some cells with the wild type codon GGT and others with the mutant codon GAT. 
5.4 TP53 mutations 
We studied two mutations of exon 8, again using a Mismatch Ligation Assay, as 
described by Dong to look for exfoliated tumour cells in the faeces (Dong et al., 2001). 
These mutations involve a change at codon 273 from the wild type codon CGT to TGT or 
CAT. 
Exon 8 of TP53 was amplified in a PCR using the primers described by Dong. 
Appropriate sized products could be obtained from all samples; an example is shown in 
figure 4.5. Each tumour was analysed in a MLA at least twice. Tumour 28 gave positive 
results on multiple occasions. An example of this is shown in figure 5.3. Tumour 5 gave a 
single apparently positive result, but this could not be repeated, casting some doubt on the 
presence of a TP 53 mutation in this tumour. The picture demonstrating this is included in 
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the appendix. Again, multiple bands are seen in this gel in both the positive control and 
the tumour with the relevant mutation, but are not present in the negative control sample. 
Pathological information about the tumours with TP53 mutations is shown in table 5.2. 
The patient with tumour 5 also had a caecal tumour, of the same stage as his sigmoid 
tumour. 
1 2 3 4 5 6 7 8 9 10 11 
Figure 5.3 Gel picture showing positive result for p53 mutation in tumour 28. 
Lane 1 negative control, lane 2 positive control (SW480 cell line), lanes 3-11 tumours 21 
to 29 in order. The positive result in lane 10 corresponds to tumour 28. 
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TUMOUR NO. DUKES'STAGE TNMSTAGE SEQUENCING 
RESULTS 
5 B T3NOMX WILD TYPE 
28 B T3NOMX CGT--;CAT 
Table 5.2 Characteristics of tumours with p53 mutations. 
PCR products from these tumours were submitted for sequencing analysis. The result 
from tumour 28 is shown as figure 5.4. Again, a mixture of wild type and mutant 
sequence is seen. 
70 
G A G G T G C N T G TT T G T 
Figure 5.4 Sequencing result from tumour 28. The wild type sequence at this site is 
GAG GTG CGT GTT TGT, and an uncertain base, showing peaks for both A and G is 
shown in this result (at position 68). 
5.5 APe Codon 1309 Mutations 
As described in section 4.7.3, attempts to design MLA experiments to detect common 
APe mutations failed . We therefore developed a mutant-allele specific PCR to detect the 
5bp deletion at codon 1309. For the detection of mutations in the primary tumour DNAs, 
we used the more stringent (i.e. more specific) conditions. We would expect a large 
proportion of the cells in our samples to have the same mutation ifit was present in a 
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particular tumour, and therefore the stringent conditions should allow the truly positive 
tumours to be detected. Each sample was tested at least twice, and results were consistent 
across repeated tests. Each reaction contained a negative control with no DNA, a control 
for specificity containing DNA from a healthy volunteer, and a positive control 
containing DNA from the LSI034 cell line, which has been shown to have the relevant 5 
base pair deletion at codon 1309 (see figure 4.9). 
Of the fifty tumours tested, three gave positive results indicating the presence of mutant 
DNA. It is possible that a mutation could have been missed in one of the tumours whose 
DNA would sometimes fail to amplify with PCR (particularly numbers 19 and 37) but 
repeating the test at least twice made this less likely. The proportion of tumours with this 
mutation seems low, given the overall frequency of APe mutations in colorectal cancer. 
However, the number of different mutations of the gene is large, and the frequency with 
which we detected this mutation is as would be expected from the literature. Table 5.3 
gives information about the tumours with APe codon 1309 mutations, and figure 5.5 
shows the results of mutant-allele specific PCR for detection of this APe mutation. 
TUMOUR NO. DUKES'STAGE TNMSTAGE SEQUENCING 
RESULTS 
4 ADENOMA 5bp DELETION 
45 Cl T3N2MX 5bp DELETION 
47 B T3NOMX 5bp DELETION 
Table 5.3 Characteristics of tumours with APe codon 1309 mutations. 
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2 3 4 5 6 7 8 9 10 11 12 13 1415 161 7 18 19 
to tumour 4. 
I 2 3 4 . .... 18 
Figure 5.Sb. Tumours 16 to 30 are shown in lanes 4 to 18. There are no positive tumours. 
1 2 3 4 5 6 7 8 9 1 0 1 1 12 13 14 1 5 16 1 7 19 2 1 23 
Figure 5.5c. Tumours 31 to 50 are shown in lanes 5 to 24. The po itive results in lanes 
19 and 21 correspond to tumours 45 and 47. 
Figure 5.5a, b & c. Gel pictures showing results of mutant-allele specific PCR for 
APC codon 1309 mutations. In 5.5a and 5.5c lane I contains I kb ladder, lane 2 negative 
control (no DNA), lane 3 DNA from healthy volunteer and lane 4 positive control. In 
5.5b Lane 1 contains ladder, lane 2 negative control and lane 3 positive control. 
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DNA from the three tumours giving positive resu lts was submitted for sequencing 
analysis. As described in section 4.7.3, this was amplified using primers designed to 
produce a product including the mutation site towards the middle of the amplicon (i.e. not 
the mutation specific primers). The results show a mixture of wild type DNA and mutant 
DNA, containing a 5 base pair deletion. Because of the position of the primers used, this 
is most clearly seen on the reverse strand, and therefore the sequence shown is 
complementary to that given in the previous chapter. Figure 5.6 shows the result of 
sequencing analysis in tumour 45. The wild type and mutant sequences are first shown, in 
alignment, with the five base pairs deleted in mutant APC highlighted. These sequences 
are compared with the result of the sequencing analysis . Up to the point of the mutation, 
the sequence is clearly seen and unambiguous. From the mutation site onwards, the 
overlapping mutant and wild type sequences are both seen. 
ATCTTTT CTTTT ATTTCTGCTA 
ATCTTTTATTTCTGCTA 
A T C TT TT C TT T C A NN T C 
~ 
Figure 5.6 APe sequen~~ ~ith and without 5bp deleti~~ compared with sequencing 
result. The first line of sequence shows the wild type sequence (reverse strand) with the 5 
bases deleted in the mutant form highlighted in red. The second line shows the mutant 
sequence, aligned for comparison. The Chromas picture shows the result of sequencing 
tumour 45, and the expected bases can be seen when this is compared with the sequences 
given above. 
5.6 BRAF Mutations 
As discussed in section I and sections 4.7.4 and 4.8.1, BRAFwas selected as an 
appropriate target for mutation detection, and a MLA was designed, which was capable 
of detecting mutant BRAF. Only one mutation specific oligonucleotide was included in 
each reaction, because only a T ~A mutation has been described at the relevant site. 
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DNA from 45 of the 46 colorectal tumours was tested for the commonest BRAF 
mutation. DNA from one tumour repeatedly failed to amplify in the appropriate PCR. 
Each tumour was tested at least twice, and results were consistent across repeated tests. 
Each MLA experiment included a positive control (PCR product from a cell line known 
to have the relevant mutation) and a negative control (PCR product from a healthy 
volunteer, or later from a tumour that had repeatedly given negative results). 
Of the 45 tumours tested for BRAF mutations, 5 gave positive results. These results were 
consistent across repeated tests. The characteristics of the tumours with BRAF mutations 
are shown in table 5.4. Figure 5.7 is an example of a gel showing a positive result in 
tumour 21. Other gel pictures, showing positive results from the other tumours, are 
shown in the appendix. 
TUMOUR NO. DUKES'STAGE TNMSTAGE SEQUENCING 
RESULTS 
21 Cl T3N2MX T~A 
27 D T4N2Ml WILD TYPE 
33 Cl T3NIMX T~A 
35 Cl T3NlMX T~A 
48 C2 T4N2MX T~A 
Table 5.4 Characteristics of tumours with BMF mutations. 
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I 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 
Figure 5.7 showing positive result for BRAF mutation in tumour 21. Lane I negative 
control , lanes 2& 3 positive controls, lanes 4-20 tumours 2-7, 9- 18 & 21 in order. 
Positive results are seen in lanes 2, 3 and 20. 
All tumours with BRAF mutations were at least Dukes ' stage C tumours. When 
comparing tumours with BRAF mutations with those in which a BRAF mutation was not 
detected, the BRAF mutant tumours were significantly more likely to be Dukes' Cor D 
rather than A or B (p<0.02, Fishers exact test). It is interesting that 3 of the tumours were 
found in the transverse colon. However, BRAF mutant tumours were not significantly 
more likely to be found proximal to the splenic flexure than those without the mutation 
(p=0.15). 
The MLA technique has not previously been described for the detection of BRAF 
mutations, so it was particularly important to check the reliability of our results. We 
therefore submitted samples from the 5 positive tumours for sequencing analysis . As 
explained in Chapter 4, different primers were used to ampl ify a product of appropriate 
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length. Four of the five tumours with mutations detected by MLA had clear evidence of a 
mutation at the expected site on sequencing analysis. A typical result is shown below, in 
figure 5.8. 
:.ou 
C ill. Di t> G A 1111 'I C ':' 
Figure 5.8 Sequencing result from tumour 48 showing codon 599 BRAF mutation. 
This tumour included both normal and mutant DNA giving a mixture of A and T at the 
relevant site, shown here at position 89. 
The fifth tumour (which appeared to contain only wild type BRAF on sequencing) is 
likely to contain a lower level of mutant BRAF. Spiking experiments have indicated that 
using MLA, one mutant cell can be detected among about 1000 normal cells, and, as 
discussed above, this is a much lower concentration than can be detected using 
sequencing. 
5.7 Discussion 
The combination of tests we have described for the detection of mutations in primary 
tumours has enabled us to detect at least one mutation in 22 of our 46 colorectal tumours. 
One tumour (a severely dysplastic adenoma) had both a K-ras and an APe codon 1309 
mutation. A tumour with a mutation was found in 21 of the 43 patients studied. Possible 
ways in which this proportion could be increased are discussed in chapter 8. 
The confirmation of the mutation detected by direct sequencing in 16 out of 23 cases is 
reassuring. As discussed above, the remaining tumours may be those in which a relatively 
low proportion of the DNA sampled contained the relevant mutation. For example, the 
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tumour with a BRAF mutation, detected on MLA but not on sequencing, gave a 
consistently weaker (although still clearly positive) band on the MLA gels. 
In summary, we were able to detect a mutation in half of the colorectal tumours we 
studied, and we were then able to continue with the analysis of the peritoneal washings 
and drain fluid samples from the patients with these tumours. 
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PAGE MISSING IN 
ORIGINAL 
Chapter 6: DETECTION OF MUTATIONS IN PERITONEAL WASHINGS AND 
POST-OPERATIVE DRAIN FLUIDS 
6.1 Introduction 
Once we had detennined which mutations were present in which tumours, we could 
attempt to answer our initial question about the presence of tumour cells in the peritoneal 
cavity at various times during and soon after surgery. As described in chapter 2, 
peritoneal washings were collected from all patients on opening the abdomen, and again 
after removal of the tumour. We also collected fluid from the abdominal drain, when 
placed, on the first and second post-operative day. All these samples were subjected to 
density centrifugation, and MACS was perfonned either on the whole sample, or in some 
cases half of the sample, with the remainder being left without separation. These split 
samples are considered further in Chapter 7. For the remainder of this chapter the results 
from the separated and non-separated halves of the sample are combined, and reported as 
positive if either gave a positive result. 
6.2 K-Ras Mutations 
All available peritoneal washing and drain fluid samples, from patients with K-ras 
mutations in their primary tumours, were tested for the presence of the same mutation 
using the MLA. Each sample was tested at least twice using independent PCR products. 
The same conditions and control samples were used as when testing the tumour samples. 
A single clearly positive result was considered to indicate the presence of mutant DNA in 
that sample. 
A median of 3 samples was available for each patient whose tumour was shown to have a 
K-ras mutation, but it should be noted that tumours 36 and 37 are from the same patient 
and therefore have the same results in the peritoneal samples. Most of the 'unavailable' 
samples occurred because a drain was not placed (3 patients (4 tumours), 6 missing 
samples), the wrong type of drain was used (suction drain with cell lysis, one patient), the 
drain stopped draining (l sample), or the samples were used to develop techniques 
(paired samples of tumour 2). 
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The results of testing the washings and drain fluids from patients with K-ras mutations in 
their primary tumours are shown in table 6.1. The 'overall' column refers to whether any 
peritoneal sample from that patient gave a positive result. 
TUMOUR 
NUMBER DUKES'STAGE PRE-OP POST-~P DAY 1 DAY2 OVERALL 
2 B P~S P~S 
4 ADENOMA NEG NEG NEG NEG NEG 
13 B POS POS P~S 
20 C1 NEG NEG NEG NEG NEG 
23 RECURRENCE POS POS P~S 
26 B NEG NEG NEG 
29 B POS NEG POS NEG P~S 
31 B POS POS POS P~S 
32 B POS POS POS P~S P~S 
36 & 37 0 POS POS I . :-: 
, P~S 
42 0 POS POS NEG 
, P~S 
49 A POS POS ~1 ,;. P~S 
Table 6.1. Results of peritoneal washings and drain fluids from patients with K-ras 
mutations in their primary tumours. POS = positive result, NEG = negative result. 
Cells shaded grey represent no sample available for analysis, empty cell indicates 
amplifiable DNA not obtained. PRE-OP = wash at start of operation, POST -OP = wash at 
end of operation, DAY I = drain fluid from first post-operative day, DAY 2 = drain fluid 
from second post-operative day, OVERALL, POS = any peritoneal sample positive, 
NEG= all peritoneal samples negative. 
As can be seen from the table, of the 12 patients with a K-ras mutation at least one 
washing or drain fluid was positive in 9 (75%). In fact, all but one of these patients had 
multiply positive samples. Of the three patients with no evidence of mutant DNA in the 
peritoneum one had a severely dysplastic adenoma, one a Dukes' B tumour (which was 
however a T4lesion) and one a Dukes ' Cl tumour (T2). 
Of the 9 patients with positive results, suggesting that cancer cells had been shed into the 
peritoneum, 2 patients (with tumours numbered 36/37 and 42) had proven metastases to 
the liver, and the patient with tumours 36 and 37 also had local involvement of the 
bladder. Another patient was undergoing surgery for di sease that had already recurred 
locally (tumour number 23). Details of the remaining patients are discussed in section 
6.5. 
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It can also be seen from the table that in all cases where any washing or drain fluid 
contained mutant DNA the wash at the start of surgery was always involved. Only two 
patients showed a mixture of positive and negative results over the time course studied. 
An example of a gel showing positive results from peritoneal samples is shown in figure 
6.1, other examples are shown in the appendix. 
Figure 6.1 Gel from experiment 23, showing positive results in peritoneal samples 
from patient with tumours 29, 49 and 31. Lane I positive control, lane 2 empty, lane 3 
negative control. Lane 6 tumour 29, with pre-operative wash and day one drain fluid in 
lanes 7 & 8 both positive. Lane 9 tumour 49, with positive results in lanes 10 and 12 
representing non-separated pre-operative wash and separated post-operative wash 
respectively. Lane 13 tumour 31, with positive results from non-separated pre-operative 
wash (lane 14), non-separated post-operative wash (lane 15), separated post-op wash 
(lane 16) and separated day 1 drain fluid (lane 18). 
109 
6.3 TP53 Mutations 
Peritoneal samples from the two patients with colorectal tumours who had TP53 
mutations in their primary tumour were tested for the presence of TP53 mutations using 
MLA. In total seven samples, all having been separated using MACS, were avai lable; no 
fluid drained between the first and second day in the patient with tumour 28 . All samples 
were tested at least twice, and any sample giving a single clearly positive result was 
treated as positive. The results are shown in table 6.2. 
TUMOUR 
NUMBER DUKES'STAGE PRE-OP POST-~P DAY 1 DAY2 ~VERALL 
5 B POS POS NEG NEG POS 
28 B POS POS POS l <~; \ POS 
Table 6.2 Results of peritoneal samples from patients with TP53 mutations in their 
primary tumours. For key, see table 6.1. 
Both tumours demonstrated mutant DNA in peritoneal samples. Again, this was always 
present at the start of surgery, and in one case was seen in the post-operative drain fluid . 
The patient with tumour 28 was thought to have undergone curative surgery. The patient 
with tumour 5 also had a caecal tumour of similar stage, and the surgeon was uncertain as 
to whether the procedure (a panproctocolectomy) had been curative. 
Figure 6.2 gives an example of a gel showing positive results, further examples are 
shown in the appendix. 
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Figure 6.2 Gel picture showing results of MLA of peritoneal samples from tumour 
5. Lane 1 negative control, lane 2 positive control, lane 3 tumour 5, lanes 4-7 peritoneal 
samples from patient with tumour 5 (pre-op, post-op, day 1, day 2 in order.) Positive 
results seen in lanes 2, 4 and 5. 
6.4 APe Codon 1309 Mutations 
As described in section 5.3.3, three of the fifty tumours had APC codon 1309 mutations. 
Four peritoneal samples were available from tumour 4, and four pairs of samples (half 
non-separated and half positive fraction after MACS separation) for each of tumours 45 
and 47. The samples were assessed for the presence of amplifiable DNA using PCRs for 
K-ras or wild type APC, and three proved unreliable. In each case the other half of the 
sample (2 non-separated, 1 separated) was available and contained easi ly amplifiable 
DNA. 
The peritoneal washing and drain fluid samples were tested using the less stringent 
conditions described in section 4.7.3, which gave positive results with a dilution of one 
tumour cell in 1000 normal cells. Each sample was tested at least twice, with the tumour 
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sample from the relevant patient included in the reaction as an additional positive control. 
None of the peritoneal washing or drain fluid samples, whether separated by MA S or 
not, gave a positive result in any test. These results are illustrated in figures 6.3a and 
6.3b. 
1 2 3 4 5 6 7 8 9 1011 1213 14 15 16 17 18 19 
Figure 6.3a Gel showing results of allele- specific PCR for APC codon 1309 mutation 
on peritoneal samples. Lane 1 I kb ladder, lane 2 negative control (no DNA), lane 3 
DNA from healthy volunteer, lane 4 empty, lane 5 positive control (LS 1034 cell line), 
lane 6 tumour 4, lanes 7-10 peritoneal samples from patient with tumour 4, lane 11 
tumour 47, lanes 12-19 peritoneal samples from patient with tumour 47. 
12345678 910 1112131415161718 
Figure 6.3b PCR for APC codon 1309 mutation. Lane 1 1 kb ladder, lane 2 negative 
control, lane 3 normal DNA, lane 4 positive control, lanes 5-9 other tumours without 
relevant mutation, lane 10 tumour 45, lanes 11-18 peritoneal samples from patient with 
tumour 45. 
6.5 BRAF Mutations 
As shown in section 5.3.4, five of the 45 colorectal tumours tested had BRAF mutations. 
In total , 15 peritoneal samples were available from these patients. Amplifiable DNA was 
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available from all samples. In one case a drain was not placed, and in three other cases it 
was not possible to collect drain fluid on the second post-operative day. All samples were 
tested for the presence of mutant BRAF using an MLA, and no sample was classified as 
negative until it had been tested at least twice. The results of testing the peritoneal 
samples are shown in table 6.3 . 
TUMOUR 
NUMBER DUKES'STAGE PRE-OP POST-OP pAY 1 DAY2 PVERALL 
21 C1 POS NEG NEG NEG POS 
27 D NEG POS NEG ~ , POS 
33 C1 POS POS !::'l :~c .... [ ,;k" pos 
35 C1 pos NEG pos l i~'~';~ POS 
48 C2 POS NEG NEG Lo:.: .,~ . .-:." POS 
Table 6.3 Results of peritoneal samples from patients with BRAF mutations in 
primary tumours. Key as for table 6.1. 
It can be seen from the table that all patients with a BRAF mutation had at least one 
positive peritoneal washing or drain fluid. This group contains the only patient with a 
positive overall result, but with a negative wash at the start of operation; this woman had 
a very locally advanced tumour and liver metastases and therefore was already known to 
have incurable disease. In the case of tumours 21 and 48, the initial positive result 
appears to have been cleared by surgery, although the results of conventional staging 
mean that both patients would have been offered adjuvant treatment if fit. 
An example of a positive result is shown in figure 6.4. 
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Figure 6.4 Gel picture showing positive result for BRAF in peritoneal samples. Lane 
1 negative control, lane 2 positive control (cell line DNA), lanes 3-6 peritoneal samples 
from patient with tumour 33 (pre-op non-separated, pre-op separated, post-op non-
separated, post-op separated). Positive results are seen in lanes 2-6. 
6.6 Discussion 
It has been possible to test peritoneal samples from 21 patients undergoing surgery for 
colorectal disease. These patients had 22 tumours in which we detected 23 mutations. 
Positive results have been obtained from at least one peritoneal washing or post-operative 
drain fluid in 16 patients. The results are summarised in table 6.4. 
It is interesting to note the different rates of positive results in patients with different 
mutations in their primary tumours; K-ras, 9 of 12, TP53 , 2 of2, APe 0 of3, BRAF 5 of 
5. This could represent different sensitivities in detection of cells with the different 
mutations, although both MLA and allele-specific peR gave positive results at a ratio of 
one mutant cell to 1000 normal cells in spiking experiments. It is possible that the 
differences could represent differences in behaviour between tumours with different 
mutations, or be due to the different stages in malignant transformation at which various 
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mutations occur, but with such small numbers of patients, any differences may welI be 
due to chance. 
TUMOUR 
NUMBER MUTATION OVERALL DUKES' tLNM 
2 K-RAS POS B 3NOMX 
4 K-RAS & APC NEG ADENOMA 
5 TP53 POS B L3NOMX 
13 K-RAS POS B tL3NOMX 
20 K-RAS NEG Cl 2N2MX 
21 BRAF POS Cl 3N2MX 
23 K-RAS POS RECURRENCE 
26 K-RAS NEG B 4NOMX 
27 BRAF POS D 4N2Ml 
28 TP53 POS B tr3NOMX 
29 K-RAS POS B 3NOMX 
31 K-RAS POS B 4NOMX 
32 K-RAS POS B 3NOMX 
33 BRAF P~S Cl n-3N1MX 
35 BRAF P~S Cl n-3N1MX 
36 & 37 K-RAS P~S D n-3N1Ml 
42 K-RAS POS D 1T3NOMl 
45 APC NEG Cl 1T3N2MX 
47 APC NEG B rr3NOMX 
48 BRAF P~S C2 tI.4N2MX 
49 K-RAS P~S A 1NOMX 
Table 6.4 Summary of results of peritoneal washings and post-operative drain fluids 
Details of the mutation detected, whether any peritoneal sample gave a positive result and 
the stage of the tumour are given. 
Of the patients with positive results, one was already suffering from intra-abdominal 
recurrence, having undergone right hemicolectomy for a Dukes' B tumour 14 months 
previously. Three other patients (including one with two tumours bearing K-ras 
mutations) had hepatic metastases and were thus Dukes' stage D. Four patients had 
Dukes' C tumours, seven Dukes' B and one Dukes' A. 
The patients with Dukes' B tumours are an interesting group to study, because they 
would not normally be considered for adjuvant chemotherapy. Of these patients, one 
patient had a T 4 tumour (number 31), with abscess formation, which was adherent to the 
vagina. Tumour was present at the resection margin, and therefore this patient is at high 
risk oflocalIy recurrent disease in the pelvis. Two other patients (tumours 2 and 13) had 
115 
tumours that clinically involved a loop of small bowel. In neither case, however, was the 
pathological stage given as T4. One of these patients presented with small bowel 
obstruction 10 months post-operatively, and at operation was found to have recurrent 
disease in the pelvis, which was confirmed histologically. She sadly died of 
complications after this second operation. A further patient (tumour 32) had an advanced 
tumour at presentation, and had undergone de functioning colostomy and pre-operative 
radiotherapy. It is therefore possible that this patient's tumour had been of a more 
advanced stage before treatment began. The accurate identification oflymph nodes after 
radiotherapy can be particularly difficult. A fifth patient (tumour 5) had synchronous 
bulky tumours, and the surgeon was uncertain as to whether he had been able to perform 
a curative procedure. The remaining 2 patients with Dukes' B tumours and the patient 
with a Dukes' A tumour had no obvious clinical or pathological risk factors for recurrent 
disease. 
Of the patients without positive peritoneal samples, one had a large adenoma, requiring 
anterior resection and two others had Dukes' B tumours (although one of these (26) was a 
T4Iesion). Of the two Dukes' C tumours, one was a T2 tumour, and the other T3. Both 
were found to have vascular invasion on histological examination, and may perhaps be 
more likely to recur at distant sites rather than locally. 
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CHAPTER 7: IS MACS NECESSARY? 
7.1 Introduction 
PCR based techniques rely on the amplification of DNA, which may initially be present 
in only tiny amounts. It makes sense intuitively that if we are looking to detect rare DNA, 
such as a colorectal cancer cell containing a specific mutation, against a background of 
large amounts of other DNA not containing the mutation, that if we can increase the ratio 
of abnormal to normal DNA this will improve our chances. We therefore began our 
project by using MACS separation on every sample. This technique has been shown in 
our laboratory to be useful in the detection of malignant cells in the peritoneal cavity 
(Wong et al., 1996). MACS has also been used by other workers looking for small 
numbers of malignant cells, for example tumour cells in the mesenteric circulation 
(Iinuma et al., 2000). The principle of the MACS technique is described in section 
2.3.2.1. 
We have demonstrated that only about 1% of cells are in the positive fraction of our 
samples after MACS separation (section 4.3). If most of the malignant cells in the 
samples are retained in the positive fraction then this procedure gives a one hundred fold 
enrichment of the target cells for our detection step, and should increase our ability to 
detect rare malignant cells if they are present. The MACS process also allows for the 
removal of any red blood cells that may remain despite density centrifugation. 
Haemoglobin from these cells, which may be incompletely eliminated during DNA 
extraction, could reduce the performance of PCR in later steps. 
However, there are some theoretical and practical disadvantages to the routine use of 
MACS. The cell counts of the whole cell pellet after density centrifugation, compared 
with the total number of cells in the positive and negative fraction added together, show 
that on average about 30% of cells are lost during the repeated manipulations required to 
label the cells with magnetic microbeads and separate them in a miniMACS column (see 
section 4.4). If only small numbers of malignant cells were present in the samples before 
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separation, and particularly if cancer cells were more vulnerable to being damaged or 
destroyed in the process, then MACS may be counter-productivc, especially in samples 
with low initial numbers of cells. 
On a practical level, it is important that if our methods do allow us to detect a group of 
patients who may benefit from extra treatment or more intensive surveillance, that the 
techniques are widely applicable. It would therefore be advantageous if our methods 
could be streamlined as far as possible. PCR and MLA techniques can be performed on 
DNA from batches of samples, which can be stored in a freezer until a convenient time. 
MACS needs to be performed on each sample or group of samples immediately after 
density centrifugation, on the day of specimen collection. Even leaving the samples on 
ice overnight appeared to lead to unacceptable numbers of non-viable cells when countcd 
using trypan blue, although this was not quantified. The combination of density 
centrifugation, and MACS with the combination of antibodies described, took 
approximately three and a half hours to perform depending on the number of samples 
collected. This could be inconvenient, especially if surgery took place on an afternoon 
operating list and samples were not brought to the lab until early evening. 
For these reasons we decided to investigate whether the MACS step improved our ability 
to detect malignant cells in the peritoneal cavity, or whether it could possibly be 
impairing our ability to detect such cells. Attempts to answer this question using spiking 
experiments produced variable results (see section 4.8.2). We therefore addressed the 
problem further with our clinical samples. 
Peritoneal samples from the last 17 patients to be recruited (19 tumours, 50 peritoneal 
samples) were split after density centrifugation, with half of the sample being pelIeted 
and frozen without further treatment and half the sample being separated using the usual 
MACS process. When a mutation was detected in one of the 19 primary tumours then 
DNA was extracted from the non-separated cell pellets and from the positive fractions of 
the relevant peritoneal samples and both were analysed by the appropriate technique 
(MLA or mutation specific PCR). 
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7.2 Results 
Mutations were detected in DNA from II of the 19 primary tumour samples. Tumours 36 
and 37, from the same patient, are considered together for the remainder of this chapter. 
Five patients had tumours with K-ras mutations (tumour numbers 31, 32, 36/37,42 and 
49), two had APC codon 1309 mutations (tumour numbers 45 and 47) and three had 
BRAF mutations (numbers 33, 35 and 48). Each peritoneal sample, both separated and 
non-separated, was tested at least twice by the appropriate method, using products from 
independent PCR reactions in the case of MLA, before being dismissed as negative. 
MACS separated samples samples not separated 
tumour preop postop day! day2 preop postop dayl day2 
31 + + + + -
32 + + + + + - - -
33 + + + + 
35 + 
- + + - -
36/37 + + - + 
42 + + - - - -
45 
- -
- -
- - -
47 
- - - -
- -
48 + - - - - -
49 + + - -
Table 7.1 showing comparison of results from separated and non-separated 
samples. + Indicates a positive result, - indicates a negative result. An empty cell 
indicates that no sample was available. Pre-op= wash at start of operation, post-op= wash 
at end of operation, day I = drain fluid from first post-operative day, day 2 = drain fluid 
from second post-operative day. 
Table 7.1 shows a comparison of the results obtained from the positive fraction after 
MACS separation with the results from the non-separated samples. 26 pairs of samples 
were available for comparison. In four cases only a single sample was available; one 
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sample was not subjected to MACS separation, and three samples did not yield 
amplifiable DNA (two after MACS, one not separated). 
Considering only those samples for which paired results are available, a positive result 
was found significantly more often in samples subjected to MACS separation, than in 
those not separated. These results are shown in table 7.2. 
Separated Non-separated 
Positive 17 6 
Negative 9 20 
26 26 
Table 7.2 comparing proportion of positive results ID samples With and without 
MACS separation. P = 0.0047 Fisher's exact test 
It is interesting to compare the results from the separated and non-separated halves of 
each sample. Of the twenty-six pairs of samples, the results of the separated and non-
separated halves were the same in 15 cases. Both were positive in 6 pairs, both were 
negative in 9 pairs. For a further 11 pairs of samples a positive result was seen in the 
samples after MACS, with a negative result (sometimes a questionable positive seen on 
the gel image) in the non-separated sample. There was no case in which a positive result 
Was seen in the non-separated sample but which gave a negative result with the positive 
fraction after MACS. This shows that MACS is not impairing our ability to detect cells 
with the relevant mutations when these are present. 
If we consider that any positive result for a particular patient may put them into a higher 
risk group for recurrence, then it is important to consider these results in terms of patients 
rather than numbers of samples. Of the 10 patients, 5 had at least one positive peritoneal 
sample with both techniques and 2 had no positive results with either. The remaining 3 
patients were 'upgraded' from having negative to positive peritoneal samples by the use 
of MACS separation before molecular analysis. 
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It seems likely that any benefit gained from MACS separation would be greatest in 
samples with largest numbers of cells in the starting material, where, for the same number 
of malignant cells in a sample, the ratio of abnormal to normal cells would be the leas t. 
However, comparing the mean number of cells in the samples giving positive results both 
with and without separation, and those giving positive results only after MACS, no 
di fference was noted (mean number of cells in initial samples 2.7 x 107 vs. 3.2 x 107 
p=O.5). 
An example of a gel showing positive results in separated, but not whole samples is 
shown below (Figure 7.1 ) . 
.. -_ ....... 
2 3 4 5 
Figure 7.1 Gel showing mutant K-ras in separated, but not non-separated, 
peritoneal samples. Lane I tumour 42, lanes 2 and 3 pre-operative wash, whole sample 
and separated respectively, lanes 4 and 5 post-operative wash, non-separated sample and 
separated sample. Positive results seen in tumour sample and both separated samples 
(Lanes I, 3 & 5). 
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7.3 Discussion 
Despite studying a relatively small number of samples we have shown that mutant DNA 
is significantly more likely to be detected in peritoneal washings or post-operative drain 
fluids if efforts are first made to enrich any epithelial cells present. This confirms our 
initial assumption that the use of MACS would be beneficial for the detection of rare 
mutant cells. 
In our group often patients, three were reclassified as having positive peritoneal samples 
when comparing results after MACS with those using non-separated samples. Although 
numbers are too small to test for statistical significance, if longer follow-up reveals a 
poorer prognosis for patients with mutant DNA in the peritoneal cavity, then it is 
important that all patients are classified as accurately as possible. 
The finding that MACS does seem to have an important role in enabling the detection of 
malignant cells in our samples may limit the general applicability of our techniques. This 
subject, and the possibility that our techniques may be more sensitive than is necessary or 
indeed desirable, is discussed further in chapter 8. 
Until further information about what sensitivity is appropriate in the detection of small 
numbers of tumour cells, we have demonstrated that MACS does improve our ability to 
detect mutant DNA in the peritoneal washings and post-operative drain fluids of patients 
undergoing surgery for colorectal cancer. 
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CHAPTER 8 : GENERAL DISCUSSION 
Local recurrence is a common problem in colorectal cancer, and until recently, the 
perception has been that it is inevitable in certain groups of patients, and almost 
uniformly fatal. Recent advances in surgical technique and the growing use of adjuvant 
treatment have helped to reduce the incidence of local recurrence. Evidence is also 
emerging that close follow up, using appropriate combinations of established techniques 
(CT scanning and CEA measurement) and newer techniques such as PET scanning, may 
allow detection of patients with local recurrence at a stage when salvage treatment is 
possible. Our aim was to describe techniques, which would allow isolated tumour cells, 
the likely precursors of local recurrence, to be detected in the peritoneal cavity around the 
time of surgery. If patients in whom such cells are detected do prove to have a poorer 
outcome, then they may be suitable candidates for adjuvant chemotherapy or targeted 
post-operative surveillance. 
Those patients with spread to the lymph nodes (Dukes' stage C or pNI or 2) normally 
receive adjuvant treatment under current protocols. Our initial aim, therefore, in 
attempting to detect colorectal cancer cells in the peritoneal cavity was to select a group 
of patients with favourable histology (who would normally be treated by surgery alone) 
who we felt were at high risk of local recurrence. At first glance we have been successful 
in this, with eight of the sixteen patients in our positive peritoneal group having Dukes' A 
or B tumours. However, as we have seen, closer inspection of the clinical and histological 
findings in five of these patients, could lead to their classification as being at high risk of 
recurrence. This perhaps emphasises the inadequacy of any single staging system taken in 
isolation, and shows the importance of good provision of information from surgeon to 
pathologist and vice versa. However, the detection of isolated tumour cells in the 
peritoneal cavity could be useful in highlighting the increased risks faced by these 
patients. 
Of the 16 patients with mutant DNA detected in the peritoneal cavity at some stage 
during or after surgery, 10 are alive and well. Four patients are alive with evidence of 
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cancer; one of these was undergoing surgery for intraperitoneal recurrence when the 
samples were collected, a second has recurrent malignant melanoma and the other two 
have liver metastases. Two patients have died; one death followed surgery for local 
recurrence (10 months after the index operation) and the other was from pelvic 
recurrence (the patient having had a T4 tumour with liver metastases at presentation). Of 
the five patients with a mutation detected in their primary tumours, but without mutant 
DNA in the peritoneal samples, one died in the early post-operative period (of a 
myocardial infarction), and the other four are alive and well. These follow-up data are not 
of sufficient duration to allow us to assess whether the patients with malignant cells in 
their peritoneal cavities are at increased risk of local recurrence. Problems may continue 
to manifest themselves for a number of years after primary surgery, and we will need to 
review the patients' notes again in the future. A review of the notes in September 2007 
would allow a minimum of five-year follow up for all patients, although three years 
would probably be adequate to allow the vast majority of recurrences to be seen. 
One of our secondary aims was to quantify any malignant cells we detected. We felt that, 
although RT -peR has a number of disadvantages, previously outlined in section 1.5.4.2, 
it would be suitable for use in those samples in which we had previously found mutant 
DNA by MLA or mutant-allele specific peR. RT -peR can be performed in a quantitative 
fashion, and an epithelial-specific marker, such as cytokeratin 20 would have been a 
suitable target. Indeed, a commercially available kit allows such tests to be performed. 
Unfortunately, it did not prove possible to extract RNA of sufficient quality from our 
frozen cell pellets, without sacrificing the DNA necessary for our diagnostic tests. 
Attempts to extract both nucleic acids from the same sample produced poor quality DNA 
and minimal RNA, which was inadequate for further use. We therefore abandoned our 
aim to quantify cells in our samples. This is unfortunate, because, as discussed below, the 
appropriate level of sensitivity for molecular biological tests for minimal residual disease 
is not known. We were surprised to detect isolated tumour cells in samples from so many 
of our patients, and it may be that these cells are so small in number that they are unlikely 
to cause recurrent disease. It is also uncertain whether these cells are viable (i.e. capable 
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of implantation and replication), although we do know that they are capable of excluding 
a vital dye. 
Our final aim was to streamline our tests, so that they would be simple to apply and 
therefore more widely applicable. One major barrier to this has been the finding, 
described in the previous chapter, that the use of MACS separation on the samples 
increases the likelihood that malignant cells will be found in peritoneal washing and drain 
fluid samples. Although we did not combine the PCR or MLA reactions for the various 
mutations studied, these can each be performed on batches of samples, which can be 
stored at -20°C until needed. The MACS process, however, is moderately time 
consuming, and often needs to be performed at inconvenient times, with relatively small 
numbers of samples in each batch. These problems arise from the observation that 
leaving the samples even overnight (at 4°C) leads to a high proportion of cells unable to 
exclude trypan blue. MACS is also costly with each miniMACS column costing almost 
£6. The column is only intended to be used for a single sample and in practice cannot be 
used for more than two samples. The antibodies required also add to the expense of the 
procedure. This combination offactors means that the combination of techniques we 
have described is more likely to remain a research tool, rather than being routinely 
applicable in clinical laboratories. 
To overcome these problems, several approaches could be used. It may be possible to 
simplify the MACS technique used. For example, the use of a single stage reaction for 
binding microbeads to epithelial cells would save time and possibly money. A human 
epithelial antibody (HEA), directly conjugated to magnetic microbeads, has become 
available and may be suitable for this purpose. 
Testing up to four samples per patient, taken from the peritoneal cavity at different times, 
also increases the volume of work. Follow up of our patients may indicate that it is only 
involvement of the peritoneal washings or the drain fluids that is significant, or perhaps 
even just one of these samples. If the number of samples per patient could be reduced 
from a maximum of four to just one or two, either by collecting fewer samples or by 
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pooling samples together for analysis, then savings in time and equipment could be 
considerable. It is interesting to note that only one patient who had any positive washing 
or drain fluid had a negative result in the first washing sample. However, the continued 
finding of malignant cells in the peritoneum after removal of the primary tumour may be 
of greater significance in determining patients' outcomes. Cells present at the time of 
surgery could be removed with the tumour or by peritoneal lavage; cells in the drain fluid 
may have been shed from cut lymphatic channels and, because of the time when they are 
released, cannot be removed by conventional treatment. The role of intraperitoneal 
chemotherapy in the early post-operative period may be relevant and is under study (de 
Bree et al., 2002). Administering chemotherapy directly into the peritoneal cavity of 
patients at high risk of local recurrence allows a greater concentration of drug to be 
applied to the tumour cells, without increasing systemic toxicity. This is advantageous 
given the relative chemo-resistance of colorectal tumours. 
One other possible alternative to the use of MACS, would be to increase the sensitivity of 
the reaction to detect mutant DNA, whether this is a MLA or a mutation specific PCR. If 
the sensitivity was improved, without sacrificing specificity, then it might be possible to 
abandon the enrichment step using MACS. 
One major advantage of using MACS is that it allows us to overcome a common 
criticism of PCR based techniques for the detection of minimal residual disease. Mutant 
DNA in peritoneal washings or drain fluids could be present in a free state after cell lysis, 
or the cells containing the mutant DNA could be lethally damaged, and therefore have no 
significance for the prognosis of the patient. The repeated washing and centrifugation 
steps during MACS ensures that free DNA will be washed away, and is likely to result in 
the loss of damaged cells. 
As discussed in chapter 5, using the combination of techniques described we were able to 
detect one or more mutations in almost half of our panel of colorectal tumours (22 out of 
46 tumours). This is a reasonable result given the wide variety of different genes mutated 
in colorectal cancer and the huge number of possible carcinogenic mutations in those 
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genes. What could be done to increase the proportion of tumours in which we can detect 
a mutation? It would be possible to look for the other TP53 mutations for which reaction 
conditions are described by Dong (2001). We initially decided not to do this because of 
the lack of a readily available positive control for these reactions. Given some of the 
difficulties in interpreting the pS3 results, an appropriate positive control is particularly 
important. Although the commonest position for a K-ras mutation is codon l2B, 
mutations are also described at codons 12A and 13. Jen (1994b) described reaction 
conditions for the detection of these mutations. Again, other cell lines would need to be 
searched to find one with a suitable mutation to act as a positive control. An alternative 
would be to test a number of tumours, and if one gave positive results, with a mutation 
confirmed by sequencing, this could be used as a control in further experiments. It may 
also be possible to use deliberately mutated DNA for this purpose. It would probably be 
possible to design an MLA reaction to look for the point mutation at codon 1450 of APC, 
if a shorter PCR product was used. 
Ifwe continue to detect further mutations in the same small number of genes, which are 
mutated in colorectal tumours developing via the same pathway, it is likely that a 
significant proportion of the mutations we detect will be second or third mutations in a 
particular tumour. While this may provide interesting information, it would be more 
helpful to identify a first mutation in one of the tumours whose peritoneal samples we are 
currently unable to study. 
All the mutations we have sought to detect occur most commonly in tumours developing 
by the classical pathway described by Fearon and Vogelstein (1990), so-called 
microsatellite stable or loss of heterozygosity tumours. As described in chapter one, about 
15% of sporadic colorectal cancers develop via a different pathway, which is similar to 
those tumours seen in patients with HNPCC, via abnormalities in DNA mismatch repair, 
so-called microsatellite instability (MSI) or replication error positive tumours. Because 
they have a different mutation spectrum when compared with microsatellite stable 
tumours, the techniques we have described are less likely to detect MSI tumours. For 
example, TP53 mutations are rare in MSI tumours. To increase the prospect of detecting 
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such tumours, it may be possible to design tests to detect mutant fonns of one of the 
genes commonly mutated in microsatellite unstable tumours, such as those for the TGFI3 
receptor or hTCF4 (see section 1.6.3.3). If it were possible to design sufficiently sensitive 
tests, it would be preferable to attempt to detect further mutations with allele-specific 
PCR rather than MLA. Simple PCR reactions are less time-consuming and avoid the 
inconvenience and risks associated with the use of 32p. The use of such tests could 
perhaps increase the proportion of tumours in which we are able to detect a mutation 
from about half to almost two thirds. 
Microsatellite instability itself is detected by PCR reactions designed to amplify a number 
of specific sites, where increases or decreases in length of a particular microsatellite have 
been well characterised. DNA from tumours with MSI will show alteration in product 
length, which appears as a ladder pattern or as a new band adjacent to the expected band 
(Ward et al., 200 I). A number of groups have described tests for DNA with 
microsatellite instability against a background ofnonnal DNA in faeces (Ahlquist et al., 
2000; Rengucci et al., 2001). It seems likely that such tests could be modified to study 
peritoneal washings and drain fluids. 
It was reassuring that we were able to confinn most of the mutations (16 of23) detected 
in our primary tumour samples by sequence analysis. This, in combination with the 
rigorous use of controls in all experiments, means that false positive results for mutations 
in tumours are unlikely. The tumours in which the mutation could not be confirmed by 
sequencing may be those where there were, for example, a large number of inflammatory 
cells (leucocytes, with wild type DNA) within the tumour, diluting the mutant DNA. 
Ongoing work in our laboratory is attempting to provide additional evidence about the 
validity of some of our results, particularly the detection of K-ras mutations. A series of 
mutation-specific PCR amplifications for the various K-ras codon 12 mutations has been 
developed, and the samples described in this thesis are soon to be analysed. It will be 
interesting to compare the specificity and accuracy of the two techniques. 
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Malignant cells in the peritoneum have previously been detected in about one quarter to 
one third of colorectal cancer patients, using the various techniques described in chapter 
one. Although we hypothesised that the use of molecular techniques would increase this 
proportion, we were somewhat surprised to find such cells in 75% of the patients in 
whom we could detect a mutation in the primary tumour. One explanation for this is that 
tumours with the mutations we were able to detect have a particularly poor prognosis, 
and that they therefore have a higher rate of peritoneal involvement than our popUlation 
of tumours as a whole. However, there was no difference in the proportion of primary 
cancers in Dukes' stage A and B compared with C and 0 between those in which a 
mutation was detected, and those in which no mutation was found. The largest group of 
mutations we detected were of K-ras codon 12B. Mutations in the ras gene have been 
associated with a poorer prognosis, but the relationship, as with many molecular 
predictors of disease behaviour, is complex, and the increased risk may apply only to 
certain mutations, particularly G~T, which was rare in our series (Houlston, 2001). 
One other explanation for the high frequency of detection of tumour cells in these 
samples is that our techniques are too sensitive, meaning that large numbers of patients 
may be classified as being at increased risk of recurrent disease when this is not 
appropriate. For example, the ability to detect one tumour cell in 107 normal cells, which 
is claimed for some molecular biological techniques, may allow the detection of DNA 
from tiny numbers of cells that are not destined to cause problems for the patient. The 
processes required for an isolated tumour cell to establish itself as a peritoneal metastasis 
are complex, and it is likely that most free tumour cells die: experiments with 
transplantable tumours in mice indicate that very large numbers of cells may need to be 
injected in order to establish a tumour. The clinically significant detection threshold for 
malignant cells in any potential site of metastasis (such as bone marrow, lymph nodes or 
peritoneum) has not been calculated, and may need to be specified for each technique in 
use. Our MLA and mutant-allele specific PCR tests were able to identify one tumour cell 
in about one thousand normal cells. When combined with an enrichment of perhaps one 
hundred fold by the use of MACS, this gives the ability, under optimum conditions, to 
detect one tumour cell in 104 to 105 normal cells. No data are available about whether 
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tumour cells present in the peritoneal cavity at this dilution are able to establish 
themselves as metastatic lesions. An added complication with our samples is the extreme 
heterogeneity of the starting material, with the number of cells varying by a factor of 103. 
The lack of a technique to determine the proportion of malignant cells in the sample, as 
might have been possible with RT-PCR, makes interpretation of the results more 
difficult. Ifthe combination of techniques we have used does prove to be too sensitive, 
with a Iow risk of local recurrence in the patients in whom we have detected isolated 
tumour cells, it may be possible to omit the MACS step without compromising the 
accuracy of our assessment. The results from those patients where both separated and 
non-separated samples are available (described in chapter 7) may be helpful in 
determining this. If MACS proved unnecessary this would, as described above, increase 
the applicability of our techniques, by removing the least 'streamlined' part of the 
process. 
Whether further, similar work will prove useful in making decisions about patient 
management is not yet clear. We will continue to follow the progress of all the patients 
who kindly took part in the study. If future work were considered, it would probably be 
reasonable to collect only a peritoneal washing at the start of operation, as this was 
positive in all but one of the patients who had any positive result. The intended 
confirmation of our K-ras results using MASA will add weight to our results, and may 
allow the use of a non-radioactive technique for further work, which would obviously be 
advantageous. The technique described for the detection of BRAF mutations has not been 
used previously, and could be applied to other situations where DNA based techniques 
have been used for the detection of minimal residual disease. 
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APPENDIX 
A.I MACS Protocol 
1. After density centrifugation cells were resuspended in 1 ml of ice cold PBS, and 
centrifuged at 2S00rpm for 4 minutes. 
2. The pellet was resuspended in 20111 of mouse anti-human Ber-EP4 antibody. If the 
cell pellet was too large to resuspend in this volume, 80111 of cold PBS was added. 
This mixture was incubated for 30 minutes on ice. 
3. The sample was washed in Iml of cold PBS as before. 
4. The pellet was re suspended in 20111 of secondary antibody, goat anti-mouse, 
conjugated to magnetic microbeads, with 80111 of cold PBS, and incubated on ice for 
20 minutes. 
5. The sample was washed as before. 
6. The sample was resuspended in O.5ml of ice cold MACS buffer (PBS containing 
0.5% bovine serum albumin (Sigma-Aldrich) and 2mM EDTA (Gibco BRL» 
7. A miniMACS column (Miltenyi Biotec) was positioned in the specially designed 
magnet (Miltenyi Biotec), and prepared by allowing O.Sml of MACS buffer to run 
through (this was discarded). 
8. A labelled 2m1 eppendorfwas positioned under the column, and the sample 
introduced into the top of the column. As it ran through the negative fraction was 
collected. When the top of the column was nearly empty, O.Sml of MACS buffer was 
added, and this was repeated twice more, giving a total volume of 2ml for the 
negative fraction. 
9. The column was removed from the magnet, and put into a second labelled eppendorf. 
1 ml of MACS buffer was introduced into the column and was forcibly pushed 
through with the 'plunger' provided with the column. This was repeated once, giving 
a total volume of 2ml for the positive fraction. 
10. 50111 from each sample was removed and mixed with trypan blue dye for cell 
counting. 
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11. The remaining fractions were centrifuged at 3000rpm for 8 minutes, the supematants 
were discarded and the cell pellets frozen at -80°C until needed for further 
experiments. 
A.2 peR 
A.2.t Primer sequences 
All sequences are given 5' to 3'; primers were obtained from Invitrogen. 
K-ras exon 1 
Sense: AGG AAT TCA TGA CTG AAT ATA AAC TTG 
Anti-sense: ATC GAA TTC CTC TAT TGT TGG ATC ATA TTC 
K-ras used for seguencing 
Sense: TT A AGC GTC GAT GGA GGA GT 
Anti-sense: GAA TGG TCC TGC ACC AGT AA 
P53 exon 8 
Sense: AGT GGT AAT CT A CTG GGA CG 
Anti-sense: TGA GGC TCC CCT TTC TTG C 
APC wild type 
Sense: GAC GAC ACA GGA AGC AGA TT 
Anti-sense: GCT TGC TT A GGT CCA CTC TC 
APC 1309 mutation, allele specific primer 
Sense: TAG CAG AAA TAA AAG ATT GG 
Anti-sense: as anti-sense for APC wild-type 
BRAF exon 15. for MLA (43 bp product) 
Sense: ACC CAC TCC ATC GAG A TT TC 
Anti-sense: GGT GAT TTT GGT CT A GCT AC 
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BRAF exon 15, for seguencing (224 bp product) 
Sense: TCA T AA TGC TTG CTC TGA TAG GA 
Anti-sense: GGC CAA AAA TTT AA T CAG TGG A 
A.2.2 peR reaction conditions 
All programmes were linked to a long hold at 4°C 
K-ras exon 1 
94°C x 5 minutes 
39 cycles of: 94°C x 45 seconds 
58°C x 45 seconds 
nOc x 45 seconds 
nOe x 5 minutes 
K-ras seguencing primers 
94°C x 5 minutes 
39 cycles of: 94°e x 30 seconds 
52°e x 30 seconds 
noc x 45 seconds 
noc x 5 minutes 
p53 exon 8. wild type APe, BRAF Seguencing primers 
95°C x 5 minutes 
35 cycles of: 95°C x 30 seconds 
62°e x 30 seconds 
noc x 30 seconds 
70°C x 5 minutes 
APC 1309 mutant 
94°C x 5 minutes 
39 cycles of: 94°C x 45 seconds 
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59°e x 45 seconds (stringent conditions) 
(OR 57°e x 45 seconds for less stringent conditions) 
72°e x 45 seconds 
72°e x 5 minutes 
BRAF primers for MLA 
95°e x 5 minutes 
35 cycles of: 95°e x 30 seconds 
55°e x 30 seconds 
72°e x 30 seconds 
72°e x 5 minutes 
A.2.3 PCR reaction mixtures 
Most reagent concentrations remained the same for all peR reactions and are listed in 
table A.I. Each peR was optimised with respect to the magnesium concentration, see 
table A.2. The change ofTaq polymerase supplier from Invitrogen to MBI Fermentas 
required some reactions to be re-optimised, and certain reactions were only successful (or 
attempted) with one or other enzyme, as shown in table A.2. 
Reagent Volume III 
10 x peR buffer (without magnesium) as supplied with Taq 2.5 
Magnesium chloride, as supplied with Taq See table A.2 
dNTP (lOmM each) (Gibco BRL) 0.5 
Sense primer (lOOng/lll) (Invitrogen) 0.25 
Anti-sense primer (I OOng/fll) (Invitrogen) 0.25 
Taq polymerase (5 units/ill) (See table A.2 for supplier) 0.125 
Template DNA 2 
Sterile water To 25111 
Table A.I showing reaction mixture for a 25fll PCR reaction. 
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PCR reaction Invitrogen Fennentas Magnesium Volume of Volume of 
Taq Taq concentration 50mM 25mM 
(mM) MgCb(lll) MgCb(lll) 
K-ras Yes 3 1.5 
K-ras Yes 4 4 
K-ras Yes 1.5 1.5 
sequencing 
TP53 Yes Yes 3 1.5 3 
APe 1309, Yes No 2 I 
allele specific. 
Stringent conds. 
APe 1309, Yes 2.5 2.5 
allele specific. 
Sensitive conds. 
APe wild type Yes Yes 3 1.5 3 
BRAFforMLA No Yes 4 4 
BRAFfor Yes 2 2 
sequencing 
Table A.2 showing magnesium concentration, volume of magnesium chloride and 
supplier of Taq polymerase for each peR reaction. 
135 
A.3 Mismatch Ligation Assay 
A.3.t Mismatch Ligation Assay (MLA) Oligonucleotides 
All oligonucleotides were obtained from Invitrogen 
Oligonucleotides for K-ras 
12B common (end-labelled): TGG CGT AGG 
12B ALA (mutation specific): TGG AGC TGC 
12B ASP (mutation specific): TTG GAG CTG A 
12B VAL (mutation specific): GTT GGA GCT GT 
12 BLOCKER: AGC TGG TGG CG 
Oligonucleotides for TP53 
P53/273CT3 (end-labelled): GTG TTT GTG 
P53/273GA3 (end-labelled): TGT TTG TGC C 
P53/273CT5 (mutation specific): TTG AGG TGT 
P53/273GA5 (mutation specific): TTG AGG TGC A 
P53 BLOCKER: AGG TGC GTG TT 
Oligonucleotides for BRAF 
BRAF 3 (end-labelled): GAA ATC TCG A 
BRAF 5 (mutation specific): TAG CTA CAG A 
BRAF BLOCKER: ACA GTG AAA TC 
MLA reaction End-labelled oligo Mutation specific oligo 
K-ras 2 2 
TP53 5 25 
BRAF 2 25 
Blocking oligo 
100 
100 
200 
Table A.3 showing concentration of oligonucleotides ('oligo') used in each MLA 
reaction. All concentrations in nglJ.l1. 
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A.3.2 Protocol for Mismatch Ligation Assay 
I. Reagents for end-labelling reaction were combined. For 20 samples: 
• Oligonucleotide for end labelling, 22~1 (for p53 experiments, 11/-l1 of each 
oligonucleotide) 
• T4 polynucleotide kinase lOU/~I, 2.2~1 
• T4 polynucleotide kinase buffer, 4.4~1 10 x buffer A for Fermentas T4 kinase 
or 8.8~1 5 x forward reaction buffer for Invitrogen T4 kinase 
• Sterile water to 42~1 
• 32PyA TP 40~Ci, 2~1 
2. The mixture was heated to 37°C for a minimum of 10 minutes (lnvitrogen T4 kinase) 
or 30 minutes (Fermentas T4 kinase). All heating steps were performed on a Hybaid 
thermal cyeler. 
3. T4 kinase was heat inactivated by heating to 65°C for 10 minutes. 
4. Reagents for master mix were combined. For 20 samples: 
• Each mutation specific oligonucleotide, 22~1 
• Blocking oligonucleotide, 22~1 
• Spermidine 20mM, 22~1 
• T4 gene 32 protein, 5~g/~l, 12~1 
• T4 ligase buffer, 88~1 of 5 x T4 ligase buffer for Invitrogen T4 ligase or 44~1 
of 10 x T41igase buffer for Fermentas T4ligase. 
• Saline to 220~1 
5. 1O~1 of master mix was placed in each labelled 0.5ml eppendorf, and 8111 of 
appropriate PCR product added. 
6. 2~1 of end labelled oligonucleotide mixture was added to each tube. 
7. Tubes were heated to 95°C for 5 minutes to denature DNA, and allowed to cool to 
room temperature for 15 minutes while annealing occurred. 
8. I unit ofT4ligase was added to each tube. For Invitrogen T4ligase this was l/-ll of I 
uniti/-ll enzyme, for Fermentas T4 ligase the 5 units/~l enzyme was first diluted I in 5 
with T4ligase buffer. 
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9. Tubes were incubated for 1 hour at 37°C. 
10. T4 ligase was heat inactivated by heating to 68°C for 10 minutes. 
11. 1111 of alkaline phosphatase (I V/Ill), mixed with 2.4 III of dephosphorylation buffer 
provided with the enzyme (Roche) was added to each tube, and incubated at 37"C for 
30 minutes. 
12. Sill of denaturing loading dye was added to each tube, and samples heated to 90"C for 
S minutes to denature DNA. Each Sml of loading dye contained 
• 4.3ml formamide 
• 0.1 ml I.2S% bromophenol blue 
• O.lml 1.2S% xylene cyanol 
• O.Sml O.5M EOT A pH 8 
13. Samples were loaded onto a pre-warrned 12% denaturing polyacrylamide gel. Each 
SOml gel mixture contained 
• 21g urea (BOH, Poole, UK) 
• SmlS x TBE 
• 29.4Sml sterile water 
• ISm140% w/v solution ofacrylamide (38%) and bis-acrylamide (2%), 19: I 
ratio in deionised water (Amresco, Ohio USA) 
• SOIlI TEMEO (N,N,N' ,N' -Tetramethylethylenediamine, Sigma-Aldrich, 
Steinheim, Germany) 
• SOOIlI 10% ammonium peroxodisulphate (BOH, Poole, VK) 
14. The gel was subjected to electrophoresis at 300V, with O.S x TBE as running buffer, 
using a VlS-17 vertical gel electrophoresis apparatus (Gibco BRL). Electrophoresis 
continued for approximately one hour 4S minutes, until the dye front reached the 
bottom of the gel. 
IS. The gel was removed from the gel tank, and the smaller glass plate removed. The gel 
was immersed in a solution of 10% v/v acetic acid and 20% v/v methanol in 
deionised water for 10 minutes. 
16. The acetic acid/methanol was poured off and the gel immersed in 20% v/v glycerol in 
deionised water for 30 minutes. 
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17. The glycerol was poured off, the gel dried with tissue paper and transferred to a 
double thickness of 3mm Chr Whatman chromatography paper. The gel was covered 
wi th cling film. 
18. The gel was transferred to a gel drier (Hoeffer Scientific Instruments, San Francisco, 
USA) and heated to 80°C for 3 hours, with a vacuum of - 30 inHg applied overnight. 
19. The gel was wrapped completely in cling film and placed in a phosphoimager 
cassette, which had previously been blanked. 
20. The gel was exposed for four hours and then read on a phosphoimager (Fuji) . The gel 
image was saved in .img format. 
A.4 Gel Pictures for Tumours with Mutations 
A.4.1 Additional gel pictures for tumours positive for K-ras mutations 
1 234567 
Figure A.I 
MLA Kras experiment I. 
Lane 1 water 
Lane 2 positive control 
Lane 3 tumour 9 
Lane 4 tumour 13 
Lane 5 normal DNA 
Lanes 6 & 7 tumours 12 & I 
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I 2 3 4 5 6 7 8 9 10 11 
Figure A.2 
K-ras experiment 29, showing positive results in lanes 1, 3, 4 & 8. 
Lane 1 positive control 
Lane 2 negative control 
Lane 3 tumour 2 
Lane 4 day 1 drain fluid from patient with tumour 2 
Lanes 5-7 tumours 14, 32 & 36 
Lane 8 tumour 37 
Lanes 9-11 drain fluids from patients without cancer. Negative control for inflammatory 
cells in peritoneum 
140 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
FigureA.3 
K-ras experiment 23, showing positive results in lanes 1, 5-10, 12- 16, 18-20. 
Lane 1 positive control 
Lane 2 empty 
Lane 3 negative control 
Lane 4 tumour 32 
Lane 5 tumour 36 
Lane 6 tumour 29 
Lanes 7 & 8 peritoneal samples from patient with tumour 29 
Lane 9 tumour 49 
Lanes 10-12 peritoneal samples from patient with tumour 49 
Lane 13 tumour 31 
Lanes 14-18 peritoneal samples from patient with tumour 31 
Lane 19 tumour 32 
Lane 20 tumour 36 
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2 3 4 5 6 7 8 9 10 
Figure AA 
K-ras experiment 24 showing clearly positive results in lanes I, 7 & 10. Possible positive 
results in lanes 5, 6, 8 & 9 are more difficult to interpret because of gel cracking. 
Lane 1 positive control 
Lanes 2 & 4 empty 
Lane 3 negative control 
Lane 5 tumour 31 
Lanes 6-9 peritoneal samples from patient with tumour 31 
Lane 10 tumour 42 
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12 3 4 5 6 7 8 9 10 11 
Figure A.S 
K-ras experiment 16 showing positive results in lanes 2,5, 8 & ll. 
Lane 1 negative control 
Lane 2 positive control 
Lanes 3 & 4 tumours 21 & 22 
Lane 5 tumour 23 
Lanes 6 & 7 tumours 24 & 25 
Lane 8 tumour 26 
Lanes 9 & 10 tumours 27 & 28 
Lane 11 tumour 29 
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A.4.2 Additional gel picture for tumour thought to be positive for TP53 mutation 
123456789 
Figure A.6 
TP53 experiment I, showing positive results in lanes 2 and 3. The result in lane 7 was 
thought to be positive on initial imaging, but on closer examination this appears to be an 
artefact. 
Lane I negative control 
Lane 2 SW480 
Lane 3 HT29 
Lanes 4-6 tumours 1-3 
Lane 7 tumour 5 
Lane 8 tumour 6 
Lane 9 tumour 10 
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A.4.3 Additional gel pictures for tumours positive for BRAF mutations 
123 11 12 18 
Figure A.7 
BRAF experiment 9, showing positive results in lanes 2, 3, 12 and 18. The result in lane 
11 is equivocal due to the presence of extra bands, and this tumour proved negative on 
subsequent testing. 
Lane 1 negative control 
Lanes 2 and 3 positive controls 
Lane 4 tumour 8 
Lanes 5 and 6 tumours 19 and 20 
Lanes 7 to 13 tumours 22 to 28 
Lane 14 tumour 42 
Lanes IS to 18 tumours 45 to 48 
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1234567 
Figure A.S 
BRAF experiment 13, showing positive results in lanes 1, 6 and 7. 
Lane 1 positive control (COL0205) 
Lanes 2 to 6 tumours 29 to 33 
Lane 7 positive control (SW1417) 
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12345678 
Figure A.9 
BRAF experiment 14, showing positive results in lanes 2, 4, 5, and 8. 
Lanes 1 negative control 
Lanes 2 and 5 positive controls 
Lanes 3 and 4 tumours 34 and 35 
Lane 6 tumour 43 
Lane 7 tumour 7 
Lane 8 tumour 21 
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A.S Gel Pictures for Positive Peritoneal Samples 
A.S.t Additional gel pictures showing positive results from peritoneal samples from 
patients whose tumours had K-ras mutations 
Throughout this section, the number of a sample refers to the tumour number and the 
letter to the time the sample was taken. 
A = wash at start of operation 
B = wash at end of operation 
C = day I drain fluid 
D = day 2 drain fluid 
+ = positive fraction after MACS separation (samples without this are non-separated 
samples) 
Figure A.tO 
Part of gel from experiment 3 
Lane I positive control 
Lane 2 tumour 13 
Lane 3 13A+ 
Lane 4 13B+ 
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12345678 
Figure A.ll Experiment 22, showing positive results in lanes 1,3, 6, 7 & 8 
Lane I positive control 
Lane 2 negative control 
Lane 3 tumour 26 
Lane 4 26B+ 
Lane 5 26C+ 
Lane 6 tumour 23 
Lane 723A+ 
Lane 823B+ 
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12345678910 
Figure A.12 Experiment 26. Clear positive results are seen in lanes 1, 7, 8 & lO 
Lane 1 positive control 
Lanes 2 & 4 empty 
Lane 3 negative control 
Lanes 5 & 6 36/37A (note that tumours 36 and 37 are from the same patient) 
Lanes 7 & 8 36/37A+ 
Lane 9 36/37B 
Lane 10 36/37B+ 
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1 2 3 4 5 6 7 8 9 10 1] 12 13 14 
Figure A.13 Part of gel from experiment 27. Positive results in lanes 1, 2, 4- 6, and 8-
11 
Lane 1 32A 
Lane 2 32A+ 
Lane 3 32B 
Lanes 4 & 5 32B+ 
Lane 6 32C+ 
Lane 732D 
Lanes 8 & 9 32D+ 
Lane 10 42A+ 
Lane 11 42B+ 
Lanes 12 & 13 42C 
Lane 1442C+ 
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A.S.2 Additional gel picture showing positive results from peritoneal samples from 
patients whose tumours had TP53 mutations 
12345678 
Figure A.14 Part of TP53 experiment 16 
Lanes 1 and 2 tumour 28 
Lanes 3 and 4 28A + 
Lanes 5 and 6 28B+ 
Lanes 7 and 8 28C+ 
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A.S.3 Additional gel pictures showing positive results from peritoneal samples from 
patients whose tumours had BRAF mutations 
.-.... - -,.,..-
- - -- . 
'2 3 4 5 6 
Figure A.IS Part of BRAF experiment 18 
Lane I Spiked sample, I mutant cell in 1000 normal cells 
Lane 2 Spiked sample, 1 mutant cell in 3200 normal cells 
Lane 3 21A+ 
Lane 4 218+ 
Lane 5 21C+ 
Lane 6 210+ 
Clearly positive results are seen in lanes 1 and 3 
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2345678 
Figure A.16 Part of BRAF experiment 19 
Lane 1 negative control 
Lane 2 positive control 
Lane 3 35A 
Lane 435A+ 
Lane 5 35B 
Lane 635B+ 
Lane 7 35C 
Lane 8 35C+ 
Positive results are seen in lanes 2, 3, 4, 6 and 8. 
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I 2 3 4 5 6 7 8 9 10 11 
Figure A.17 Part of BRAF experiment 15 
Lane 127A+ 
Lane 2 27B+ 
Lane 3 27C+ 
Lane 448A 
Lane 5 48A+ 
Lane 648B 
Lane 748B+ 
Lane 848C 
Lane 948C+ 
Lane 10 spiked sample, I mutant cell in 100 normal cells 
Lane 11 spiked sample, 1 mutant cell in 320 normal cells 
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Department of General Surgery 
Warwick Hospital, Lakin Road, Warwick, CV34 5BW 
Tel 01926495321 ext 4155 Fax 01926 482602 
STUDY INTO FREE TUMOUR CELLS 
Patient infonnation sheet (April 200 I) 
Walsgrave Hospital, Coventry 
South Warwickshire NHS Hospital Trust, Warwick 
You are being invited to take part in a research study. Please take time to read this leaflet and to discuss it 
with family or friends if you wish. Please ask us if there is anything that you do not understand. 
What is the aim of the research? 
The purpose of the study is to look for free tumour cells close to the main tuI1!0ur before and after surgery 
using the most advanced genetic biological techniques now available. The results of these studies may help 
us decide in the future which patients will benefit from further treatment in addition to surgery. 
Who is doing the research? 
A group of eleven consultant surgeons, several pathologists and a research worker in the Coventry, 
Warwick and Nuneaton hospitals. They will be working in conjunction with scientists in the Biological 
Sciences Department at Warwick University. ' 
Which patients are in the study? 
Patients having surgery on the oesophagus (gullet), stomach, pancreas and rectum (lower bowel). Most of 
these patients will be suffering from cancer but some patients will have other diseases. 
Do I have to take part? • 
No. It is entirely your decision. If you do decide to take part you are free to change your mind at any time. 
What does the study mean for me if I consent? 
1 We will· wash 100 ml of saline (salt water) around the operation site at the start and end of the 
operation and collect this fluid for analysis. 
2 We will collect the fluid in your "drain bottles" on the first and second day after your operation 
and analyse it. This fluid is usually thrown away. 
3 We will take a minute piece of the primary tumour from the specimen after surgery is 
completed. The major part of the tumour is analysed in the usual way. 
4 We will monitor your progress over several years from your notes. This information will be 
, kept confidential. 
5 The fluid of some patients who have benign conditions will be used to check the accuracy of 
our tests. 
6 None of this is harmful or detrimental to your care. 
7 The results of our tests will be recorded in your notes. The results will not be used to change 
your care in any way because we do not know yet whether our tests are reliable. This is what 
we are trying to find out. 
8 We will inform your own GP of the results if you wish. 
9 This study has been accepted by the Warwick Area Health Authority Ethics Committee. 
"Working to Achieve Excellence in Health Care" 
Chairman: David Evans Chief Executive: Andrew Ri/ey 
-2-
Your treatment will not be affected in any way if you do not wish to take part in the study. 
Thank you for reading this information sheet. If there is anything you do not understand 
please speak to the researcher or your own consultant surgeon. 
The researcher (Karen Busby) can be contacted by pager. Phone 07654 36915.1: 
If you decide that you would like to take part in this study we will ask you to sign a consent fonn. 
We will give you a copy ofthe consent fonn and a copy of this sheet to keep . 
. 
. 
"Working to Achieve Excellence in Health Care" 
Chairman: David Evens Chief Executive: Andrew Ri/ey 
Department of General Surgery 
Warwick Hospital, Lakin Road, Warwick, CV34 5BW 
Tel 01926495321 ext 4155 Fax 01926482602 
Study into free tumour cells 
Patient consent form 
.-
r confinn that I have read and understood the infonnation sheet for the above study and have 
had the chance to ask questions. 
2 r understand that my participation is voluntary and that I am free to withdraw at any time, 
, 
without giving any reason, without my medical care or legal rights being affected 
3 I understand that my medical notes may be looked at by responsible researchers involved with 
the study. I give pennission for these people to have access to my records. 
I agree to take part in the research study 
Signature ..•.•......•.•...............•............................................ 
Name 
Date ........................................ \ ................................ . 
I agree to let my GP know the results 
Signature ........................................................................ . 
I have explained the study to the above patient 
Signature of researcher or consultant 
Date 
Re'search Doctor 
Copy for patient 
Miss Karen Busby 
Surgical Unit Office 
Warwickshire NHS Trust 
Lakin Road 
Warwick CV34 5BW 
Tel: 01926495321 Ext 4155 or pager 07654 369151 
Copy for researcher Copy for hospital notes 
"Working to Achieve Excellence in Health Care" 
Chairman: David Evans Chief Executive: Andrew Ri/ey 
,.'l:k] 
West Midlands South Strategic Health Authority 
(Including Coventry, Warwickshire, Herefordshire & Worcestershire) 
WARWICKSHIRE RESEARCH ETHICS COMMITTEE 
Lewes House, 
George Eliot Hospital, 
College Street, 
'Nuneaton 
C.V10 7DJ 
Direct Line 
Fax 
E-Mail 
02476 865244 
02476865058 
pat. horwell@geh.nhs.uk 
17th September 2003 
Dr. P. Murphy, 
Consultant Surgeon, 
South Warwickshire General Hospitals NHS Trust, 
Warwick Hospital, 
Lakin Road, 
Warwick 
CV345BW 
Dear Dr. Murphy, 
Warwickshire Local Research Ethics Committee 
AJ:>proval Letter 
RE 464 The evaluation of molecular biol99ical techniques in the 
identification of tumour cells in the post operative drainage fluid after 
resection of oesophageal gastric and rectal caners 
. 
I am pleased to advise you that your application to participate as a Local Investigator 
in the above RE-approved study was reviewed by the Warwickshire Research Ethics 
Committee at their meeting on 31 It January 2001 has now been approved. The 
Committee works in accordance with ICH/GCP guidelines 
• Please quote our RE reference number and title in all correspondence . 
...... . JJ.l~1~q3 ...... , .. , , ..
Date 
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